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Introduction
Background 
The incidence of congenital heart disease (CHD) is estimated to vary between 4 to 50 
per 1000 live births [1, 2] . This wide range of incidence is due to different phenotypes 
of CHD, as well as the inclusion criteria used. All together, CHD can be seen as the most 
common birth defect worldwide with approximately 1 million children born with a 
CHD each year [3]. Epidemiological studies in the Netherlands report an incidence of 6 
per 1000 children born with a CHD each year [4]. 
When looking at causes of infant death, congenital anomalies are the leading cause. One 
third of these deaths are due to CHD [5]. However, the introduction of modern surgery 
as well as improved treatment strategies for CHD resulted in a decline in mortality from 
CHD [6]. In addition, death resulting form CHD shifted from newborns to young adults 
[7]. Thus, this prolonged survival results in an increase in patients with CHD that need 
treatment not only at birth, but also during adolescence and even during their adult 
live. In a selected group of these patients, the structural abnormalities that define a 
particular CHD phenotype results in prolonged RV pressure overload, such as Tetralogy 
of Fallot, left hypoplastic heart syndrome or congenitally corrected transposition of 
the great vessels. In addition, other diseases such as pulmonary hypertension or even 
ischemic heart disease can result in increased RV loading conditions. The effects of 
prolonged RV pressure overload on the heart’s function, as well as the effects on 
molecular and cellular level is not yet fully understood. However, patient data suggest 
that the RV is unable to cope with prolonged periods of (systemic) overload resulting 
in RV failure [8-12]. Therefore, it is of utmost importance to understand the effects of 
prolonged pressure overload on the RV in terms of ventricular function, as well as at 
the molecular level. 
Right ventricular properties
The effects of prolonged pressure overload on the left ventricle (LV) have been widely 
studied. The results of those studies, however, cannot be simply translated to the RV. 
The RV distinguishes from the LV in various ways. First of all, the stroke volume of the 
RV is similar to the LV but using approximately 25% of the stroke work because of the 
low resistance of the pulmonary vasculature [13]. Given Laplace’s law, which states 
that the pressure within a sphere is proportional to the wall tension (wall stress times 
wall thickness) and is inversely proportional to the internal diameter, the RV is thin 
walled under normal physiological circumstances. In addition, the geometry of the RV 
is different from the LV. Where the LV is more round shaped, the RV has a more crescent 
shape with an inlet (sinus) portion and an outlet (conus) section, separated by the crista 
supraventricularis. The RV stroke volume mostly results from longitudinally shortening 
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of the RV wall, whereas in the LV circumferential shortening is more important [14]. The 
two chambers cannot be seen as two separate units since they are linked by a shared 
wall, the interventricular septum, and are encircled by common muscle fibers. Therefore, 
alterations in the geometry of one ventricle by for instance hypertrophy of dilatation can 
influence the systolic or diastolic function of the contralateral ventricle [15].
Right ventricular adaptation to prolonged afterload
Prolonged elevations in RV afterload result in extensive remodelling of the RV. An 
important first adaptation mechanism is the development of hypertrophy [16]. This 
initial increase in ventricular mass helps the RV to cope with the increased afterload but 
gradually progressive contractile dysfunction will set in. Eventually, the right ventricle 
will dilate to allow for compensatory preload in order to maintain stroke volume despite 
reduced fractional shortening. When the contractile function deteriorates even further, 
clinical signs of RV failure (systemic congestion) will become eminent [17].  
This adaptive process of RV hypertrophy to increased afterload and the subsequent 
development of RV failure is a complex, dynamic process which evolves over time. The 
characterisation of the hypertrophic response is not uniform. Several classifications 
and definitions of the type of hypertrophic response, such as physiological and 
pathological hypertrophy, have been proposed [18-22]. Despite the different point of 
views, it is acknowledged that the process of hypertrophy is, in addition to an increase 
in muscle mass, accompanied by various changes in both physiological behaviour of 
the myocardium as well as biochemical changes.  
Biochemical changes in right ventricular hypertrophy
Until recently, most research available on the molecular mechanisms involved in 
cardiac hypertrophy and the progression to failure is derived from studies on the LV. 
This was merely due to underestimation of the pivotal role of the RV in the systemic 
circulation [13]. Some of the mechanisms involved in LV hypertrophy may be present 
in the RV, however, given the various structural, functional and even developmental 
differences between RV and LV, it is also reasonable to assume that other mechanisms 
are involved. Therefore, to increase our understanding of the transition from RV 
hypertrophy to failure, it is mandatory to conduct studies specifically aimed at RV 
pathobiology and -physiology. 
In general, (pathological) cardiac hypertrophy is accompanied by changes at the 
cellular level such as changes in calcium handling [23], β-adrenergic signalling [24], 
mitochondrial energy metabolism [25], and the activation of several signal transduction 
cascades that in turn can lead to altered gene-transcription activity  with alteration in 
gene expression levels [26].
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Research on most of these aforementioned mechanisms has been done in either in 
vitro experiments or in  in vivo models of LV hypertrophy. At present, little is known 
about the contribution of each of these mechanisms in RV hypertrophy. In addition, RV 
hypertrophy that develops after prolonged periods of pressure overload is a continuous 
process in which the pathological changes at the molecular level are time related. In 
particular, crucial changes can be expected in the transition phase of compensated 
hypertrophy to decompensated hypertrophy, i.e. heart failure. 
In this present thesis, the protein changes after various periods of RV pressure overload 
are studied using proteomics technologies. 
Analyzing protein changes in right ventricular hypertrophy - proteomics
As mentioned above, during the development of RV hypertrophy or heart failure, many 
alterations occur in signal transduction cascades that eventually will lead to alterations 
in gene expression. The total number of genes present in a cell at a given time and 
condition is called a genome. The determination of these genes can be done using 
genomics technologies, such as micro array experiments. Data from these genomics 
experiments on heart hypertrophy and failure have provided insight on gene 
expression profiles that are present in various stages of hypertrophy [27]. However, 
alterations in gene expression levels during hypertrophy do not necessarily correlate 
with changes in the protein level since not all gene alterations will lead to protein 
syntheses. In addition, proteins can undergo modifications after their translation 
(so-called post-translational modifications (PTMs)). The eventual phenotype of the 
cells is a result of the proteins present. In analogy to genomics, the complement of 
proteins that are present in the cell in a given time and under certain conditions (the 
proteome), can be studied using proteomics. One of the main characteristics of the 
proteomics approach is the holistic view on the protein changes. Unlike the “classical” 
or “reductionists”  approach which involved the study of single proteins at the time 
with for instance Western blotting, proteomics aims to display changes in groups of 
proteins. The resulting advantage of proteomics is that changes can be detected in 
proteins that were formerly unknown to be involved in certain diseases. In addition, 
many proteomics techniques also allow the study of proteins with PTMs. A detailed 
review on proteomics in general and the application in cardiovascular research is given 
in chapter 2
Right ventricular physiology
RV physiology differs substantially from LV physiology due to multiple factors, such as 
difference in wall thickness and degree of afterload. Given its position in the circulatory 
system, between systemic venous and the pulmonary circulation, the main function 
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is to provide adequate pulmonary perfusion. In addition, a sufficient pump function 
of the RV also prevents congestion of tissues and organs by maintaining low systemic 
venous pressures [17]. Furthermore, the RV also influences the LV via the shared 
intraventricular septum, thereby playing a role in maintaining global cardiac function. 
Due to its positioning within the circulatory system, the RV is subject to a lower 
afterload as compared to the LV. The pressures generated by the RV under normal 
physiological circumstances are also lower. As a result, the RV uses approximately 5 
times less energy to pump the same amount of blood [28]. The mechanisms involved 
in RV contraction and subsequent ejection of blood are also different from the LV. The 
RV free wall will move toward the interventricular septum, thereby reducing the septal-
to-free wall distance [29]. The majority of blood will be ejected by this motion. The 
complete emptying will result from the contraction of circular LV fibers that enhance 
the convexity of the interventricular septum. 
The cardiac cycle can be defined in periods such as isovolumic relaxation, diastolic 
filling phase, isovolumic contraction and finally ejection. For the LV, these periods are 
well defined. In the RV the isovolumic contraction is less well defined as it is rapidly 
followed by RV ejection. In addition, the RV ejection is still ongoing while RV pressures 
already start to decline [30]. In addition, the amount of stoke work is about 5 times 
less as compared to the LV [28]. Despite the physiological differences between both 
ventricles, there is also a great deal of interaction between LV and RV. In the diastolic 
phase, the filling of RV will lead to reduced LV chamber dimensions and result in 
upward displacement of diastolic pressure-volume relations [31, 32]. The systolic 
ventricular interaction mainly consists of LV contraction contributing to the generation 
of RV systolic pressure [33]. It is thought that approximately 20-40% of total RV systolic 
pressure development is the result of LV contraction [34].
Analyzing right ventricular function by pressure-volume loops
The assessment of right ventricular function is a challenging task. The continuos 
measurement of RV pressure has been possible for a long time, but the pressure 
changes alone are not sufficient for determining the RV performance. In addition to 
pressure, one should also measure RV volume. This parameter, however, is challenging 
to obtain since the geometry of the RV is rather complex. In addition, there is a 
great deal of inter-individual variation in the size of the RV [33]. A precise volumetric 
analysis should therefore consist of techniques that measure volume independent of 
geometrical assumptions [35-37]. Preferably, the RV volume and pressure should be 
measured continuously and simultaneously so pressure-volume (PV) relations can be 
constructed that give insight into the mechanical function of the heart. 
In this present thesis we have used PV-relations to describe cardiac function. 
Faber.indd   12 28-02-12   12:47
General introduction and outline thesis
13
In figure one a schematical pressure-volume loop is shown. On the horizontal axis 
ventricular volume is plotted, on the vertical axis ventricular pressure. Segment A-B 
reflects the diastolic filling phase, followed by the isovolumic contraction phase (B-C), 
ejection phase (B-C) and the isovolumic relaxation (C-D). From these loops the end-
diastolic and end-systolic points (resp. point B and D) can be derived. The width of 
each loop represents stroke volume, the surface area represents stroke work. For the 
RV, the pressure-volume loops are smaller in size and more triangular due to the more 
difficult definition of isovolumic contraction and relaxation intervals.
Figure 1: Schematic representation of a Pressure-Volume loop. See text for more details.
When preload is reduced, for instance by partial occlusion of the vena cava inferior, 
the ventricular pressure- and volume both decrease. This results in a downward- and 
leftward shift of the PV-loops. This manoeuvre enables us to derive several parameters 
that can be used to determine ventricular function. One of these parameters is the 
end-systolic pressure-volume relation (ESPVR). The ESPVR is a linear relation between 
pressure and volume at end-systole (also termed: elastance) and is a relative load 
independent measure of end-systolic performance [38-40].  A leftward or upward 
displacement of the ESPVR reflects an increase in myocardial contractility, whereas an 
opposite displacement reflects a decreased level of contractility. Besides the slope of 
the ESPVR, also the intercept with the volume-axis at a certain pressure can be used 
to determine changes in inotropy [41-43]. Besides the ESPVR, also other parameters 
can be used to describe systolic function. The preload recruitable stroke work (PRSW) 
relation is a preload-independent measure of systolic function and is relative insensitive 
to changes in afterload [44-46].  It’s a ventricular function curve using stroke work and 
end-diastolic volume. A third parameter is the dP/dtmax-Ved (end-diastolic volume)
relation. Whereas the dP/dtmax is commonly used as an isovolumic parameter of 
Faber.indd   13 28-02-12   12:47
Chapter 1 General introduction and outline thesis
14
contractile function, it is very sensitive to changes in preload. To correct for the preload-
dependence, the dP/dtmax was linearly related to the end-diastolic volume [47]. This 
resulted in a very sensitive parameter of systolic function with minor dependence 
on preload. However, the large variations observed in the dP/dtmax make it a less 
stable parameter of contractile function as compared to the ESPVR [44]. As all three 
parameters of systolic function have their own limitations, we have used more than 
one parameter to describe the systolic function of the RV.
The diastolic function can also be derived from the PV-loops. When constructing the 
end-diastolic pressure and - volume points during a preload reduction manoeuvre, 
one obtains the end-diastolic pressure-volume relation (EDPVR). This parameter 
reflects the passive characteristics of the ventricle, ie. chamber stiffness [48, 49]. 
A second parameter used to describe diastolic function is tau. This index reflects 
isovolumic relaxation by describing the time needed for ventricular pressure to fall 
to 1/e (approximately 37%) of its initial value [50]. In addition, the dP/dtmin was used 
as a determinant of early diastolic performance as it reflects the peak rate of pressure 
decline during isovolumic relaxation.
outline of this thesis
This present thesis consist of several studies that aim to elucidate biochemical and 
physiological changes that occur during (prolonged) right ventricular pressure 
overload. As an introduction to the biochemical techniques used, a review on 
proteomics methods is presented in chapter two. The application of proteomics 
technologies on RV protein changes after 6 weeks of PAB is presented in chapter three. 
The application of biventricular PV-loops is presented in chapter four, where the effects 
of PAB on RV and LV physiology are described. A detailed study on longitudinal protein 
changes during RV pressure overload is presented in chapter 5. Chapter 6 describes 
the changes in LV and RV systolic and diastolic function that occur after various time 
periods of PAB. Finally, chapter 7 presents a method for assessing cardiac myofilament 
changes using HPLC.
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Abstract
The key components to the molecular understanding of the pathophysiology of 
various forms of heart failure involve global and/or large-scale identifications of 
proteins, their patterns of expression, post-translational modifications, and functional 
characterization. Particularly, proteins involved in the induction of cardiac (mal)
adaptive hypertrophic growth, the interstitial fibrosis, and contractile dysfunction, are 
of interest. In general, with the accumulation of vast amounts of DNA sequences in 
databases, researchers have become aware that merely having complete sequences 
of genomes and transcriptional changes for thousands of genes simultaneously, will 
not be sufficient to elucidate, in molecular terms, the etiology and pathophysiology 
of cardiovascular disease. In the last decade, a new technology called proteomics, 
has become available that allows biological and (patho)physiological questions to be 
approached exclusively from the protein perspective. Proteomics may enable us to map 
the entire complement of proteins expressed by the heart at any time and condition. 
This approach creates the unique possibility to identify, by differential analysis, protein 
alterations associated with the etiology of heart disease and its progression, outcome, 
and response to therapy. In order to illustrate the true power of proteomics, most of 
the current available methodologies are first reviewed including their limitations. In 
this review will also be dealt with the current status and the perspectives of proteomics 
applications in research on heart failure in general. Furthermore, examples of recent 
own data on global protein profiling of the pressure-overloaded rat right ventricle, and 
of endothelin-1 stimulated cultures of neonatal rat cardiac myocytes, will be provided. 
A last section is devoted to the continuous advances in proteomic technologies, 
including protein separation methods, MS instrumentation, computational analysis 
and bioinformatic tools, together with integrative databases. 
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Introduction
Cardiovascular diseases remain the most common cause of mortality in adults 
worldwide [1]. In the past few decades, however, the clinical expression of cardiovascular 
disease has changed considerably. Significantly less people now succumb in the 
immediate aftermath of a cardiovascular event, such as acute myocardial infarction or 
stroke. This results in an increased burden of chronic manifestations of slowly progressive 
heart failure on the aging population. Heart failure is not a uniform disease entity, but 
a syndrome with various causes such as cardiomyopathy, congenital heart disease, 
hypertension, and myocardial infarction. The molecular basis of this syndrome remains 
poorly understood. The heart failure syndrome is largely treated symptomatically by 
a complex regimen of drugs. However, the effect of pharmacotherapy is not always 
satisfying [1]. The identification of single gene mutations that are responsible for 
inherited forms of hypertrophic and dilated cardiomyopathy, has allowed to pinpoint 
several of the initiating events that can lead to features of heart failure in humans 
[2]. However, even in these rare forms of cardiomyopathy, there is still a broad gap 
between the mutation and the understanding how the abnormality in the encoded 
protein leads to cardiac failure. Likewise, the molecular basis of chronic overload-
induced heart failure is only slowly emerging. A key component to the molecular 
understanding of the pathophysiology is the identification and characterization of 
proteins. Particularly, those proteins involved in the induction of cardiac (mal)adaptive 
hypertrophic growth, the interstitial fibrosis, and contractile dysfunction are of interest. 
Changes in cardiac phenotype, i.e. quantitative (amount) and qualitative (isoform and 
post-translational modifications (PTMs)) alterations in protein expression, are likely 
to be the main determinants in the deterioration of cardiac function. The classical 
approach of molecular research, such as measurement of activities or quantities of 
already known proteins and/or enzymes in normal and diseased myocardium, typically 
focus on the analysis of one or a few known proteins per experiment. However, the 
key to the understanding of the molecular regulators of cardiac function in health 
and disease, lies in the identification of the complex interplay between global protein 
expression and modification patterns associated with clinical phenotype. The concept 
of mapping the human proteome was already put forward almost 20 years ago, but 
rapid advances in molecular biology techniques shifted the emphasis towards to the 
genome, ultimately leading to the human genome project [3]. Nowadays, sequence 
information on numerous proteins can be inferred from the open reading frames from 
the more than 50 complete genome sequences, including human and rodents (www.
tigr.org/tdb/tgi) [3, 4]. Microarrays, or DNA “chips”, have emerged as another powerful 
tool that now is applied to many areas in cardiovascular physiology and pathology 
[5]. This genomic approach allows large-scale parallel assessment of gene expression 
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profiles in various stages of developing cardiac hypertrophy and heart failure [5]. 
Additionally, the ability to engineer precise mutations in the heart, coupled with the 
ability to quantitate the effects of these mutations on cardiac function in vivo, has 
led to the recognition of a previously unsuspected set of signalling pathways and 
proteins that stimulate specific effects of cardiac hypertrophic growth [2]. The effects 
of both over-expression and knock-out of individual genes in animals have provided 
models that replicate human heart diseases [6-8]. Taken together, understanding the 
failing heart at a molecular level seems approachable by breaking down this complex 
disease into specific endpoints, and identifying key pathways and checkpoints for 
each important clinical phenotype during heart failure progression [1]. The in vivo 
models are very often (partially) extended to, and refined by, cell culture models. In this 
approach, homogeneous preparations of one cardiac cell type (myocytes, fibroblasts, 
etc.) are studied with respect to e.g. neurohormonal-, pacing-, or stretch specific 
cellular responses [9, 10]. The present state of knowledge on key signalling pathways, 
master switch proteins, and critical enzymes, may give the impression that the overall 
molecular characterization of several heart diseases will be complete in the near future. 
However, only the known pieces of a puzzle are described at a detailed level, neither 
knowing nor investigating which part of the puzzle has been resolved. Proteomics 
allows to map the entire complement of proteins expressed by the heart at any time 
and condition, which creates the unique possibility to identify, by differential analysis, 
protein alterations associated with the etiology of heart disease and its progression, 
outcome, and response to therapy. 
This review will address the current status of proteomics applications in research on heart 
failure in general, together with a description of some of our recent data. To illustrate 
the true power of proteomics, an overview of the current status of the methodologies 
is provided, including the last new technological advances in this rapidly growing 
field. The potential pay-off of global proteomic analysis is the identification of novel 
therapeutic targets by uncovering distinctive protein signatures associated with heart 
failure. If such a protein is discovered, information on amino-acid sequence, obtained 
by tandem mass spectrometry (MS/MS), can be rapidly obtained. This can be used for 
designing nucleic acid based vectors  specifically overexpressing or silencing protein 
production. Furthermore, protein action can be blocked specifically by a dominantly 
negative mutant protein [11, 12]. 
Why proteomics approach?
With the accumulation of vast amounts of DNA sequences in databases, researchers 
are increasingly realizing that merely having complete sequences of genomes is not 
sufficient to elucidate biological function. The existence of an open reading frame in 
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genomic sequences does not necessarily imply the existence of a functional gene. 
Thus, verification of a gene product by proteomic methods is an essential step in 
“annotating the genome” [13]. There are several other compelling reasons to approach 
biological and (patho)physiological questions exclusively from the protein perspective: 
1) Proteins, not genes, are responsible for the phenotype of cells. Proteins are the 
functional output of the cell and therefore are expected to provide the most relevant 
information for molecular understanding of (patho)physiological processes. The level 
of complexity resulting from co- and post-translational modification events can only 
be dissected and understood through qualitative and quantitative studies at the level 
of the functional proteins themselves [14]. Particularly, when interpretation of protein 
expression takes into account the dynamics of this expression in specific biological 
contexts (see also point 4) [15].
2) It will be impossible to elucidate mechanisms of disease, aging, and effects of 
environment, solely by studying the genome and its expression at the level of mRNA 
[16]. For the study of proteins in bodily fluids, such as serum and urine, this is most 
evident in view of the remote mRNA source. The cellular expression or function of 
proteins is modulated at many steps from transcription to post-translation. Indeed, 
there generally is a poor correlation between the abundance of mRNA transcribed 
from the DNA and the respective proteins translated from that mRNA. Many different 
protein isoforms can be generated from a single gene at the first step of formation 
of mRNA. The initial transcript can be spliced in various ways to yield different 
protein forms [17]. Extensive alterations can also be introduced during or after 
translation. Indeed, the concept of “one gene, one protein” is an oversimplification. It is 
estimated that up to 200 different types of PTMs exist, such as the addition of specific 
carbohydrate side-chains (glycosylation) or phosphorylation of serine, threonine or 
tyrosine groups. Mechanisms, such as regulation of protein function by proteolysis, 
recycling, recruitment, and sequestration in cell compartments, affects gene products, 
not genes [15].
3) Protein-protein interactions and molecular composition of cellular structures, can 
be determined only at the cellular level. The human body may contain more than 
half a million modified proteins [17]. Understanding of their interplay is a formidable 
undertaking, even at the cellular level, where only 5,000 – 10,000 genes (although 
many more proteins) may be expressed. A key question about a protein is: with 
which other protein(s) does it interact [16]? Interaction partners are an immediate 
lead into biological function and can also be potentially exploited for therapeutical 
purposes. Biological function usually arises from the interaction of several proteins in 
tight complexes rather than as an intrinsic feature of an individual protein [18]. The 
systematic investigation of protein interactions for the purpose of elucidating protein 
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functions is termed “functional or interaction proteomics”, and its application can make 
an important contribution to the study of protein-protein interaction [19]. 
4) The cell’s proteome consists of all (modified) proteins present within the cell at any 
given time and/or any condition, which dictates the phenotype at a precise moment 
and/or under a specific condition [20]. Unlike the static information contained within 
the genome, the transcriptome and proteome are dynamic, reflecting the conditions to 
which a cell is exposed or, for example, a specific disease process. There are potentially 
huge numbers of proteomes for each cell type and its condition at a given time.
The execution of a proteomics-based study involves the integration of a number 
of technologies and expertise in biochemistry/molecular biology, physiology, 
bioinformatics/statistics and analytical protein chemistry. The term “proteome”, defined 
as the protein complement of a genome, was first coined by Wilkins in 1995 at the 
Siena meeting for protein separation based on 2-DE [21]. Today, the field of proteomics 
covers essentially all efforts in separation, detection, quantification, identification and 
(functional) characterization of proteins and protein-protein interactions [16]. The 
most significant breakthrough in proteomics has been the MS identification of gel-
separated proteins, which extends analysis far beyond the mere display of proteins on 
2-DE, feasible since the seventies [22, 23]. For this major advance in proteomics, John 
Fenn and Koichi Tanaka shared the Nobel Prize in Chemistry in 2002 [24, 25].
proteomic technologies including its current limitations 
protein separation by 2-DE
The initial step in global proteomic analysis is the separation of a complex protein 
mixture derived from e.g. a total tissue extract, a derived subfraction, or a homogenate 
of a primary cell culture or cell line. The use of 2-DE remains one of the best techniques 
to separate complex protein mixtures. Proteins are first separated based on their pI, 
by iso-electric focusing (IEF). In the second, perpendicular dimension, they are further 
resolved based on their relative molecular mass (M
r
), by SDS-PAGE. One can routinely 
resolve 2,000 to 3,000 proteins from a single sample preparation, or up to 10,000 
proteins when using large-scale custom gels [26]. Today’s standard 2-DE technique is 
rather simple to perform, has a reasonable reproducibility, and is in principle the same 
as the method originally described 25 years ago [23]. Its reproducibility is improved by 
the introduction of immobilized pH gradients [27, 28]. An even further development 
of these so-called IPG strips was the development of narrow-ranged pH gradients 
which increased the resolving power and enabled “zooming at the proteome” [27, 
29]. Also the sensitivity of protein detection was greatly enhanced by the introduction 
of novel staining protocols (discussed below). Although 2-DE analysis of proteomes 
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is conceptually simple, it suffers from several limitations that preclude widespread 
application for proteome analysis. It is technically demanding, labor intensive, and 
fraught with potential artifacts that hamper gel comparisons. Hydrophobic proteins 
and basic proteins are poorly solubilized in buffers used for 2-DE. Likewise, very high- 
and low-molecular weight proteins are poorly resolved by this technique. Basic proteins 
have the tendency to form pronounced streaks rather than spots due to electro-
endoosmotic effects, the migration of reducing agents, and the potential hydrolysis 
of acrylamide at basic pH values [30]. These effects can be partially overcome using 
dithiothreitol replenishment during IEF and inclusion of glycerol to suppress electro-
endoosmosis. Membrane-associated proteins pose a particular challenge with respect 
to solubilization and are therefore significantly underrepresented on 2-DE gels. One 
attempt to improve their solubility has been the use of alternative detergents [31]. 
Since many of the important regulatory proteins in cardiac muscle are highly charged 
(e.g. troponin I, pI 9.8), hydrophobic (e.g. SR membrane protein SERCA), or hydrophobic 
and large (e.g. ryanodine receptor in SR), or soluble but large (heavy-chain myosin), 
the global 2-DE patterns will surely not be complete. The higher resolution of 2-DE, 
compared to 1-DE, allows to detect proteins with alterations in mass and/or charge 
due to PTMs. This excellent resolving power of 2-DE can, however, work as a “dual-
edged sword” [32] because artifactual modifications such as protein carbamylation can 
be picked up as well [33]. 
Methods for protein detection 
Coomassie blue is a beloved staining dye for 2-DE gels [34, 35]. The low costs, ease of 
use, and probably most noteworthy, the good compatibility with downstream protein 
identification on MS, contributed to its popularity [36]. The dye is moderately sensitive 
(detection level: 8-10 ng), but its linear dynamic range makes it suitable for quantitation 
in a certain range of protein concentration. Silver staining has much higher sensitivity, 
approximately 0.1 ng protein per spot [37]. However, its dynamic range is nonlinear 
and PTMs can interfere with the staining [38]. Another drawback of the silver staining 
is its interference with MS-identification [36]. However, some studies have shown 
that minor modifications to the staining protocol can improve the compatibility with 
peptide mass profiling methods, however, at the expense of detection sensitivity [39, 
40]. Radiolabelling, if applicable, such as when active protein phosphorylation occurs, 
can also achieve very high sensitivity, whereas western immunoblotting techniques 
makes it possible to detect as few as 1,000 molecules per cell [14]. Recently, as a typical 
example of radiolabelling, a first elegant analysis of β-adrenergic agonist-dependent 
phosphoproteome of isolated cardiomyocytes was reported by Chu et al., using 2-DE 
in combination with 32P-autoradigraphy and MALDI-MS in conjunction with computer-
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assisted protein spot matching [41]. A novel development in protein detection for 
2-DE is called fluorescence 2-D difference gel electrophoresis technology (2D-DIGE) 
using pre-electrophoretic labeling with fluorescent dyes (Figure 1). It has the potential 
to improve the sensitivity and to increase the dynamic range of protein detection [42, 
43]. Moreover, molecular weight and charge matched cyanine dyes enable multiplex 
labeling of different samples to be run in the same 2-DE gel allowing more accurate 
relative protein quantitation than the conventional methods. The most common 
used labels are amine reactive cyanine dyes (Cy2, Cy3, Cy5), allowing up to 3 different 
protein mixtures (e.g. control, treated and mixed plus treated as internal standard) to 
be labeled individually prior to mixing them and running them simultaneously on the 
same 2-DE gel. This experimental design reduces gel-to-gel variation over conventional 
2-DE and facilitates the use of 2-D analysis software (DeCyder (Amersham Biosciences)) 
for automated and accurate spot quantitation, gelmatching, and statistical analysis. 
A major concern is still the detection sensitivity. For optimal solubilization of the 
proteins, only 1-2 % of the lysine residues in the proteins can be labeled with the 
fluorescent dyes [44]. Optimized DIGE can detect up to four times as many proteins 
as Coomassie blue staining, but only half the amount of proteins that can be detected 
by conventional silver staining [42]. However, DIGE technology is surpassing the MS 
adjusted silver staining with regard to sensitivity, although the SYPRO Ruby staining 
remains superior to DIGE [45].  Another issue that should be taken into account is 
the slight mass difference between the fluorescent labeled and unlabeled proteins. 
Registration errors between labeled and unlabeled proteins occur in 95% of the spots 
complicating the excision of the spots which may give erroneous results on MS [42, 
44]. Post-staining can solve this problem but the detection sensitivity of this stain 
should be high enough to reveal all differentially displayed proteins that were initially 
detected by the cyanine dye. Therefore, the fluorescent (SYPRO Ruby) dye prevails the 
Coomassie blue staining and has been accepted as the post-staining of choice for 
DIGE analysis [42, 45, 46].
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Figure 1: Schematical illustration of the basic principles of the DIGE (gel-dependent-), ICAT, and 
16O to 18O exchange (both gel-independent-) technologies for relative protein quantitation (see 
text for details). 
011-029.Lamers (2704)  12/29/05  10:52 AM  Page 15
(m/z = mass to charge ratio).
Qualitative and quantitative analysis including differential display 
The main purpose of the application of 2-DE in proteomics is to carry out differential 
protein profiling and/or creation of 2-DE gel protein databases. Coomassie blue dyes, 
designated as G-250 and R-250, are conventionally used to stain for proteins separated 
by 2-DE for quantitative purposes. Image acquisition is most often accomplished with 
an imaging densitometer resulting in a digital image of the 2-DE gel [14]. Software 
packages are currently commercially available for analysis of 2-DE gel images. The 
current generation of packages include e.g. PDQUEST (BioRad Laboratories, Hercules, 
Ca, USA) and Progenesis (Nonlinear Dynamics, Newcastle-upon-Tyne, UK). Image 
analysis entails detection of spots on the gel-image, quantification of abundance, 
and matching of protein spots on different gels [14]. Matching requires the definition 
of several “anchor points” or “landmarks” used as reference on all gels. In practice, 
depending on the type of software used, about 30 spots are chosen across the full 
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length and width of the images. Although spot detection is an automated procedure, 
inherent variations in the 2-DE process invariably necessitate a considerable manual 
editing. In the differential profiling approach, protein expression levels between two 
samples are compared, both qualitatively and quantitatively. By process of subtraction, 
differences (e.g. presence, absence, intensity of proteins, or different forms) can be 
found [15]. The gain or loss of protein spots yields information on the differential 
protein expression, while the spot intensities are used for calculating the relative up- or 
downregulation. Examples of such type of proteomics studies in the cardiovascular field 
will be described below. On the other hand, the creation of 2-DE gel protein databases, 
which started in the 1990s, has been essential for proteomics in the heart to become 
a powerful tool in the research of heart diseases. Pioneering proteomic work by the 
laboratories of Dunn and Jungblut led to the creation of several online 2-DE databases 
of human, dog, rat, and mouse atrial and ventricular myocardium [26, 47-49]. The three 
main databases are HEART-2D-PAGE [26, 48], HSC-2D-PAGE [47, 49, 50], and HP-2D-
PAGE [51]. Over the years many groups have contributed to these databases (reviewed 
by [32]). However, these databases are still far from complete with roughly 200 proteins 
identified. Nevertheless, these freely accessible protein inventories are tremendously 
important because they provide researchers with a basis for visualization of changes in 
protein patterns resulting from conditions of their particular study [32].
MS identification and characterization of proteins 
Two-DE provides information on the abundance, pI, and M
r 
of the separated proteins, 
but most often gives no direct clues as to their identities or functions [14].  Over the 
past few years, MS methods have become increasingly important for the analysis of 
proteins and peptides. This was made possible by the development of matrix assisted 
laser desorption (MALDI) and electrospray ionization methods (ESI)  that are capable 
of ionizing very large molecules such as peptides with little or no fragmentation. 
If the excised spot is first in-gel digested with trypsin, which cleaves proteins at 
specific amino-acid sequences (if present), the proteins can be broken into a mixture 
of peptides. The mass of each of these peptides can then be measured by MS to 
produce a so-called “peptide mass fingerprint” (PMF) [15]. This discriminating signature 
is compared to the peptide masses predicted from theoretical digestion or protein 
sequences currently contained within databases allowing protein identification. If 
necessary, actual sequence information can be obtained by MS/MS, in which discrete 
peptide ions can be selected and fragmented and complex algorithms are used 
to correlate the experimental data derived from peptide sequences with protein 
databases. The MS/MS method is technically more complex and less scalable than 
MALDI fingerprinting. The main advantage of MS/MS is that sequence information 
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derived from several peptide fragments is much more specific for the identification of 
the protein, than a list of peptide masses [13]. The success of PMF is highly dependent 
on the existence of comprehensive, searchable databases (e.g. Mascot search engine at 
http://www.matrixscience.com), for the species under investigation [20]. Besides these 
databases that allow for identification of proteins, also other internet-based databases 
are available that facilitate further characterization ranging from the calculation of their 
physicochemical properties to the prediction of potential PTMs and 3-dimensional 
structures (links from http://www.expasy.org). Annotated protein and 2-DE databases 
are the bioinformatic core of proteome research For example, a database of human 
cardiac proteins has been established on http://www.expasy.ch/ch2d/2d-index.html 
[15]. PMF data are often coupled with MS/MS to increase the degree of confidence 
of identification. One approach, termed peptide sequence tagging, is based on 
interpretation of a portion of the electrospray ionization (ESI)-MS/MS fragmentation 
data to generate a short sequence or “tag”. This is used in combination with the mass 
of the intact parent peptide ion to provide significant additional information. A second 
approach uses the database searching algorithm SEQUEST to match uninterpreted 
experimental MS/MS spectra with predicted fragment patterns generated in silico 
from sequences in protein and nucleotide databases [14, 15]. 
Isolation of subproteomes to detect low-abundance proteins and to reduce 
complexity 
Because of the limited resolution power of separation technologies presently applied 
in proteomics research, additional fractionation steps upstream of 2-DE and MS are 
required [52]. Subcellular fractionation consists of disruption of the cellular organization 
(homogenization) and fractionation of the homogenate to separate different 
populations of organelles. A major limitation in successful subcellular fractionation is 
the association of organelles with cytoskeletal elements surrounding the nucleus or 
their entrapment in large aggregates, which readily sediment. In cardiac muscle there 
is also a wide difference in abundance between the myofilament proteins and the 
vast majority of other cellular proteins, which makes organelle proteomics necessary 
[17]. Reproducible subcellular fractionation methods will therefore become essential 
for enrichment of organelle-specific or low-abundance proteins for proteomic 
analysis [52]. A simple cardiac homogenate subfractionation includes separation of 
myofilament proteins from all the other cellular proteins by isolation and detergent 
extraction of the isolated myofilament fraction [53]. This approach has also been 
used in our setting for subfractionation of right ventricular homogenates (see later). 
A different approach, now called “functional proteomics”, is prior protein fractionation 
based on specific affinity of multiple low-abundant proteins for a common interaction 
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partner. The latter has recently been successfully applied on the PKC-signaling network 
in the heart [18, 54]. This affinity-based separation is based on the fact that PKC-e 
forms functional complexes with numerous structural proteins, signaling molecules, 
and stress-activated proteins to accomplish task-specific signal transduction. These 
complexes can be isolated by a gluthation-S transferase (GST)-based affinity pull-down 
method using recombinant GST-PKC-e proteins. Alternatively, immunoprecipitation by 
PKC-e antibody on protein G-Sepharose beads can be used. The comprehensive list of 
cardiac proteins identified in PKC-e complexes presently contains a total of 93 proteins, 
which includes also proteins involved in metabolism and transcription and translation 
processes [18, 54]. 
Multi-dimensional liquid phase based separations 
Taken into account the drawbacks of 2-DE, together with the lack of on-line integration 
with MS, various multi-dimensional (MuD) liquid-phase based separation techniques 
have recently been explored [55]. These systems separate proteins based on a variety 
of properties, such as pI and relative molecular mass, size and charged state, or 
hydrophobicity and charged state. In particular, with the emergence of techniques such 
as nanoflow capillary high-performance liquid chromatography (HPLC) in conjunction 
with MS/MS (HPLC-ESI-MS/MS), attention is gradually refocusing on developing 
comprehensive MuD-liquid chromatography-based separation techniques. The latter 
techniques will soon dominate the field of protein identification [55]. Nevertheless, 
there are still only few examples of 2-D HPLC, in which proteins are separated using 
two sequential steps [53]. The first dimension separations are carried out based on 
protein’s pI, through ion exchange chromatography [56], chromatofocussing [57], or 
based on protein mass, such as in the case of size-exclusion LC [58]. Each of these 
separation methods are followed by reversed phase (RP) HPLC, the second dimension. 
In each case, the power of protein separation is primarily achieved in the first 
dimension. Neverova et al. used the RP-HPLC to resolve extremely complex protein 
mixtures, including cardiac muscle proteome, on the basis of hydrophobicity [53]. The 
HPLC fractions, collected within distinct regions of the chromatograms, were analyzed 
by MS and immunoblot analysis. Two myofilament proteins, troponin T and myosin 
heavy chain, which are known to be problematic for separation on 2-DE only, were 
identified and found differentially modified in the failing swine heart. Therefore, RP-
HPLC used in conjunction with 2-DE provides additional information, particularly 
about the myofilament proteome [53]. Limitation of the latter approach, however, 
is the inability to accurately quantitate the relative protein abundances on a global 
scale. In principle, using HPLC-ESI-MS/MS in proteomics, quite a few different strategies 
may be undertaken [59]. In one approach, close to the conventional one, 2-DE is still 
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employed for the separation of intact proteins. Subsequently, the excised spots are 
digested and analyzed by LC-MS or LC-MS/MS, which is complementary to the results 
obtained on MALDI-TOF-MS. Such a parallel MALDI peptide mapping and ESI-LC-
MS/MS approach therefore typically enhances protein coverage [59]. Using another 
approach, the proteins in the total proteome are only separated and resolved by 
molecular mass using 1-DE. Subsequently, this 1-DE gel is cut into pieces, all proteins 
in a band digested, and the mixture of proteins is analyzed by LC-MS and/or LC-MS/MS. 
This approach provides several advantages over 2-DE gels; it is less elaborate, very large 
and basic proteins are much easier to handle, and the non-abundant, as well as many, 
if not all, membrane proteins are included. However, an important disadvantage of 
1-DE is that it is not amenable for differential analysis of protein abundancy comparing 
extracts from e.g. control versus diseased tissue. In a third, non-gel “shotgun” approach, 
whole protein extracts are digested by proteases generating a very complex set of 
peptides which is beyond the separation capacity of 1-DE and 2-DE gels [59, 60]. 
Especially the Yates’ group has introduced the so-called multidimensional protein 
identification technology (MudPIT) by employing for instance a biphasic column with 
a section of RP material flanked by a strong cation-exchange-resin for e.g. proteome 
wide analysis (e.g. 1484 identified proteins of Sacharomyces Cerevisiae ) [61]. Compared 
to the conventional 2-DE based approach, MuD-LC has proven to be profitable for the 
analysis of membrane proteins [62, 63]. The MuDPIT accomplishes the need to obtain 
the largest protein coverage of a biological sample, but again, as it is feasible with 
images of 2-DE gel, the MudPIT does not really offer an alternative for quantification of 
relative expression levels of individual proteins. 
Identification and mapping of pTMs(ites)
As already mentioned in this review, detection and site-identification of co- or post-
translational modifications of proteins is the domain of proteomics research where 
it surpasses genomics [60]. These modifications are likely to be the most intriguing 
part of the puzzle in understanding disease processes. As an illustration, various toxic 
reactions, such as oxidation of proteins by generated reactive oxygen species (ROS) 
belong to the covalent protein modifications occurring during ischemia-reperfusion 
injury in the heart or advanced glycation of proteins associated with a number of the 
diabetic complications. The evolution of the concept of oxidative stress triggered by 
ROS has led to therapeutic strategies consisting in the administration of anti-oxidant 
molecules in a variety of pathological conditions. Likewise, nitrosative stress, defined as 
excessive or deregulated NO formation, leads to an increase of reactive nitrogen species 
production and has been associated with a number of cardiovascular disorders [64, 65]. 
The so-called “redox proteomics” is the collection of technologies presently available 
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for identifying proteins based on their redox state. The modifications include e.g. lysine- 
and arginine carbonylation, tyrosine nitration and thiol-disulfide chemistry of cysteines. 
Most of the detection methods are conceptually based either on derivatization 
or conjugation of the modified group prior to 2-DE and/or immunoblotting with a 
specific antibody. Until now, only the relatively stable modifications, such as nitration 
of specific tyrosine residues, are suitable to be identified by MS [64]. 
Since the discovery of O-linked β-N-acetylglucosamine (O-Glc-NAc) more than 
20 years ago, the recognition of O-GlcNAc as a PTM has been slow, albeit similar 
to phosphorylation, because of the lack of tools available for its study [66-68]. For 
instance, serine/threonine-O-GlcNAc is as abundant and dynamic as O-phosphate on 
nucleocytosolic proteins site. Interestingly, the recently discovered novel regulator of 
cardiac development and pathological hypertrophy [69], glycogen synthase kinase-
3β (GSK-3β), has been shown to be not only O-phosphorylated but also O-Glc-Nac 
modified [70]. A complete understanding of the complex regulation of protein activity 
and protein-protein interaction attributable to O-GlcNAc and O-phosphate will 
require site-mapping of these GSK-3β modifications under hypertrophic conditions. 
The advanced proteomic techniques that allow determination of sites of O-GlcNAc 
modification and their interplay with phosphorylation on proteins within the 
signalling pathways for understanding their molecular role in the etiology of diabetes 
and cardiovascular disease, have recently been reviewed [71]. 
Gel-independent quantitative protein profiling 
Proteomic technologies detecting differences in protein profiles need to be 
quantitative. MS is inherently not a quantitative technique, because peptides analyzed 
will produce different signal intensities depending on their chemical composition, the 
matrix in which they are present, and other poorly understood variables. However, 
two peptides of the same chemical structure that differ in mass because they differ 
in isotopic composition are expected, according to stable isotope dilution theory, 
to generate identical specific signals in a MS [72]. The technique of stable isotope 
dilution has proven to be highly suitable for quantitative protein profiling. It is based 
on intrinsic labeling, with a stable isotope (2H, 13C, 18O or 15N), of peptides of one of the 
two samples to be compared. Subsequently, the samples are mixed and analyzed on 
the MS. Each peptide will appear as a pair of signals differing in mass. The ratio of the 
signal intensities precisely indicates the ratio of abundance of the protein from which 
the peptide originates. The principles of the two stable isotope dilution techniques, 
ICAT and the 18O to 16O exchange, in comparison to DIGE , are schematically presented 
in Figure 1.
In one approach, C-terminal labeling is performed by tryptic digestion in H
2
18O or H
2
16O, 
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which results e.g. in MALDI-post source dissociation (PSD) mode-MS, peak doublets 
with 2 Da mass difference [72, 73]. This approach can be very powerful because labeling 
is universal and high labeling efficiencies can be obtained. A potential complication 
is that trypsin can continue to exchange 18O or 16O into the peptide at the second 
oxygen [59]. However, this problem can be solved by starting trypsin cleavage prior to 
the  exchange, resulting in the incorporation of two 18O‘s generating a mass difference 
of 4 Da. An analogous strategy is based on a class of reagents termed isotope-coded 
affinity tags, or ICAT [72]. These reagents consist of an alkylating group (iodoacetic acid) 
that covalently attaches the reagent (a polyether mass-encoded linker containing 8 
hydrogens (d0) or 8 deuteriums (d8)) to reduced cysteine residues. Of course, these 
need to be present in the peptide that is to be quantitated and identified. Moreover, 
the reagent contains a biotin affinity tag through which ICAT-labeled peptides, 
derived from a mixture of two samples, can selectively be enriched by avidin affinity 
chromatography before analysis on LC-MS/MS. Thus, in a single, automated operation, 
this method identifies the proteins present in two related samples and determines the 
relative abundance. The ICAT technology specifically targets the cysteine containing 
peptides, which has the advantage of substantial reduction in sample complexity, but 
the disadvantage of lack of analysis of cystein-free peptides. In addition, peptides must 
contain appropriately spaced protease cleavage sites flanking the cysteine residues. 
Finally, the ICAT tag is large (about 450 Da) and remains with each peptide throughout 
the analysis. This can make database searching more difficult, especially for small 
peptides with limited sequence [16]. Sensitivity may also be a concern, since tagged 
peptides derived from low-copy proteins are likely to be poorly recovered during the 
affinity step as a result of non-specific interactions with the avidin-Sepharose, hence 
uncovering its, in potential, greatest weakness. Furthermore, the hydrophobicity of the 
biotin moiety is very dominating over the overall elution pattern of the ICAT-labeled 
peptides. Thereby, the retention behaviour is equalized, such that the peptides labeled 
with the original ICAT label elute off the column in a fairly small time window. This 
generally reduces the number of peptides which can be sequenced during a standard 
LC-MS/MS experiment. Also the detection by MS is not always accurate, especially 
when the size of the ICAT tag versus the small peptide is taken into account. More 
recently, the ICAT protocol has been considerably improved  [74, 75]: 1) the heavy 
and light reagents are now 13C-based and the mass difference is 9 Da. instead of 8 
Da., eliminating potential confusion between oxidized methionine and doubly labeled 
peptides; 2) the biotin portion of the ICAT tag is cleaved with acid after the ICAT-
reagent labeled peptides are eluted from the avidin columns. Biotin cleavage reduces 
the size of the tag on the peptides from 442 Da. to 227 Da., which allows analysis of 
larger peptides and minimizes the effect of the label on the LC elution pattern [74, 75].
Faber.indd   33 28-02-12   12:47
Chapter 2 New perspectives offered by proteomics and its implementation in the study of cardiac hypertrophy and failure.
34
proteomics in the study of heart hypertrophy and failure 
Heart failure is a complex multi-factorial disease, ultimately diagnosed on the basis 
of the inability of the heart to maintain sufficient cardiac output to meet metabolic 
needs of the body [5]. So far, proteomic investigations of human heart failure have 
been concentrated on dilated cardiomyopathy (DCM) [30], a disease of unknown 
etiology, in which contributory factors are genetic factors, prior viral infections, cardiac 
specific autoantibodies, toxic agents, etc. These studies have been complicated by 
factors such as differences in underlying causes of disease state, genetic variability, 
medical history, and therapeutic interventions. Furthermore, heart failure is not only 
caused by DCM but also originates from ischemia and/or hypertension, or congenital 
heart defects. Animal models of various forms of heart disease are available and are 
potentially useful approaches to overcome the above-mentioned complex interfering 
factors in the human situation. Until now, proteomic studies of heart failure in large 
animals (e.g. pacing induced heart failure in the dog and bovine hereditary DCM) have 
been performed [76-79]. Important biochemical similarities to human DCM have been 
observed in these studies. The causes of contractile dysfunction in heart failure are 
still largely unknown, but are likely to result from underlying alterations in gene and 
protein expression level, including modifications [30]. Therefore, proteomic studies are 
likely to give new insights into cellular mechanisms involved in cardiac dysfunction 
and may also provide new diagnostic and therapeutic markers. As cardiac myocytes 
are mainly responsible for contractility and hypertrophic growth, the use of in vitro 
models of more or less homogenous cardiomyocytes (either isolated or in culture) 
for protein profiling purposes, in combination with the application of stress or the 
addition of neurohumoral factors (ET-1), may be advantageous. 
Current status of proteomic studies on DCM
The etiology of DCM still remains largely unknown, although some of the genetics 
have been elucidated [80]. Proteomics has been used for molecular characterization 
of DCM, both at the level of human heart biopsies and animal models. Knecht et al. 
characterized alterations in DCM protein patterns using conventional 2-DE and silver 
staining [26, 81, 82]. These studies revealed only few significantly altered proteins of 
which only a few proteins could be identified. The latter was certainly limited by the 
lack of MS identification. Pleissner et al. also studied (chamber-specific) DCM protein 
patterns and presented them in a world-wide-web accessible database [83, 84]. 
Corbett and colleagues used 2-DE to determine quantitative and qualitative changes 
in protein expression in heart tissue from patients with DCM compared with ischemic 
heart disease and undiseased controls [85]. Among the 88 spots, that were found 
to be downregulated in DCM compared to ischemic cardiopathy, multiple desmin 
Faber.indd   34 28-02-12   12:47
New perspectives offered by proteomics and its implementation in the study of cardiac hypertrophy and failure.
35
containing spots were found as well as several metabolic enzymes and stress-related 
proteins. The involvement of stress proteins in DCM (also compared to ischemic 
heart failure tissue and normal (LV) controls) is also illustrated by Scheler et al [86, 
87]. With the help of immunostaining, differences in HSP-27 patterns between DCM, 
ischemic heart failure, and controls could be detected. These data suggest that HSP-
27 degradation is enhanced in the failing heart [88]. In view of the limiting factors 
regarding the availability of human DCM tissue, appropriate DCM animal models have 
been developed. Besides a turkey model of idiopathic DCM [89], several bovine DCM 
models have been put forward [78, 79, 90, 91]. Weekes et al. performed proteomic 
analysis on bovine DCM resulting in the identification of 35 up-or downregulated 
proteins, compared to controls [78]. An interesting finding is the increase of the 
ubiquitin C-terminal hydrolase enzyme in the diseased ventricles. This enzyme is 
thought to release free ubiquitin from poly-ubiquinated proteins, thereby increasing 
the pool of free ubiquitin in the cytoplasm. The authors discuss the possibility that 
this increased free pool of ubiquitin leads to an increased cellular level of ubiquitin, 
which in turn can drive inappropriate ubiquitination of proteins. This incongruous 
ubiquitination can result in the proteolysis of these proteins by the 26S proteasome 
[92, 93] and can contribute to the development of heart failure [94]. Pacing induced 
heart failure in dogs can be used as an alternative model for DCM. Heinke et al. presents 
two 2-DE studies on protein changes in this canine model [76, 77]. By using both a 
linear immobilized pH gradient (IPG) strip (4-7 pH range) and a non-linear IPG strip (3-
10 pH range) a total of 100 proteins were found to be altered (69 alterations in 4-7 IPG 
strip; 31 alterations in 3-10 IPG strip). Among these protein changes, large numbers of 
metabolic and mitochondrial proteins were detected. 
Above-mentioned studies are examples of the implementation of proteomics in 
studying heart disease in both human and animal tissue. Inter-comparison of human 
and animal DCM (-models) reveals similarities although many of the significant protein 
alterations are not yet identified. The limited use in these studies of MS still hampers 
proper identification of proteins, and their PTMs. Furthermore, an adequate inter-
comparison is still limited due to differences in regional origin of the left ventricular 
tissue and the limited number of patients studied, together with the limited amount 
of proteins identified. Also the etiology of heart failure in the human studies versus the 
animal studies differ considerably (e.g. DCM (i.e. genetic, idiopathic, viral? vs. pacing 
induced)). Therefore, the significance of protein alterations, especially in human 
studies, in terms of disease pathogenesis, are not well determined. The use of a more 
controlled situation, as in an animal model, might be more informative [85]. 
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Figure 2: During the progression of heart disease (from initial event to eventual heart failure) 
numerous alterations of the cardiac proteome occur, each disease type having its own 
characteristics. In the initial phase the protein changes are mainly due to PTMs. These PTMS 
can continue to play a role during the progression of heart disease. During the progression 
of the disease, alterations in gene and protein expression will predominate eventually. (CHD = 
Congenital Heart Disease, DCM = Dilated Cardiomyopathy, MI = Myocardial Infarction).
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Towards an integrated approach
Theoretically, proteomics-based approaches offer the advantage of a holistic view 
of relatively abundant proteins that are present in the cell at a given time. With this 
method, unlike the more conventional “targeted” approach, both expected and 
unexpected alterations of known and unknown proteins can be found. The major 
challenge will be to investigate the contribution of these changes to alterations in 
cellular functions ultimately resulting in cardiac dysfunction. For this purpose, three 
important interrelated aspects (see also Fig. 2) should be considered: 1) time-related 
changes. Heart failure is not a fixed state but rather a dynamic and progressive disease, 
evolving in time; 2) different etiologies. Heart failure can be the result of different types 
of pathology, including ischemic heart disease, hypertension, and congenital heart 
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disease. These different underlying causes of heart failure may be reflected in different 
proteomes; 3) different definitions. Heart failure may be defined on basis of clinical, 
hemodynamic or biochemical features. Therefore, each measured proteome in fact 
should be accompanied by a description of the state of the heart failure process. One 
strategy to investigate the time-related changes that eventually lead to heart failure, 
is composed of the longitudinal collection of tissue of hearts at risk of failure, and to 
correlate the proteomic results with measurements of cardiovascular hemodynamics 
at each time point. These correlations will allow the identification of those protein 
changes that most likely are of functional importance. As an example of this strategy, we 
recently conducted a pilot study in which proteomic as well as hemodynamic profiles 
of the hypertrophied right ventricle of the rat heart were determined [95]. Male Wistar 
rats underwent either a pulmonary artery banding (PAB) operation or a sham operation. 
After a sustained period of PAB, the banded animals all developed RV hypertrophy and 
right atrial enlargement (sham vs. PAB; 0.70 ± 0.04 vs. 1.29 ± 0.05 mg/g RV/BW and 0.10 ± 
0.01 vs. 0.25 ± 0.02 mg/g RA/BW, p<0.05). Hemodynamics, measured in a parallel group, 
revealed a compensated state of the RV [96]. All RV tissue was collected from the PAB 
animals and subsequently pooled and homogenized. The resulting solubilized protein 
sample was prefractionated into a cytosolic and a myofilament fraction and hence 
separated via 2-DE (Figure 3). The same process was repeated for the control animals. 
The gels (ie. PAB and sham) were stained using Coomassie Blue, and matching and 
analysis was performed using PDQUEST (BioRad) software. A total number of 27 spots 
were at least 2-fold increased or decreased in intensity. Among these proteins, several 
metabolic, cytoskeletal, and stress-related proteins could be identified by MALDI-TOF 
MS. It should be noted that this pilot study was performed on homogenates of the 
RV that were pooled on equal protein basis. The separate examination of individual 
samples will not only lead to more accurate protein quantification, but, together with 
hemodynamic profiling, is also a requirement to study possible correlations between 
individual hemodynamics and protein expression levels. While already with the pooled 
homogenates clear changes in protein composition of the pressure overloaded RV 
were demonstrated, the hemodynamic measurements appeared still compatible 
with preserved RV contractility and global function. This suggests that the observed 
protein changes occurred in the absence of heart failure, and are signs of attempted 
compensation. Moreover, it demonstrates the dynamic nature of heart failure. It also 
shows that profiling of the stages preceding actual heart failure may provide us with 
more insight into the mechanisms involved in the progression from (compensated) 
hypertrophy towards heart failure.
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Figure 3: Example of a Coomassie stained 2-DE gel of cytoplasmic fractions of the control 
versus pressure-overloaded right ventricle of the rat (see text for more details). Zoomed images 
of two spots representing differentially expressed proteins are shown as examples. L1, L2 and L3 
correspond to three landmark proteins.
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Towards the cellular level
In the heart, like many other organs, various cell types (e.g. the coronary endothelial 
and smooth muscle cells, fibroblasts and myocytes) exist and, therefore, different 
cellular phenotypes make up the (patho)physiological responses in vivo to e.g. 
increased stretch and neurohumoral stimulation. Therefore when cardiovascular 
responses and diseases are investigated in the human situation and/or experimental 
setting in vivo, the interplay between various cell types should always be taken into 
account as well. Proteomic investigations of cells isolated from the heart are rare and, 
unfortunately, accessible databases on the internet do not exist [32]. The current 
approach is to analyse both tissue, separated cells and cells in (co)culture. A first 
successful attempt was made by Corbett et al. [85] who submitted to 2-DE whole 
tissue samples, endothelial and mesothelial cells, cardiac fibroblasts and myocytes 
obtained from human patients affected either by dilated DCM or ischaemic heart 
disease (IHD). The most prominent changes occurred in the contractile protein MLC-
2 and in a group of proteins identified as desmin. Interestingly, these proteins were 
not apparent in electrophoretic separations of vascular tissue or cultured endothelial 
cells, mesothelial cells or cardiac fibroblasts, which were clearly distinguishable 
from the 2-DE patterns of whole heart and of isolated cardiac myocytes. Moreover, 
the observed protein changes did not appear to reflect variations in the cellular 
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composition of biopsy samples [85]. Likewise, studies at the cellular level are essential 
to sort out the functional significance of the various PTMs observed in total protein 
extracts of ventricular tissue. For example, it is known that sustained activation of the 
β-adrenergic signalling pathways, as occurs during development of heart failure, can 
exert deleterious effects on the myocardium, promoting hypertrophy, left ventricular 
dysfunction, apoptosis, etc. Proteomic techniques were recently used in combination 
with phospholabeling to analyze (-agonist-evoked) protein phosphorylation profiles 
in isolated mouse cardiomyocytes [41]. Apart from changes in the well-known target 
proteins such as troponin I and phospholamban, a remarkable finding in this study 
was the observed phosphorylation of a cardiac isoform of p20 (member of the family 
of heat shock proteins). Adenovirus-mediated overexpression of cardiac p20 increased 
cell contractility and intracellular Ca2+ transient amplitudes  which demonstrates 
the potential role of this newly discovered protein in cardiac (patho)physiology 
[41]. Two-DE electrophoresis combined with 32P-autoradiography and MS-protein 
identification and phosphorylation mapping provides a novel and sensitive platform 
to analyze cardiac phosphoproteome and its modifications in response to various 
stimuli and in disease states. To give another example of proteomics at the cellular 
level, we recently applied differential 2DE combined with MALDI-TOF-MS to cultured 
neonatal rat cardiomyocytes which is known as a well-established in vitro model for 
cardiac hypertrophy [2, 9, 97]. Methods of isolation of this primary culture have been 
described in detail [97]. Cells were stimulated for 48 hrs with 10 nM ET-1 to induce 
the hypertrophic phenotype (Figure 4). Cells were lysed directly in 800 μl rehydration 
buffer (5M urea, 2M thiourea, 0.25% CHAPS, 0.8% Triton X100, 10% isopropanol, 12.5% 
water saturated isobutanol, 5% glycerol, 1% DTT, protease inhibitor complete and 
biolytes and incubated at 25 0C for 1 hr and stored frozen at -80°C. Thawed extracts, 
after centrifugation, were subjected to 2-DE, after fixing and staining with colloidal 
Commassie blue. Gel images were acquired by means of a BioRad GS-800 scanner 
and differential display analysis performed by PDQUEST 7.1 program (BioRad). For the 
first time we were able to detect changes in a cluster of protein spots which were 
all identified as desmin, an intermediate filament (IF) protein known to maintain 
myofibrillar and mitochondrial positioning in cardiac muscle (Figure 4) [85, 98, 99]. 
Several authors have reported on desmin changes in cardiac hypertrophic phenotype 
by applying proteomics on in vivo models [85, 100]. Two well-established features for 
hypertrophy-failure transition are myofibrillar re-and disarrangement and contractile 
failure. Desmin modifications could impair both myofibrillar arrangement and energy 
delivery. On the other hand, diverse cytoskeletal mutations have been associated 
with DCM in both clinical and experimental settings (reviewed by [1, 2]). Based on 
their specific locations within the cytoskeletal network, distinct classed of cytoskeletal 
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defects have been uncovered that include components of the dystrophin/dystroglycan 
complex and mutations in nuclear and IFs, such as desmin and lamin A/C. Since the 
cytoskeleton serves multiple functions in the cardiomyocyte, a number of theories 
have been proposed that might link the observed defects with chamber dilation, 
force generation and transmission, sarcolemmmal integrity, sarcomeric organization/
assembly and intercalated disc stability [1]. As far as cardiac energy metabolism is 
concerned, it is postulated by Capetanaki et al. [99] that desmin may play a role in 
positioning mitochondria along the sarcomere thus allowing the coupling between 
energy production and demand. In agreement with the previous observations on 
Ca2+-activated protease induced IF degradation by Nelson and Traub [101], in our 
recent in vitro study of cultured cardiomyocytes we could confirm changes in desmin 
molecular mass compatible with a proteolytic PTM-type. 
Figure 4: Representative gel images of a total protein extract from control and endothelin-1 (ET-
1) stimulated (48 hrs) neonatal rat cardiomyocytes (see text for more details). Interesting spots 
were excised from gel, destained and in-gel digested with trypsin and used for MALDI-TOF-
MS and, if needed LC-tandem MS analysis. Histograms report different expression of 3 desmin 
species in terms of relative intensity of Coomassie blue staining.
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Beyond the first decade of proteomics 
In 1995, when for the first time the term proteome was defined as the protein 
complement of a genome, the process of studying the proteome became known as 
proteomics. The initial goal of proteomics was the rapid identification of all the proteins 
expressed by a cell or tissue, a goal that, however, has yet to be achieved for any species 
[72]. Notwithstanding, the possibility of MS identification of gel-separated proteins 
led to a renaissance in biochemical approaches to protein function. As described in 
great extent in the foregoing sections, the current goal of proteomics is more varied 
and directed to systematic determination of diverse properties of proteins such as 
sequence, abundance, state of modification, interactions with other proteins, functional 
activity, subcellular distribution, structure, etc [72]. Many different technologies have 
been, and still are being, developed to collect the information contained in these 
diverse properties of proteins. Although, it should be noted that there is no single 
technology platform that can satisfy all the desired proteomic measurements and that 
there is no mature, “true” proteomic technology. In practice, proteomic approaches 
still focus on limited aspects of the broad menu of protein attributes, which in most 
studies are abundance, identification, and sequence. Comprehensive understanding 
of the (mal)functioning of living cells will require a quantitative, dynamic description 
of the stoichiometry of protein complexes or networks, the kinetics and energetics 
of formation, and the functional consequences of each protein(complex) in a cellular 
pathway [4]. 
Several exciting new developments in the field of MS will gain in importance and 
increase its impact on biological sciences. Although the measurement of sequence 
tags (ESTs) by LC-MS/MS techniques is a very powerful tool in proteomics for protein 
identification, alternatives have been introduced which omit the tandem MS step and 
make use of the fact that many tryptic peptides have unique masses [59]. The group of 
Smith has pioneered this strategy by making use of high resolution Fourier-transform 
cyclotron resonance (FT-ICR)-MS [102]. This novel MS application has the potential to 
expand the scope of proteomics from quantification and identification of the most 
abundant proteins to real proteome-wide determinations [103, 104].The methodology 
increases the throughput of measurements at the whole proteome level using 
peptide accurate mass and time of elution tags (AMT tags) as markers for proteins 
[103]. The approach has the advantages that it extends the sensitivity, dynamic range, 
comprehensiveness, and throughput of proteomic measurements [59] For example, 
Lipton et al. detected more than 50,000 putative peptides in a certain bacterium 
[105]. They showed also that this approach might be easily combined with stable 
isotope labelling, making it amenable for quantitative proteomics [59, 105]. When 
nanoLC–MS/MS and FT-ICR-MS will increasingly be used for high-throughput analysis 
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of complex protein samples, a major challenge lies in the consistent, objective and 
transparent analysis of the large amounts of data generated by such experiments and 
their dissemination and publication [106]. The currently available computational tools 
have recently been reviewed including discussion of the needs for statistical criteria in 
the analysis of large proteomic datasets [106].
A second novel MS application is the direct coupling of biomolecular interaction 
analysis (BIA) with MALDI-TOF-MS or nanoLC-MS/MS. This enables us to link protein 
detection, capture, and analysis of binding kinetics, with the measurement of protein 
and peptide masses and protein identification [107, 108]. The unique feature of the 
BIA-MS technology is the real-time monitoring of protein-protein (protein-DNA or 
protein-RNA) interactions by surface plasmon resonance and the simultaneous MS 
or MS/MS identification of the protein components. Another potential of the BIA-MS 
technology is the discovery of PTMs of the interacting protein, which determines the 
interaction with other molecules. A third example of an advanced MS technology 
is surface-enhanced laser desorption-ionization retentate chromatography (SELDI-
RC)-MS, by which proteins can be captured on chemically modified chip surfaces 
(ProteinChip Array from Ciphergen Biosystems Inc, Fremont CA) that are derivatized 
with chromatographic separation moieties, such as ion exchange, and hydrophobic 
surfaces [109-111]. The chip surface serves to fractionate and enrich for subpopulations 
of proteins from complex protein mixtures, thereby simplifying analysis. 
Protein microarrays, another emerging class of proteomic technologies, have broad 
applications for discovery and quantitative analysis [112]. The concept of protein 
expression profiling arrays, inspired by the success of DNA microarrays, is now most 
advanced in its development [113]. Nevertheless, to be successful, design and use 
must take in consideration enormous analytically challenges. There are several reasons 
why DNA microarray technology cannot readily be adapted towards development of 
protein microarrays [113]. In contrast to the straightforward design and synthesis of 
gene-specific capture probes, based on simple base-pair rules and standard solid phase 
phosphoramidite chemistry, capture agents for protein arrays are far more complicated 
and require significantly more time for development. Currently, the preferred capture 
agents for protein expression profiling arrays are antibodies or antibody fragments 
which have a very long and costly development time [113]. Furthermore, protein 
expression levels span a huge range (up to 8 orders of magnitude). To avoid multiple 
measurements of the same sample at different dilutions, protein capture agents 
with different affinities have to be developed to address such dramatic differences in 
expression level. It appears also to be difficult to immobilize protein capture agents 
onto the array while retaining the integrity of their 3-D structures and binding activity, 
an issue not relevant to the production of DNA arrays. 
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Interplay of genomics, transcriptomics and proteomics
The dramatic advances in the nature and throughput of molecular technologies are 
making possible the global, genome-wide analysis of changes in DNA (genotyping), 
RNA expression and protein expression. A future approach that integrates various 
“omic” platforms and their data is key to unravelling the complexity and to gain 
a comprehensive understanding of physiology and pathophysiologies [114]. The 
total complement of mRNA in a cell or tissue at any given moment constitutes its 
transcriptome. A transcriptome forms the template for protein synthesis, resulting in 
the corresponding proteome. Unlike proteomics, of which the technologies still are 
in infancy, transcriptomics a rather robust and high through-put technology capable 
of simultaneously quantifying tens of thousands of defined mRNA species in a 
miniaturized, automated format [114]. Yet, with the numerous advances in proteomics 
technologies, a first challenge will be the parallel profiling of transcripts and proteins 
on a global scale. Despite the obvious attraction of integrating knowledge on global 
scale from genomic and proteomic technologies, there will be many practical 
(dynamic range) and biological  (mRNA and protein turnover, alternative splicing , 
PTMs, etc) differences involved in this application. Nevertheless, the transcriptomic 
date can be compared and contrasted provided the studies are carefully designed 
and interpreted. Some reports on cross comparison of mRNA and protein expression 
are already available e.g in yeast Saccharomyces cerevisi [115] . These authors identified 
997 genes with significantly altered mRNA levels. A mean correlation of r = 0.6 was 
found between corresponding mRNA and protein levels, which is quite high taking 
into account the above-mentioned considerations.
Both the generation and the analysis of proteomic data are becoming increasingly 
widespread, and as explained above, the field of proteomics is moving rapidly towards 
high-throughput approaches. The representation of gene and genome sequence 
data is already fairly well standardized and the databases and tools for their analysis 
are widely used [116]. However, the situation is less developed for transcriptome, and 
especially proteome, data. This is because both fields are relatively young and rapidly 
evolving and they produce data that are only meaningful in the context. For example, 
there are many different subsets of total proteome of an organism, just as there are 
different patterns of transcription, distinguished by cell type and condition. Thus, there 
exists a need for public repositories that contain details of proteomic experiments 
as opposed to the gel image databases that exist currently which offer little readily 
accessible information about where samples came from and how, by whom, spots of a 
gel were analysed. Recently, some journals have begun to require that papers reporting 
transcriptome experiment results be accompanied by the MIAME-defined minimum 
set of information about the microarray experiments [116]. Likewise, a systemic 
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approach to modelling, capturing, and disseminating proteomics experimental data 
has been reported. Once these models for transcriptomic and proteomic databases 
are generally accepted and implemented, the integration of proteomic databases 
with each other and with other resources, such as sequence databases can proceed. 
It is evident that linkage between and integration of different protein and nuclei acid 
databases, along the related annotation, will greatly improve the information content 
and knowledge base with regards to protein data [117].
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Abstract
Right ventricular (RV) hypertrophy is an important problem in congenital heart disease. 
We determined the alterations in phenotype that occur in the initial phase of RV 
hypertrophy and their possible correlations with the degree of hypertrophy. Therefore 
we performed a differential proteomic profiling study on RV hypertrophy using an 
animal model of pulmonary artery banding (PAB) in parallel with hemodynamic 
characterization. RV homogenates were subfractionated in myofilament and 
cytoplasmic proteins which subsequently were separated by two-dimensional 
gel electrophoresis (2-DE), excised and analysed by mass spectrometry (MS). The 
cytoplasmic fraction showed expression changes in metabolic proteins, indicative for 
a shift from fatty acid to glucose as substrate for energy supply. Upregulation of three 
HSP-27’s (1.9, 1.7 and 3.5 fold) indicated an altered stress response in RV hypertrophy. 
Detailed analysis by immunoblotting and MS showed that two of these HSP-27’s were 
at least phosphorylated on Ser15. The myofilament fraction showed upregulation of 
desmin and α-B-crystallin (1.4 and 1.3 fold respectively). This alteration in desmin was 
confirmed by 1-DE immunoblots. Certain differentially expressed proteins, such as 
HSP-27, showed a significant correlation with the RV weight to body weight ratio in 
the PAB rats, suggesting an association with the degree of hypertrophy. 
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Introduction
The incidence of congenital heart disease (CHD) is approximately 6 per 1,000 live 
births [1]. Because of the ongoing improvement in the treatment of patients with CHD, 
the number of patients reaching adulthood after correction or palliation of complex 
congenital heart disease is steadily increasing over the last decades [2]. In many of 
these patients, residual loading abnormalities , including pressure overload, have 
been imposed on the right ventricle (RV). Thus, RV function has been demonstrated 
to be an important determinant of long-term outcome after (surgical) correction for 
complex CHD [3]. Distinct phenotypes could be associated with RV hypertrophy and 
ultimate RV failure due to RV pressure overload. Specific changes in protein expression 
could provide us with more insight into the molecular mechanisms involved in (the 
development of ) RV dysfunction. Results of proteomic analysis of the failing human 
and animal heart are available but most of these studies pertain to the dilated-type of 
left ventricular (LV) failure [4]. There are no studies that have systematically evaluated 
the alterations in protein expression and PTMs in the pressure-overloaded RV in 
vivo. Although proteomic analysis of RV biopsies from CHD patients would be most 
favorable, this material can rarely be obtained. Furthermore, such study design would 
be complicated by difficulties in obtaining adequate control tissue. 
Therefore, the aim of this animal study was to analyze the changes in the RV proteome 
resulting from chronic RV pressure overload in parallel with in-depth characterization of 
RV hemodynamics and hypertrophy. For these purposes we set up a young rat model 
of RV hypertrophy due to chronic pressure overload by means of pulmonary artery 
banding (PAB). Invasive hemodynamic measurements using pressure-volume loop 
analysis were performed before excision of the heart. 2-D-PAGE was used for separation 
and quantification of proteins. Prior to this, subfractionation of RV homogenates 
into cytoplasmic and myofilament (-associated) proteins was performed in order to 
enhance the protein coverage. Proteins that were found to be significantly up- or 
downregulated in the hypertrophic RV were subsequently analyzed with the MS for 
identification. The analysis of some of the key protein changes, such as those of HSP-
27 and myofilament-associated desmin, were substantiated with immunoblot and/or 
phosphorylation analysis.  Finally, data on relative protein expression were linked to the 
degree of hypertrophy in order to investigate possible correlations.
Material and methods
All experimental procedures and protocols used in this study were reviewed and 
approved by the institutional animal care and use committee and are in accordance 
with the National Institutes of Health “Guide for the care and use of laboratory animals” 
(NIH publication No. 85-23, revised 1996).
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Male Wistar rats (Harlan, Zeist, The Netherlands) underwent PAB or sham operation. 
The first group consisted of 6 rats that underwent PAB at the age of 8 weeks. A second 
group consisted of 6 age-matched control rats that received a sham operation at the 
same age. After the initial operation (Sham or PAB) the animals were housed for a 
period of 6 weeks at a 12h-light/dark cycle with standard rat chow and water available 
ad libitum. 
pulmonary artery banding procedure
Anesthesia was induced with pentobarbital (60 mg/kg i.p.). After intubation, the animals 
were mechanically ventilated via a volume-controlled respirator (3 ml; 45 strokes/min) 
with oxygen enriched room air. Positive end-expiratory pressure was maintained with 
4 cm H
2
O. A lateral thoracotomy was performed and the main pulmonary artery (PA) 
was exposed. An 18 Gauge needle was placed alongside the PA and a 4-0 silk suture 
was tied around the PA and the needle. Next, the needle was rapidly removed, setting 
a fixed diameter for the PA. The combination of a fixed banding around the PA and 
the growth of the animal eventually resulted in a constrictive narrowing of the PA. 
This will subsequently lead to increased RV pressures (see later). After the banding 
procedure the thorax was closed in layers and extra oxygen was supplied during the 
first hour post-operatively in order to let the animals recover from the procedure. The 
sham animals underwent the same procedures except for banding of the PA.
Hemodynamic measurements
After a housing period of 6 weeks, hemodynamic measurements were performed. 
The study protocol was the same for both sham and PAB animals. After induction 
of anesthesia, as described above, the heart was exposed by thoracotomy and a 
pressure- and conductance catheter were inserted into both ventricles to measure 
both ventricular pressures and volumes simultaneously. From these measurements, 
pressure-volume loops of RV and LV were constructed out of which the following 
parameters were derived: heart rate, cardiac output, stroke work, dP/dt-max, and 
ventricular end-systolic and end-diastolic pressures. At the end of the hemodynamic 
measurements the animals were killed and the heart was rapidly removed and divided 
into RV, LV, right atrium, left atrium and septum. Tissues were weighed and stored at 
-80°C. 
Tissue Sample preparation
RV tissue was homogenized in 100 µL of sample buffer (15 mM Tris-HCl, 1 mM EGTA, 
protease inhibitor cocktail Complete™ (Roche, Mannheim, Germany)) with a micro-
dismembrator (Braun, Melsungen, Germany). Subsequently, protein concentration was 
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measured with the DC protein assay (BioRad, Hercules, CA, USA). Homogenates were 
stored at -80°C. Subfractionation of the homogenates (600 µg) was achieved by adding 
5% Triton X100 (v/v 1:4), incubation for 1 hr at 4°C and subsequent centrifugation for 
15 min at 13.400 x g (4°C). The first supernatant (cytoplasmic fraction) was collected 
and the pellet (myofilament fraction) was resuspended in 10 µl 1 % Triton X100 
and centrifuged. The second supernatant was added to the first, completing the 
cytoplasmic fraction. 
Two-Dimensional Electrophoresis
Isoelectric focussing was performed using immobilized pH gradient (IPG) strips 
(Amersham Biosciences, Little Chalfont, Buckinghamshire, UK) with a nonlinear pH 
range of 3-10. Rehydration buffer (350 µL: 7.8 M urea, 2.2 M thiourea, 0.28 % CHAPS, 0.9 
% Triton X100, 11.1 % isopropanol, 13.9 % water saturated isobutanol, 5.6 % glycerol, 
protease inhibitor cocktail Complete™ (Roche), a few grains of bromophenol blue, 69 
mM DTT, 0.6% (v/v) Biolytes) was added to both subfractions. The homogenates were 
applied to the IPG strips and rehydration was performed overnight at room temperature 
in a reswelling tray. Next the strips were focused in a Protean IEF Cell (BioRad) according 
to the following protocol: 250 V; 1hr, 500 V; 1 hr and 8,000 V until 60 kVh was reached. 
Next, the IPG strips were equilibrated in SDS-equilibration buffer (50 mM Tris-HCl pH 
8.8, 6 M urea, 30 % glycerol, 2 % SDS) with the addition of DTT  (10 mg/mL) for 15 min, 
followed by 15 min in the same buffer with the addition of iodoacetamide (25 mg/
mL). SDS-PAGE was performed (180 mm x 180 mm x 1 mm polyacrylamide gel (12%)) 
using the Protean II XL Cell System (BioRad). The IPG strips were sealed in place with a 
1 % agarose solution, together with a protein mass standard. The second dimension 
electrophoresis (2-DE) was carried out at 25 V/gel for 1 hr and next 24 mA/gel and was 
stopped when the bromophenol blue front reached the bottom of the glass plate 
(total duration 4-6 hrs). Temperature was kept constant at 25°C by a cooling unit.
After 2-DE separation, the gels were fixed overnight in 40 % ethanol and 10 % acetic 
acid. Next, the gels were washed in distilled water. Coomassie Blue staining was 
performed for minimal 24 hr in a 34 % methanol, 17 % (NH
4
)
2
SO
4
, 2 % H
3
PO
4
 and 0.066 
% Coomassie Blue G-250 solution. 
Analysis of 2-DE gels
The Coomassie Blue stained gels were scanned with a GS-800 calibrated densitometer 
(BioRad) and imaged and analyzed with PDQUEST software (BioRad). In PDQUEST, the 
6 images of the sham RV’s and the 6 images of the hypertrophic RV’s were compared. 
Normalization of the gels was based on the total staining density of the image. 
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protein identification
Significantly up-or downregulated spots were excised in duplicate from the Coomassie 
Blue stained gels. Subsequently, these gel-plugs were destained using a destaining 
solution (1 g (NH
4
)HCO
3
, 175 ml distilled water, 75 ml acetonitril) until colorless. 
Subsequently, the gel-plugs were dried using a centrifugal evaporator. The gel-plugs 
were incubated overnight with trypsin (ultra sequencing grade, Promega, Madison, 
WI, USA) at room temperature. Trypsin digestion was stopped by adding a solution of 
1:2 acetonitrile and 0.1 % trifluoroacetic acid to the gel-plugs. This sample solution was 
co-crystalized with a matrix (6 mg alpha-cyano-cinnamic-acid, 1 ml acetonitrile) onto a 
400 µm anchorchip plate and air-dried before loading into the MALDI-TOF MS (Bruker 
Daltonics, Billerica, MA, USA). When necessary, the QTOF MS/MS (Waters, Milford, MA, 
USA) was used for generating peptide mass fingerprints. Peptide masses were used 
to search the MASCOT protein database (http://www.matrixscience.com). The Swiss 
Prot database (http://www.expasy.org) was searched to obtain further details on the 
proteins that were identified. When the confidence of identification was minimal or 
when there was a lack of protein identification the Q-TOF MS/MS was used for protein 
identification.
Alkaline phosphatase treatment
Alkaline phosphatase (Boehringer Mannheim, Mannheim, Germany) treatment was 
applied to 3 consecutive spots (1103, 1104, and 2106) which were suspected to be 
phosphorylated. The enzymatic dephosphorylation protocol was adapted from Larsen 
et al. [5]. Briefly, the alkaline phosphatase treatment was performed directly on the 
MALDI target plate. The original samples were spotted (0.5 µL) on the MALDI target 
plate followed by alkaline phosphatase (0.05 U in 50mM NH
4
CO
3
) treatment. The 
treated samples were placed for 30 min. at 37 °C and prevented from drying. Next, the 
samples were acidified by adding 0.5 µL of 5% TFA and co-crystallized with a matrix 
(alpha-cyano-cinnamic-acid) . MS spectra from untreated and treated spots were 
compared.
Western blotting
Western blotting was used to add confidence to the data on the differential expression 
of two key proteins observed after 2-DE separation of both fractions. From the 
myofilament fraction the expression of desmin was analyzed. From the cytoplasmic 
fraction the expression of total and phosporylated (P-Ser-15) HSP-27 was analyzed.
Myofilament fractions were resuspended in 1% SDS with protease inhibitor. An 
aliquot was mixed with Laemmli loading buffer and heated for 5 minutes at 95°C. 
Clear supernatants were used to measure protein concentration (BioRad RcDc 
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kit). The cytosolic fractions were also mixed with the Laemmli loading buffer and 
subsequently heated at the same temperature as the myofilament fraction. Proteins 
were separated by 1D-PAGE, using 10% (desmin) and 15% (HSP-27) gradient gels. 
Samples were reheated for 5 minutes at 95°C and 20 µg of protein was applied per 
sample. Proteins were blotted overnight at 40V onto PVDF membranes (Immunoblot, 
BioRad). Blots were blocked in TBS with Tween (TTBS)-buffer (10 mmol/L Tris-HCl pH 
7.6, 150 mmol/L NaCl, 0.1% Tween) supplemented with 0.5 % nonfat milk powder for 
1 hr at room temperature and incubated with the diluted primary antibodies for 1 
hr at room temperature and overnight at 4°C. The following primary antibodies were 
used: Desmin mouse monoclonal DE-U-10 1:5000 diluted (Sigma, St. Louis, MO, USA), 
total HSP-27 and P-HSP-27 (Ser15) rabbit polyclonal each 1:1000 diluted (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). After washing with TTBS, blots were incubated 
with 1:4000 diluted goat anti-rabbit conjugated horseradish peroxidase (Pierce) in 
TTBS buffer. Results were visualized by recording the ECL signal (Pierce Biotechnology, 
Rockford, IL, USA) on film (Hyperfilm™ ECL, Amersham Biosciences) and quantitated 
with a GS-800 calibrated densitometer (BioRad).
Additionally, western blotting on 2-DE gel parts, cut out at the 27 kDa mobility region, 
were performed with the above described antibodies against total and phosphorylated 
(Ser15) HSP-27 to specifically look at the spot nrs 1103, 1104 and 2106 (compare with 
Figure 2).
Statistics
The statistical comparison software within PDQUEST (Mann-Whitney) was used for 
identification of significantly up-or downregulated spots when comparing sham gels 
to PAB gels. The statistical software program SPSS (version 10.1 for Windows, Microsoft) 
was used to re-evaluate the Mann-Whitney statistics and to calculate exact p-values. 
Correlation data between the individual proteomics spot intensities and parameters of 
RV hypertrophy were also calculated in SPSS by means of a linear regression analysis. 
Data are presented as mean ± SEM. A p-value < 0.05 was considered statistically 
significant.
Results
Degree of hypertrophy and hemodynamics.
RV and right atrium weights relative to body weight (BW) were significantly increased 
(respectively 1.8 an 1.6 –fold) in the PAB animals after 6 weeks, which demonstrates the 
presence of a robust hypertrophic response (Table 1). RV end-systolic pressures were 
significantly increased in the PAB animals (29 ± 2 vs. 66 ± 8 mmHg, p<0.01) as well as 
the RV end-diastolic pressures (5 ± 1 vs. 10 ± 2 mmHg, p<0.01), stroke work (5472 ± 
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597 vs. 12515 ± 2176 mmHg·μl, p<0.05) and the dP/dt-max (1442 ± 107 vs. 3435 ± 
359 mmHg/s, p<0.01). Heart rate did not differ between sham and PAB animals (309 
± 10 vs. 297 ± 12 bpm, p=NS), as well as the cardiac output (70 ± 4 vs. 57 ± 6 ml/min, 
p=NS). LV function was not affected as indicated by LV end-systolic pressures (96 ± 
7 vs. 107 ± 7 mmHg, p=NS), end-diastolic pressures (13 ± 2 vs. 11 ± 3 mmHg, p=NS), 
stroke work (16540 ± 1617 vs. 17798 ± 1929 mmHg·μl, p=NS), and the dP/dt-max (6331 
± 503 vs. 5559 ± 795 mmHg/s, p=NS). Clinically, the rats did not show clear signs of 
RV failure. Moreover, an increase in liver weight was not observed in the PAB group as 
compared to the sham group (14.0 ± 0.8 vs. 14.6 ± 0.5 g, p=NS). These results indicate 
a compensated state of hypertrophy. 
Table 1: Heart and bodyweight characteristics of the study groups
Weights Sham (n=6) PAB (n=6) P value
BW start (g) 212 ± 5 206 ± 9 NS
BW end (g) 376 ± 16 374 ± 13 NS
RA/BW (mg/g) 0.13 ± 0.01 0.21 ±  0.03 0.02
RV/BW (mg/g) 0.58 ± 0.02 1.03 ± 0.05 < 0.01
LA/BW (mg/g) 0.05 ± 0.00 0.05 ± 0.00 NS
LV/BW (mg/g) 1.38 ± 0.03 1.42 ± 0.05 NS
Septum/BW (mg/g) 0.66 ± 0.02 0.71 ± 0.03 NS
Data presented as average ± SEM. P-value < 0.05 (Student’s T-test) was considered significant. BW = body 
weight, RA = right atrium, RV = right ventricle, LA = left atrium, LV = left ventricle, NS = non-significant
Reproducibility of subfractionation and 2-DE
The reproducibility of the 2-DE was tested. Therefore, 4 gels were run out of one pooled 
cytoplasmic fraction. With the image analysis, described in Methods, we matched 304 
spots across all 4 gels. The coefficient of variation for all spot intensities was found to be 
15%, which is well within the acceptable range of technical variation [6]. Furthermore, 
the spot intensities showed a high correlation (r2=0.94) among all gels. These gel-to-
gel correlations were comparable with data reported in literature [7].
We also evaluated the percentage of spill over between both the cytoplasmic 
and myofilament extracts. The myosin light chain 1 and 2 proteins are parts of the 
myofilaments. Our extraction method resulted in an average spill over of these proteins 
into the cytoplasmic fraction of 2%, which was relatively constant among the 2-DE gels 
of sham and PAB group. For typical cytosolic proteins such as malate dehydrogenase 
and lactate dehydrogenase, an average spill over of 6% to the myofilament fraction 
was observed which likewise was constant comparing all 2-DE gels from both animal 
groups. 
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protein changes in the cytoplasmic fraction
An example of the pattern of proteins from normal rat RV tissue separated by 2-DE 
is shown in Figure 1. On average a total of 363 protein spots were matched. Several 
spots were clustered and non-distinguishable and, therefore, were not included in 
the analysis. Most of these spots reside at the basic side of the gel as can be derived 
from Figure 1. After comparison of the 2-DE patterns from all sham vs. PAB animals we 
identified a group of 25 protein spots that were significantly up-or downregulated. 
Spots in the 2-DE gels unique to either control or PAB 2-DE patterns were not observed. 
Figure 1: 2-DE image of Rv cytoplasmic fraction
Representative image of a 2-DE gel resembling the cytoplasmic subproteome of a normal rat right ventricle. 
More information on the labelled protein spots is given in table 2.
Out of the 25 altered protein spots, 20 proteins were identified. For the 5 remaining 
spots, no adequate peptide mapping could be performed either due to too low 
amount of protein or to technical limitations. The protein alterations were divided into 
three categories: 1) metabolic proteins, 2) stress proteins, and 3) miscellaneous. A list 
of the identified proteins together with their accuracy of identification as indicated by 
the Mowse score and significance of up- or downregulation is given in Table 2. 
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Table 2: List of identified differentially expressed proteins in the cytoplasmic fraction
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Identification was achieved using MALDI-MS in combination with the Mascot search engine (www.
matrixscience.com). The search was performed in the NCBI database (species: rattus). 
a) Mann-Whitney test was used for statistical comparison
b)  Mascot Mowse score of 58 is the threshold for p<0.05  
c) Determined by MSDB database search (instead of NCBI); Mowse score of 54 (instead of 58) is the threshold 
for  p<0.05
d) Identification using (own) 2-DE map comparison
e) Observed pI different from theoretical pI (Δ  pI > 0.5)
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One particularly interesting finding was the presence of 3 spots that were identified as 
HSP-27 (respectively 1.9, 1.7 and 3.5 fold upregulated in the PAB group, see also Figure 
2). To add confidence to this observation, western blotting using various antibodies 
against HSP-27 on 1-DE separated cytoplasmic fractions was performed (Figure 3 A). 
When using an antibody against total (unphosphorylated and phosphorylated) HSP-
27, a 1.5 fold upregulation was found. However, the signals were recorded at a lower 
molecular mass range (22-23 kDa) compared to the Coomassie blue stained and 
MS-identified HSP-27 spots on 2-DE. The antibody against a phosphorylated form of 
HSP-27 (P-Ser15) revealed a marked (3.6 fold) upregulation of recorded signal at the 
mobility range of 27 kDa. Additionally, western blotting on 2-DE at the mobility range 
of 27 kDa was performed (Figure 3 B). This analysis showed that all three HSP-27 spots 
(1103, 1104 and 2106) reacted with the antibody against total HSP-27, whereas only 
spot nrs. 1103 and 1104 reacted with the antibody against P-HSP-27-Ser15. 
Figure 2: Differential expression of three HSp-27’s on 2-DE
Enlarged 2-DE gel images of the individual right ventricle cytoplasmic subproteomes of 6 sham and 6 PAB 
rats in order to show the differential expression of three spots identified as HSP-27 at the 27 kDa mobility 
range with apparent pI values of 5.4, 5.6 and 5.8.
Faber.indd   63 28-02-12   12:48
Chapter 3 Proteomic Changes in the Pressure Overloaded Right Ventricle after 6 Weeks in Young Rats
64
Figure 3: Western blots of desmin and HSp-27 species
A. Western blots of desmin (myofilament fraction; ECL signal is 1.4 fold upregulated in PAB), total HSP-27 
(ECL signal is 1.5 fold upregulated in PAB), HSP-27 phosphorylated at Ser-15 residue (ECL signal is 3.6 fold 
upregulated in PAB). All HSP-27 1-DE separations are from cytoplasmic fractions. Notice that no ECL signal 
is found in the 27 kDa mobility range with the antibody against total HSP-27, likely due to the relative low 
amount of right ventricular cytoplasmic protein which was loaded in the wells of the 1-DE gels (20 µg) 
B. Western blots of 27 kDa mobility area of 2-DE gels using the same antibodies as in A. The upper ECL image 
shows three spots reacting with the antibody against total HSP-27. These spots comigrate with the three 
HSP-27s detected by Coomassie blue as described in Figure 2. The lower part shows that two out of these 
three spots are reacting with the antibody against phosphorylated HSP-27 at the Ser-15 residue. Notice that 
350 µg of right ventricular cytoplasmic protein is loaded on to the 2-DE gels.
To further strengthen the hypothesis that the HSP-27 spots were phosphorylated we 
applied on-target enzymatic dephosphorylation of the trypsin digested spots. First, 
we recorded an MS spectrum from the original sample and thereafter one was made 
from the alkaline phosphatase treated peptide digest. By comparing these spectra we 
identified a HSP-27 fragment peptide at a m/z ratio of 2098 in the original spectrum of 
all spots which shifted leftwards to a m/z ratio of 2018 in the spectrum of the treated 
sample. This was observed for HSP-27 spot nrs. 1103 and 1104 but not for spot nr. 2106 
(Figure 4). The leftward shift of approximately 80 Da is indicative for the presence of a 
phosphorylated peptide which indeed carries Ser-15. 
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Figure 4: Identification of the phosphorylation site in the differentially expressed HSp-27’s
A. MALDI-MS spectrum of one of the phosphorylated HSP-27 spot after in gel digestion with trypsin. The 
peaks used for identification (Mascot) are labelled with the precise  values.
B. The upper panel shows a part of the MS spectrum of a phosphorylated HSP-27 spot before on-target 
treatment with alkaline phosphatase. After enzymatic dephosphorylation the peak corresponding to the 
phosphorylated peptide shifted leftwards (lower panel). This mass shift of 80 Da corresponds with the 
removal of one phosphate group. Similar phosphopeptide results were obtained with HSP-27 spot nrs 1103 
and 1104 which refer to Figure 2.
C. The sequence coverage of HSP-27 from spot nr 1103 (compare Figure 2) by peptide ion signals in the 
mass spectrum. The peptide sequences corresponding to the z values indicated in A are given in bold. The 
sequence coverage is 52%. The peptide fragment (referring to  value 2098.3 in B), including its most likely 
phosphorylation site Ser-15, is given in italic and underlined.
Changes in myofilament protein expression
Figure 5 shows a typical example of a 2-DE separation pattern of the myofilament(-
associated) proteins from the RV of a sham-operated rat. It became clear that the 
separation of the myofilament subfraction is complicated by too wide differences 
in relative expression levels of the bulk of myofilament components, such as myosin 
binding protein C, actin, tropomyosin and troponins on one hand and the associated 
proteins, such as those of the cytoskeleton, on the other hand [8, 9]. Nevertheless, 
on average a total of 211 protein spots could be properly matched. As with the 
cytoplasmic fraction, many clustered spots were excluded from the analysis. The 
comparison of the 2-DE maps between sham and PAB animals resulted in the detection 
of 13 altered protein spots, of which 7 spots were upregulated. With the help of Q-TOF 
MS/MS we were able to identify 8 protein spots including one which appeared to be 
a contamination. Interestingly, among the altered proteins, an upregulation of both 
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desmin and α-B-crystallin (CryAB) was found (1.4 and 1.3 fold respectively) which was 
substantiated for desmin by immunoblotting of myofilament fractions separated 
on 1-DE (Figure 3). Besides these respectively intermediate filament and chaperone 
proteins, also alterations in apparent non-structural proteins like α-enolase were found. 
Table 3 shows a list of the differentially expressed (identified) proteins, including details 
on identification accuracy and statistical evaluation. 
Figure 5: 2-DE image of Rv myofilament fraction
Representative image of a 2-DE gel resembling the myofilament subproteome of a normal rat right ventricle. 
More information on the labelled protein spots is given in Table 3.
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Table 3: List of identified differentially expressed proteins in the myofilament fraction
% sequence coverage 13 17 21 13 25 23 32
Mowse threshold  p 
< 0.05 2
9 54 30 54 30 31 31
Mowse Score 93 87 31
7
62 25
9
26
6
28
6
Theoretical
pI
5.
16
 d
5.
21
6.
16
6.
33
6.
84
7.
60
 d
7.
57
Mw
17
58
4
53
39
0
47
42
8
61
42
8
19
94
5
27
89
8
21
13
1
p-valuec)
0.
01
6
0.
01
0
0.
02
5
0.
02
5
0.
02
5
0.
01
6
0.
03
7
Change in intensity 
pAB/sham
-1
.9
 ±
 0
.3
6 
(↓
)
1.
4 
±
 0
.1
8 
(↑
)
1.
5 
±
 0
.2
1 
(↑
)
2.
0 
±
 0
.4
0 
(↑
)
1.
3 
±
 0
.1
1 
(↑
)
-1
.9
 ±
 0
.5
2 
(↓
)
-2
.8
 ±
 1
.1
0 
(↓
)
protein accession 
number
gi
 | 
20
80
61
53
gi
 | 
38
19
76
76
gi
 | 
69
78
80
9
gi
 | 
20
13
56
83
gi
 | 
57
58
0
gi
 | 
51
94
84
12
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27
66
79
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Identification was achieved using the Mascot search engine (www.matrixscience.com) using de NCBI 
database seach (species: rattus)
a)  Identification by Q-TOF MS/MS
b) Idenification by MALDI-MS
c) Mann-Whitney test was used for statistical comparison
d) Observed pI different from theoretical (Δ pI > 0.5)
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Correlations with the degree of hypertrophy
In order to investigate potential relationships between the observed protein changes 
and the degree of hypertrophy, we analyzed the significances of correlations between 
the proteomic data (individual relative intensities of each spot) and RV weight to BW 
ratio in the PAB group (Figure 6). This approach resulted in the detection of 4 spots 
that were significantly correlated with the degree of hypertrophy. One spot, HSP-27 
(spot number 1103/cytoplasmic fraction), was positively correlated with the degree 
of hypertrophy (r2=0.89, p<0.01). Furthermore, both spots containing β-enolase (5502 
and 6501) were negatively correlated with the RV weight to BW ratio (r2=0.99, p<0.01 
and r2=0.87, p<0.01 respectively). From the myofilament fraction only one spot (7003, 
NADH dehydrogenase ubiquinone) was found to be negatively correlated with the 
degree of hypertrophy (r2=0.76, p<0.05). 
Figure 6: Correlation with the degree of hypertrophy
Individual correlations between relative protein intensity (ppm) and the degree of hypertrophy (RV/BW) in 
PAB animals. Spot 1103 = HSP-27, 5502 = β-Enolase, 6501 = β-Enolase and 7003 = NADH dehydrogenase 
(ubiquinone) beta subcomplex.
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Discussion
In this study we demonstrate, for the first time, that 6 weeks of RV pressure overload in 
young rats leads to alterations in the proteome as studied by means of a differential 2-DE 
and MS analysis. Since the RV hypertrophy was well characterized by hemodynamic 
measurements, these alterations in the proteome are occurring in a compensated state 
of RV hypertrophy. We showed that the majority of the protein changes that occur in 
the cytoplasmic fraction of the hypertrophied RV belong to the category of metabolic 
and stress related proteins. Two out of the three upregulated HSP-27 species appeared 
to be phosphorylated, most likely on the Ser-15 residue, as shown by immunoblotting 
and MS analysis. The alterations found in the myofilament subproteome concern 
metabolic proteins, intermediate filament protein desmin, and the desmin-associated 
chaperone protein CryAB, which in principle all are myofilament associated proteins. 
Interestingly, significant correlations between the degree of hypertrophy (RV weight 
to BW ratio) and relative RV content (% staining intensity on 2-DE gel) of several of the 
differentially expressed proteins were found. 
From Table 2 one can appreciate that at least 20 proteins are changed significantly in 
the hypertrophic RV compared to the normal RV. The majority of protein changes in 
the cytoplasmic fraction concern alterations in the metabolic proteins. Metabolism 
related changes include a decrease in beta-oxidation enzymes (spots 4602 and 5104 
as in Table 2) and an increase in glycolytic enzymes (spots 1203, 5106, and 7605 as in 
Table 2). In the normal heart the myocardium preferentially oxidizes fatty acids [10-12]. 
In various models of LV hypertrophy it was demonstrated that the energy supplying 
pathways return to a fetal state of metabolism [13-19]. This shift in metabolism is 
characterized by a decreased oxidation of fatty acids and an increased glucose 
metabolism [20-25]. The metabolic shift in energy supply from beta-oxidation towards 
glycolysis has been less well documented for the RV [26]. The results of our proteomics 
study can be interpreted to suggest that the shift in energy substrate utilization in the 
hypertrophic RV resembles the situation in the hypertrophic LV. Several mechanisms 
have been proposed that should provide an explanation for this metabolic shift, such 
as an imbalance in O
2 
supply/demand ratio in the hypertrophic hearts [27, 28].
Besides alterations in the expression of metabolic proteins, proteins involved in the 
stress response were also altered in our study. Three altered protein spots could 
be identified as HSP-27 which suggested the presence of PTMs. HSP-27 is a stress 
related protein that has received special interest in cardioprotection as well as heart 
failure. The HSP-27 protein is an actin-cap binding protein that can inhibit actin 
polymerization [29]. Its function is mainly dependent on its phosphorylation state 
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and these modifications can therefore play an important role in cardiac remodeling 
processes. The presence of HSP-27 alterations in cardiovascular diseases has been 
reported by several groups [30-32]. However, the effect of altered phosphorylation of 
HSP-27 on the development of RV hypertrophy or its influence on alterations in cardiac 
function that occur in RV hypertrophy are unknown. In the study of Scheler et al. HSP-
27 protein expression patterns of normal and failing hearts (LV) were compared [31]. 
In that study, HSP-27 expression profiling was performed using 2-DE in combination 
with immunostaining. Numerous HSP-27 containing spots were detected, which 
were located in two separate mass series (27-28 kDa and 22-23 kDa) that reacted with 
the anti-HSP-27 antibody. Multiple spots in the lower mass range were found to be 
upregulated whereas some spots from the high mass range were downregulated 
in the LV of dilated cardiomyopathy (DCM) type hearts, suggesting that some form 
of HSP-27 degradation is occurring in the failing heart [31]. In our present study we 
did not observe an upregulation of lower mass range HSP-27’s by 2-DE. However, 
an upregulation of lower mass range HSP-27’s was found by western blotting of 
1-DE separated cytoplasmic fractions using the HSP-27 antibody reacting with the 
unphosphorylated as well as the phosphorylated form. This indicates that in the rat RV 
the HSP-27’s of 22-23 kDa are less abundant, at least non-detectable with staining by 
Coomassie blue. Nevertheless, we did find an upregulation of HSP-27’s of 27-28 kDa by 
2-DE. This latter finding was confirmed by western blotting using a specific antibody 
against phospho-Ser-15 HSP-27 (Figure 3). Moreover, using MS we could observe a 
phosphorylation for two HSP-27 spots (1103 and 1104) by comparing spectra before 
and after enzymatic dephosphorylation of the Ser-15 containing peptide fragment of 
HSP-27. These data suggest that those two HSP-27 spots are at least phosphorylated 
at the Ser-15 residue. The third spot (2106) is also very likely to be modified since its 
observed pI on the gel is still different (approximate pI=5.8) from its theoretical value 
(pI=6.12). More in depth studies, specifically on the sites and degree of phosphorylation 
of HSP-27’s and its possible association with hemodynamic alterations, are needed to 
clarify the role of HSP-27 in the hypertrophic RV. 
The myofilament fraction revealed 13 protein alterations of which only 7 proteins 
could be identified as shown in Table 3. Perhaps the most interesting observation are 
the upregulations found for desmin and CryAB. The CryAB, a protein that was found 
in both myofilament and cytoplasmic subfractions, is known for its regulatory role in 
desmin distribution [33, 34]. The CryAB binds to both desmin and cytoplasmic actin 
and functions as a quality control in the formation of intermediate filaments [35]. An 
upregulation of CryAB has been found in the LV in DCM, a downregulation in end-
stage congestive heart (LV) failure [30] [36-38]. From our model of RV hypertrophy 
we can conclude that CryAB is also upregulated in the myofilament subproteome of 
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the RV. Remarkably, the CryAB was unchanged in the cytoplasmic fraction, indicating 
that the cytoplasmic concentration of this protein is not affected in RV hypertrophy. 
From several studies by Robbins et al. it can be concluded that specific desmin 
localization is crucial for optimal cardiac function [33-35, 39]. We observed an increase 
in myofilament-associated desmin in the hypertrophic RV. Altered desmin expression 
has been observed in other pressure overloaded types of cardiac hypertrophy, as well 
as familial cardiomyopathies and DCM [40-42]. However, no discrimination was made 
between cytoplasmic and myofilament fraction. In the present study we were able to 
discriminate between both cellular fractions, resulting in the detection of upregulated 
myofilament-associated desmin. This upregulation was confirmed by western blotting 
of 1-DE separated myofilament fractions.
Hemodynamic assessment shows that the relative protein expressions were studied in 
a compensated state of RV hypertrophy. This degree of hypertrophy, as expressed by 
the RV weight to BW ratio, was correlated with multiple relative protein spot intensities. 
We correlated protein spot intensities of only the PAB group with this parameter of 
RV hypertrophy. In the PAB group the RV weight to BW ratio will differ among the 
individual animals due to slightly different pressure loads and different hypertrophic 
responsiveness. Therefore, protein spots from the PAB group that show significant 
correlations between RV weight to BW ratio and the relative protein expression might 
be important in determining the hypertrophic responsiveness. Two of these proteins 
that showed such a correlation are β-enolase and HSP-27. Further evaluation of the 
exact role of these proteins and their modifications in the pathological hypertrophic 
response of the RV is needed. Nevertheless, the present data suggests that these 
specific protein spots are part of a protein signature that changes with the degree of 
hypertrophy. Additional studies with varying degrees of hypertrophy or duration of 
pressure overload are needed to underscore this hypothesis. 
Despite the fact that this study reveals important protein changes in RV hypertrophy, 
limitations of this approach should also be considered. An extensive review on 
proteomic studies and the limitations is given by McGregor and Dunn [4]. The staining 
used in this study, Coomassie blue, is well known for its good downstream compatibility 
with MS and its linearity and dynamic range making it suitable for quantitation [43-45]. 
However, the detection sensitivity is moderate compared to silver staining protocols 
limiting the protein coverage [46]. In the future, more advanced 2-DE gel based 
proteomic profiling methods may be applied to the field of cardiovascular proteomics, 
like the DIGE system. Also non-gel based quantitative proteomics methods using 
stable isotope labeling, such as ICAT, could be promising. 
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The application of a subfractionation step prior to 2-DE analysis is necessary for whole 
heart homogenates in order to reduce the sample complexity, increase the quality and 
resolution of the 2-DE gels, and to enhance the overall protein coverage [47]. In the 
present study we applied a detergent-extraction of the isolated myofilament fraction 
to pre-separate at least the myofilament(-associated) proteins from all other cellular 
proteins.
Specific limitations may apply to the study of myofilament proteins. Although desmin 
and (to a lesser extent) CryAB are known as myofilament associated proteins, many 
of the proteins identified in this study would not be expected in the myofilament 
fraction. Moreover, several myofilament proteins are known to be difficult to separate 
and/or to be quantitated by 2-DE due to their extreme pI values and/or high molecular 
weights. On the other hand, immunoblot analysis of the myofilament-associated 
desmin convincingly demonstrated the agreement between the relative intensity of 
Coomassie blue staining on 2-DE and the ECL staining on 1-DE (r2=0.71, p<0.01). In 
addition to these limitations, staining problems with specific myofilament proteins 
have been reported [48]. To overcome these limitations, RP-HPLC has been proposed 
in addition to 2-DE, to study the myofilament proteins [48].
In conclusion, we present for the first time, a proteomic analysis of RV hypertrophy 
in a hemodynamically well characterized rat model. Our study reveals many protein 
alterations in compensated RV hypertrophy, in both cytoplasmic and myofilament 
subfractions. The metabolic protein changes are consistent with a shift from fatty acid 
to glucose as substrate for the energy supply. Furthermore, the increased expression 
of phosphorylated HSP-27 species is indicative for an altered stress response. Likewise, 
changes were found in the expression of myofilament-associated proteins, such as 
desmin and CryAB. Interestingly, some of the differentially expressed proteins, such 
as HSP-27, showed a significant correlation with the RV weight to BW ratio in PAB rats 
suggesting an association with the degree of hypertrophy. 
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Abstract
In many patients with congenital heart disease, the right ventricle (RV) is subjected to 
abnormal loading conditions. In order to better understand the state of compensated 
RV hypertrophy, which could eventually progress to decompensation, we studied the 
effects of RV pressure overload in rats. In the present study we report the biventricular 
adaptation to 6 weeks of pulmonary artery banding (PAB). PAB resulted in a RV pressure 
overload to approximately 60% of systemic level and a 2-fold increase in RV mass 
(p<0.01). Systemic hemodynamic parameters were not altered and overt signs of heart 
failure were absent. Load-independent measures of ventricular function (ESPVR, PRSW, 
dP/dt
Max
-Ved), assessed by means of pressure-volume (PV) loops, demonstrated an 2-3 
fold increase in RV contractility under baseline conditions in PAB rats. RV contractility 
increased in response to dobutamine stimulation (2.5 μg/kg/min) both in PAB as in 
sham operated rats in a similar fashion, indicating preserved RV contractile reserve 
in PAB rats. Left ventricular (LV) contractility at baseline was unaffected in PAB rats, 
although LV volume in PAB rats was slightly decreased. LV contractility increased in 
response to dobutamine (2.5 μg/kg/min) both in PAB and sham rats, while the response 
to a higher dose of dobutamine (5 μg/kg/min) was blunted in PAB rats. Six weeks of 
RV pressure overload in rats resulted in a state of compensated RV hypertrophy with 
preserved RV contractile reserve, while LV contractile state at baseline was not affected. 
Furthermore, this study demonstrates the feasibility of performing biventricular PV-
loop measurements in rats.
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Introduction
Right ventricular (RV) function is an important determinant of long-term outcome 
in patients with complex congenital heart disease, chronic pulmonary obstructive 
diseases, or pulmonary hypertension. In many of these patients the RV is subjected 
to (residual) abnormal loading conditions, including pressure overload. Although 
compensated hypertrophy will develop initially, ultimately RV failure will ensue. 
The mechanisms underlying the progression from compensated RV hypertrophy 
to decompensated RV hypertrophy (ie. RV failure) have not been well defined. As 
the survival of the patients improves, a better understanding of these mechanisms 
becomes mandatory in order to be able to design preventive strategies and to time 
surgical (re)intervention in these patients.
To study the mechanisms underlying the transition from a compensated state of 
hypertrophy to a decompensated state in patients is very difficult, because invasive 
data cannot be easily obtained. For this purpose animal models may be beneficial. 
Small experimental animals, such as rats, are widely used in cardiovascular research 
since they can provide a variety of disease models including heart hypertrophy and 
failure. A major advantage of the use of these small disease models is that cardiac 
material can be easily sampled to study critically involved molecular changes over 
time and the possibility to study effects of transgenesis and gene ablation [2, 5, 
22, 23, 34]. Recently, we performed a proteomic profiling study on RV hypertrophy 
showing multiple expression and post-translational changes in metabolic-, stress-, and 
myofilament proteins [12]. To interpret these molecular findings in terms of possible 
mechanisms involved in RV remodelling, an accurate assessment of RV function is 
required, preferably by using load-independent parameters of cardiac contractility [13, 
24, 29, 30]. We present a biventricular hemodynamic characterization using pressure-
volume (PV) loops of RV hypertrophy in a rat model induced by 6 weeks of pressure 
overload as a result of pulmonary artery banding (PAB). 
Methods
All experimental procedures and protocols used in this investigation were reviewed and 
approved by the institutional animal care and use committee and are in accordance 
with the National Institutes of Health “Guide for the care and use of laboratory animals” 
(NIH publication No. 85-23, revised 1996).
Male Wistar rats (190-220 g, Harlan, Zeist, The Netherlands) underwent PAB or sham 
operation. Complete hemodynamic studies were performed in 15 animals: 6 rats 
underwent PAB at the age of 8 weeks, whereas 9 rats underwent a sham operation and 
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served as control. The animals were housed after the initial operation (ie. sham or PAB) 
for a period of 6 weeks, prior to the hemodynamic studies, in groups of 2 or 3 animals, 
on a 12/12-h light/dark cycle with standard rat chow and water ad libitum. 
pulmonary artery banding procedure
Anesthesia was induced by pentobarbital (60 mg/kg i.p.). After intubation, the animals 
were mechanically ventilated with the use of a volume-controlled respirator and 
oxygen-enriched room air. Positive end-expiratory pressure was maintained at 4 cm 
H
2
O. A left thoracotomy was performed and the pulmonary artery (PA) was carefully 
dissected free from the aorta. A silk thread was positioned under the PA and an 18 
gauge needle was placed alongside the PA. A suture was tied tightly around the 
needle and the needle was rapidly removed in order to produce a fixed constricted 
opening in the lumen equal to the diameter of the needle. The combination of a 
fixed banding around the PA and the growth of the animal will eventually result in a 
markedly increased RV afterload. After the banding, the thorax was closed in layers and 
post-operative pain relief was obtained by applying buprenorphine (15 μg/kg s.c.). The 
sham animals underwent the same procedure except for the banding of the PA.
Hemodynamic instrumentation
After a housing period of 6 weeks, hemodynamic measurements were performed. The 
study protocol was the same for sham and PAB animals.
After induction of anesthesia (pentobarbital; 60 mg/kg i.p.) the animals were intubated 
and ventilated as described above. A catheter (PE-50) was placed in the abdominal 
cavity for i.p. administration of pentobarbital for maintenance of anesthesia. Both 
femoral veins were canulated with a catheter (PE-50) for the infusion of hypertonic 
saline for calculation of the parallel conductance (see later) and for the administration of 
dobutamine. The right carotid artery was canulated with a catheter (PE-50) connected 
to a fluid-filled pressure transducer to monitor systemic blood pressures and to obtain 
samples for blood-gas analysis. The right jugular vein was canulated with a catheter 
(PE-50) for the infusion of Haemaccel (Hoechst, Behring-Werke, Marburg Germany) to 
maintain adequate fluid levels. A right thoracotomy was performed and an ultrasonic 
flow-probe (Transonics Systems Inc., Ithaca, NY), connected to a Transonics flow meter 
(TS420), was placed around the aorta and used for calibration of the conductance 
catheter (see later). A left thoracotomy was performed for maximal exposure of the 
left side of the heart to facilitate an adequate catheter insertion in the LV. For preload 
reduction, required to obtain systolic and diastolic PV-relations, a silk thread was placed 
around the vena cava inferior, just above the diaphragm. A conductance catheter (CD 
Leycom, Zoetermeer, The Netherlands) and a pressure-tip catheter (Millar Instruments, 
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Houston, TX) were inserted in the RV through the ventricular wall, at the level of the 
outflow tract, and positioned towards the apex. Similarly, conductance and pressure-
tip catheters were inserted in the LV apex and positioned along the LV long axis. The 
conductance catheters consisted of 5 segments of which, on average, 2-3 segments 
were used for measurement of ventricular volumes. Positioning of the conductance 
catheters was optimized by observing the pressure and segmental volume signals 
with appropriate phase relationships. The conductance catheters were connected to a 
Leycom Sigma-5 DF signal processors (CD Leycom) and the pressure-tip catheters were 
connected to pressure transducer units (Millar Instruments, Houston, TX). Signals were 
recorded at a minimal sample rate of 500Hz using the Conduct 2000 data-acquisition 
hard- and software (CD Leycom) installed on an IBM compatible personal computer.
Conductance catheter calibration
In order to obtain absolute volumes, the conductance catheter derived signals must be 
calibrated for parallel conductance and slope factor (α). Conductance catheters were 
calibrated as previously described. Briefly, parallel conductance was determined by the 
hypertonic saline method and slope factor α by matching uncalibrated conductance 
stroke volume with stroke volume derived from the aortic flow signal [1, 28].
Hemodynamic study protocol 
When hemodynamic stability was reached, a set of measurements was performed 
to calibrate the conductance catheter method and to assess hemodynamics and 
contractile performance in baseline conditions. Data were recorded with open chest 
at steady-state baseline conditions and during transient preload reduction. The parallel 
conductance of both ventricles was measured (in duplo) by injecting 50 μL NaCl 10% 
intravenously [28]. All measurements were made during short suspension of the 
ventilation at end-expiration. To determine inotropic reserve we infused dobutamine 
at 2.5 (dobu-2.5) and 5 μg/kg/min (dobu-5) via a pump. The same set of measurements 
as described above were performed and started at least 10 minutes after the onset of 
dobutamine infusion. Moreover, the parallel conductance was re-calculated for each 
dobutamine step since parallel conductance changes during the administration of 
dobutamine [33]. Before each set of measurements a blood sample was drawn and 
analyzed (Roche Diagnostics, Almere, The Netherlands) to ensure proper oxygenation 
and acid/base balances. 
Hemodynamic measurements and calculations
The biventricular signals were analyzed by custom made software (Circlab). The steady 
state data were averaged over two separate intervals that each consisted of at least five 
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cardiac cycles. From these steady state data the following parameters were calculated: 
heart rate, cardiac output, stroke volume (SV), end-systolic pressure, end-diastolic 
pressure, end-systolic volume, end-diastolic volume, maximal first time-derivative of 
pressure (dP/dt
Max
), and stroke work.   
PV loops acquired during vena cava occlusion were used to derive ventricular PV 
relations (Figure 1). The end-systolic point was defined as the point in the cardiac 
cycle of maximal elastance. Elastance was defined as P(t)/[V(t)-V
0
], where P(t) is the 
instantaneous pressure, V(t) instantaneous volume, and V
0
 the theoretical volume at 
zero pressure [8]. V
0
 was determined by an iterative algorithm as previously described 
by Kono et al [16]. The following relations were determined and used as parameters of 
systolic function: the end-systolic pressure-volume relation (ESPVR)[29], the dP/dt
max 
-Ved relation[24], and the preload recruitable stroke work relation (PRSW)[13]. Slopes 
and intercepts of these relations were previously validated as sensitive and relative 
load-independent parameters of ventricular function.
Figure 1: Representative right-and left ventricular pv loops 
In both sham (dotted loops) and PAB (solid loops) animals during preload reduction. The black solid lines 
represent the end-systolic PV relations (ESPVR) in both groups.
Statistical analysis
The differences in hemodynamic parameters between the control group and the PAB 
group at baseline were analyzed using a Student’s T-test. The effect of dobutamine 
stimulation for each group were analyzed using repeated measures ANOVA. Differences 
in response to dobutamine stimulation between groups were tested by repeated 
measures 2-way ANOVA. Post hoc testing, when appropriate, was performed using the 
Bonferroni correction. The software packages SPSS and SAS (PROC MIXED) were used 
for data analysis. A two-sided p-value < 0.05 was considered statistically significant. 
Data are presented as mean ± SEM
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Results
During the banding period, the rats did not show overt signs of heart failure and/or 
cyanosis. The average body weight of the PAB group at the start of the protocol did not 
differ significantly from the control (sham) group (resp. 206 ± 9 vs. 210 ± 4 g, p=NS). 
The weight gain during the 6 week housing period was similar between groups (PAB: 
168 ± 9 vs. sham: 172 ± 10 g, p=NS). Right atrial and RV weight were increased in PAB 
rats, while left heart weights were unaffected (Table 1). 
Table 1: Heart weight to body weight characteristics of the study groups. 
Weights Sham (n=9) pAB (n=6) p-value
RA/BW (mg/g) 0.13 ± 0.01 0.21 ± 0.03 <0.01
RV/BW (mg/g) 0.59 ± 0.02 1.03 ± 0.05 <0.01
LA/BW (mg/g) 0.05 ± 0.00 0.05 ± 0.00 N.S.
LV/BW (mg/g) 1.37 ± 0.04 1.42 ± 0.05 N.S.
Septum (mg/g) 0.69 ± 0.02 0.71 ± 0.03 N.S.
Values are mean ± SEM. BW=body weight, RA=right atrium, RV=right ventricle, LA=left atrium, LV=left 
ventricle, PAB=pulmonary artery banding, N.S.= non-significant
Baseline hemodynamics (Table 2)
In baseline conditions the heart rate and cardiac output did not differ between sham 
and PAB rats. The RV peak-systolic pressures in PAB rats were increased to 60% of peak-
systolic LV pressure. RV end-diastolic and end-systolic volumes were slightly decreased 
in PAB rats, although this did not reach statistical significance (p≥0.26). Both RV stroke 
work and dP/dt
max
 were increased in the PAB rats as compared to the sham group. 
The slopes of the ESPVR, PRSW, and the dP/dt
max
 -Ved relations (henceforth called the 
three PV-relations) were all steeper in the PAB rats, indicating an increased contractile 
function of the RV (Figure 2). 
In the LV the end-systolic and end-diastolic pressures were similar in both groups. The 
end-diastolic volumes were similar for both groups while the end-systolic volumes 
were decreased in the LV of the PAB rats. Both LV stroke work and dP/dt
max 
were similar 
for both sham and PAB rats. The contractility of the LV, as expressed by the three PV-
relations, was not altered in the PAB rats. 
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Table 2: Hemodynamics at baseline and during dobutamine infusion.
parameters Baseline Dobu-2.5 Dobu-5
HR sham 310 ± 8 396 ± 6 † 421 ± 10 ‡
PAB 297 ± 12 379 ± 8 † 407 ± 10 ‡
CO sham 51 ± 4 52 ± 4 63 ± 5 ‡
PAB 49 ±5 51 ± 3 53 ± 4 
SV sham 164 ± 11 132 ± 11† 149 ± 13 ‡
PAB 164 ± 13 134 ± 7 † 130 ± 7 
MAP sham 90 ± 6 89 ± 6 90 ± 6
PAB 101 ± 6 97 ± 10 92 ± 8
RV Ved sham 315 ± 44 218 ± 28† 222 ± 22
PAB 259 ± 32 223 ± 24 284 ± 36
Ves sham 151 ± 34 89 ± 19† 78 ± 10
PAB 95 ± 30 90 ± 19 118 ± 23
Pes sham 29 ± 1 34 ± 3 37 ± 4
PAB 63 ± 8 * 74 ± 8† 89 ± 7 ‡ b
Ped sham 5 ± 1 3 ± 1 4 ± 1
PAB 7 ± 1 9 ± 1† 10 ± 1 
SW sham 3963 ± 500 3746 ± 506 4879 ± 709 ‡
PAB 11087 ± 2179 * 9005 ± 1653 † a 9911 ± 1618 ‡
dP/dt
max
sham 1429 ± 94 2114 ± 128 † 2708 ± 144 ‡
PAB 3435 ± 359 * 4278 ± 458 † 4973 ± 623 ‡ 
LV Ved sham 337 ± 26 203 ± 21 † 199 ± 22
PAB 265 ± 26 168 ± 8 † 169 ± 9
Ves sham 172 ± 21 71 ± 12 † 50 ± 12 ‡
PAB 101 ± 20 * 34 ± 2 † 39 ± 6 b
Pes sham 93 ± 6 98 ± 12 111 ± 13
PAB 107 ± 7 107 ± 6 103 ± 7
Ped sham 10 ± 2 7 ± 1 8 ± 2
PAB 10 ± 3 7 ± 2 8 ± 2
SW sham 15344 ± 1634 14402 ± 2219 17502 ± 2391
PAB 18169 ± 2114 15819 ± 1469 15078 ± 1584
dP/dt
max
sham 6331 ± 503 8845 ± 764 † 10629 ± 688 ‡
PAB 5559 ± 795 8234 ± 1070 † 9109 ± 1068
Values are mean ± SEM. HR=heart rate (beats/min), CO=cardiac output (mL/min), SV=stroke volume (µL), 
MAP=mean arterial pressure (mmHg), Ved=end-diastolic volume  (µL), Ves=end-systolic volume (µL), 
Pes=end-systolic pressure (mmHg), Ped=end-diastolic pressure (mmHg), SW=stroke work (mmHg· µL), dP/
dt
max
=maximum first time derivative of pressure vs. time (mmHg·s-1)
* p<0.05 versus corresponding control in baseline
† p<0.05 versus baseline
‡ p<0.05 versus dobu-2.5   
a p<0.05 difference in dobutamine response (baseline – dobu-2.5) between sham and PAB
b p<0.05 difference in dobutamine response (dobu-2.5 – dobu-5) between sham and PAB
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Hemodynamics during dobutamine stimulation (Table 2)
Heart rate increased significantly at each step of dobutamine infusion in both PAB 
and sham rats and the magnitude of the response was similar in both groups. Cardiac 
output did not significantly change in PAB rats and increased in sham rats only at 
dobu-5. In concert, stroke volumes significantly decreased in both PAB and sham rats 
to a similar extent at dobu-2.5. Only in sham animals stroke volume increased at dobu-
5, but did not return to baseline level. No alteration in systemic blood pressure was 
observed in response to dobutamine.
In many respects, the responses of the RV to dobutamine stimulation were similar in 
PAB and sham rats. End-systolic RV pressures increased somewhat in both groups, but 
only significantly in PAB rats at each level of dobutamine stimulation. End-diastolic 
volumes decreased in response to dobu-2.5 in both groups, but the response was only 
significant in sham rats (p<0.001, PAB: p=0.32). At dobu-5 the end-diastolic volume 
increased non-significantly in PAB rats (p=0.18) and was unaltered in sham rats. 
Further analysis did not reveal any statistical trends in the response of RV end-diastolic 
volumes between PAB and sham rats at the two levels of dobutamine stimulation (all 
p≥0.20). RV dP/dt
max
 increased at each level of dobutamine in both groups. RV SW, 
however, tended to decrease at dobu-2.5 and subsequently increased at dobu-5. All 
three PV relations increased significantly in response to dobu-2.5 in both groups (Fig 
2). In contrast, at dobu-5 all three PV relations demonstrated no further significant 
alterations as compared to dobu-2.5. Although, Ees decreased slightly in both groups 
(p≥0.34) and PRSW and dP/dt
max
-Ved increased slightly (p≥0.32), no differences in the 
response between PAB and sham could be demonstrated (p>0.50). Together, these 
results indicate an increased RV contractile response at dobu-2.5, without a further 
increase at dobu-5.
The LV of the PAB animals also responded in a similar fashion to dobutamine stimulation 
as compared to its sham counterparts. LV end-diastolic and end-systolic pressures did 
not change significantly as a result of dobutamine stimulation. The LV end-diastolic 
volume and end-systolic volumes decreased in both groups equally, mainly as a result 
of the first dosage of dobutamine. Furthermore, the LV dP/dt
max 
increased in both 
groups while the stroke work remained unaltered. LV contractility increased in both 
sham and PAB rats as represented by an increase in the slopes of the PV-relations (Figure 
2). At dobu-5 only the LV of sham animals was capable of increasing contractility as 
represented by an increase in Ees and dP/dt
max
-Ved. In summary, the LV contractile 
response to dobutamine stimulation was similar for both groups at dobu-2.5 and the 
response of the PAB animals at dobu-5 was blunted. 
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Figure 2: Alterations in three load-independent parameters of contractility at baseline 
and during dobutamine infusion for the Rv (A) and Lv (B).
Ees=end-systolic elastance (mmHg· µL-1), PRSW=preload recruitable stroke work (mmHg), dP/dt
max
-
Ved=maximum first time derivative of pressure divided by end-diastolic volume (mmHg·s-1· µL-1)
* p<0.05 versus corresponding control in baseline
† p<0.05 versus baseline
‡ p<0.05 versus dobu-2.5   
§ p<0.05 difference in dobutamine response (dobu-2.5 – dobu-5) between sham and PAB 
Discussion
Our findings indicate that 6 weeks of RV pressure overload in our rat model resulted 
in enhanced baseline RV contractility and that RV contractile reserve was maintained 
indicating a state of compensated RV hypertrophy. Furthermore, baseline LV 
contractility was unaffected while the LV response to dobutamine stimulation was 
blunted. These data are in line with the observation that RV pressure overload did not 
result in alterations in systemic hemodynamic parameters and that overt signs of heart 
failure were absent.
Assessment of cardiac contractile state by load-independent parameters of LV function 
by means of the conductance catheter technique is well established [15, 29]. It has 
been shown that the technique is applicable in the LV of large animals and humans, 
as well as small animals such as rats [7, 27]. More recently, it was shown that despite 
the complex geometry of the RV, this approach is also useful in characterizing RV 
contractile state and reserve in various conditions [3, 4, 8, 10, 17, 19, 25, 31]. Some 
investigators have used this technique simultaneously in both LV and RV studying 
LV and RV responses and their interaction in various derangements of the normal 
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circulation. The application of this biventricular conductance catheter technique so far 
has been limited to larger animals such as lambs [19]. To our knowledge, this study is 
the first to apply the biventricular conductance catheter (multi-segment) technique in 
small experimental animals such as rats. 
In our study RV systolic pressure was increased to about 60% of systolic LV pressure, a 
level of RV pressure overload that is commonly encountered in patients with residual 
abnormalities after palliative or corrective surgery for complex congenital heart 
disease. This resulted in a robust hypertrophic response: increasing RV mass 2-fold in 
the PA banded rats (Table 1). We used three load-independent measures of contractility 
(ESPVR, PRSW and dP/dt
max
-Ved) to determine the contractile state of both the RV 
and LV. These indices all indicated a 2-3 fold increase of RV contractility at baseline 
in the pressure overloaded RV. Contractile reserve of the RV was demonstrated by a 
further increase of RV contractility at the lowest dose of dobutamine.  Qualitatively, 
the responses of the RV were similar in the sham and PAB rats. Similarly, baseline 
LV contractility was the same in sham and PAB rats. At each level of dobutamine 
stimulation (2.5 and 5 μg/kg/min, resp.) LV contractility increased in sham rats, but in 
PAB rats LV contractility did not increase further at the highest dose of dobutamine. 
Qualitatively, the responses of the LV were similar in both sham and PAB rats, except for 
a blunted response at the highest dose of dobutamine in PAB rats.  RV volumes were 
slightly, but not significantly, lower in PAB rats, while LV end-diastolic volumes tended 
to be somewhat lower in PAB rats (p=0.09). 
The effects of pressure overload on RV contractile function have been studied 
previously under various conditions and by using various techniques. The onset of 
and the duration of the pressure overload determine the RV hypertrophic response 
and the effects on RV hemodynamics. For example, in patients with acute RV pressure 
overload the RV dilates and stroke volume reduces. Initially, the increased end-diastolic 
RV volume serves to maintain cardiac output, but eventually RV dysfunction results 
in a diminished cardiac output [14, 26]. In contrast, in young lambs with acute RV 
pressure overload, RV end-diastolic volume was unaltered, while RV contractile state 
increased [8, 9]. These studies implicated RV homeometric autoregulation as an 
important immediate adaptation to RV pressure overload. In patients with chronic RV 
pressure overload, induced by either COPD or primary pulmonary hypertension, MRI 
studies have demonstrated an increased RV mass, a decrease of both RV and LV end-
diastolic volume, and a maintained RV systolic function [18, 32]. Similar results have 
been obtained in experimental studies using the conductance catheter technique. 
Leeuwenburgh and coworkers induced 8 weeks of RV pressure overload in lambs by 
gradually increasing and maintaining RV pressures at systemic levels [19]. In response, 
Faber.indd   87 28-02-12   12:48
Chapter 4 Right- and left ventricular function after chronic pulmonary artery banding
88
these lambs developed compensated RV hypertrophy as demonstrated by the 
increase of RV contractile indices at a normal RV end-diastolic volume. Furthermore, 
LV contractile function was not affected by the RV hypertrophy, as parameters of LV 
contractility were unaltered, while LV end-diastolic volume was decreased. The results 
from these previous studies are in line with the major findings from our study: in 
response to chronic RV pressure overload RV and LV contractile function is maintained 
at a normal or somewhat decreased RV end-diastolic volume and a somewhat 
decreased LV end-diastolic volume. 
In their study on chronic RV pressure overload, Leeuwenburgh and coworkers 
suggested that the increase in RV contractile state was out of proportion to the 
amount of hypertrophy, indicating a hypercontractile state of the RV. The results of 
our study are in line with the observations made by Leeuwenburgh and co-workers, 
although the increase in RV contractile state in our study seemed more in proportion 
with the amount of hypertrophy. When normalising the three PV-relations for RV 
weight, no difference was seen in two out the three PV-relations (Figure 3). Although 
the PV relations increased significantly at dobu-2.5 in the sham animals, the qualitative 
response in sham and PAB animals to dobutamine was similar. This suggests that the 
intrinsic RV contractility of the PAB rats is similar or slightly higher as compared to 
controls and that contractile reserve is maintained.
Figure 3: Right ventricular pv relations corrected for Rv weight (see Discussion for more 
details). 
Ees / RV
weight 
=end-systolic elastance divided by RV weight (mmHg· µL-1· g-1), PRSW / RV
weight 
=preload 
recruitable stroke work divided by RV weight (mmHg· g-1), dP/dt
max
-Ved / RV
weight 
=maximum first time 
derivative of pressure divided by end-diastolic volume divided by RV weight (mmHg·s-1· µL-1· g-1)
* p<0.05 versus baseline
Notably, in the study in lambs the LV contractile state was maintained at a lower LV 
end-diastolic volume, suggesting a slight hypercontractile state of the LV as well. In 
our study the LV end-diastolic volumes also tended to be lower in the PAB rats. The 
finding that the baseline LV ESPVR was shifted leftward (LV V
100 
= 194 ± 22 vs. 114 
± 32 sham vs. PAB, p=0.05) also supports a hypercontractile LV function in the PAB 
rats. The drive for this hypercontractile state is unknown, but we found no signs of 
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increased systemic sympathetic nervous stimulation. LV response to the 5 µg/kg/min 
dobutamine stimulation was blunted in the PAB animals. Whether a downregulation of 
LV β – adrenergic receptors plays a role in this response is uncertain. LV β – adrenergic 
receptors were downregulated 4 weeks after monocrotaline treatment in rats, while RV 
β – adrenergic receptors were unaffected [6]. However, other studies have not found 
a downregulation in LV β – adrenergic receptors in RV hypertrophy [20, 21]. Therefore 
additional research to elucidate the mechanisms behind this LV blunted response is 
necessary. 
Relevance of the study
Many patients with corrected congenital heart disease, pulmonary hypertension 
and/or chronic obstructive pulmonary disease have (residual) abnormal RV loading 
conditions making them prone for the development of RV failure. One of the 
challenges is to identify the turning point from compensated RV hypertrophy to 
(irreversible) RV failure. In a previous study, we reported the changes in the myocardial 
protein expression in response to RV pressure overload [12]. We demonstrated 
alterations in expression of metabolic proteins, compatible with a shift from fatty 
acid to carbohydrate metabolism. Furthermore, we found upregulation of several low 
molecular weight heat shock proteins and could demonstrate the phosphorylation of 
HSP-27. The expression of several proteins seemed to be correlated with the degree 
of hypertrophy. For example, a phosphorylated HSP-27 was positively correlated with 
the degree of hypertrophy (r2=0.89, p<0.01). This study demonstrates the feasibility of 
characterizing biventricular responses to RV pressure overload in a small animal model. 
This allows to characterize the progression of RV compensated hypertrophy to RV 
failure over time and to correlate these findings with alterations in myocardial protein 
expression.  By using this approach relevant changes in myocardial protein expression 
can be correlated with the onset of RV failure [11]. Therefore, further longitudinal 
studies are needed to correlate hemodynamics with alterations in the myocardial 
proteome.
In conclusion, 6 weeks of RV pressure overload in rats resulted in a state of 
compensated RV hypertrophy, while LV contractile state at baseline was not, or only 
marginally affected. Furthermore, this study demonstrated the feasibility of performing 
biventricular measurements using a multi-segment conductance catheter technique 
in rats. This hemodynamic profiling of the preceding stages of heart failure in a small 
animal model will facilitate an integration between physiology and biochemistry 
ultimately leading to a more accurate interpretation of heart hypertrophy and failure. 
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Abstract: 
In many forms of congenital heart disease, the right ventricle (RV) is subject to 
abnormal loading conditions resulting in RV hypertrophy and remodelling. We 
determined the alterations in RV cytoplasmic proteomic phenotype that occur during 
prolonged periods of RV pressure overload. We performed a differential proteomic 
profiling study on RV hypertrophy using an animal model of various durations of 
pulmonary artery banding (PAB) in parallel with hemodynamic characterization. This 
hemodynamic evaluation showed that after 6, 12 and 20 weeks of PAB, the RV is in 
a compensated state of hypertrophy. Overall, the majority of protein changes was 
metabolism related indicating a shift towards the glycolytic pathway at the expense 
of β-oxidation in the RV of the PAB animals. The changes in proteins related to the 
glycolytic pathway, exemplified by enolase and creatine kinase B-chain, tended to 
precede changes in β-oxidation. In parallel, increases in stress chaperones, exemplified 
by several phosphorylated HSP-27 species, are present from the 6 week time point, 
whereas increases in anti-oxidant proteins, exemplified by peroxiredoxin 2 and 6, 
appears to be restricted to the 12 week time point. The p38 MAPK signal transduction 
pathway appears not to be activated. Observed protein changes are likely part of a 
protective mechanism against the development of RV failure. 
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Introduction
Right ventricular hypertrophy (RV) is an important problem in congenital heart disease 
(CHD). The ongoing improvement in the treatment of patients with CHD has led to 
an increased survival but concomitantly has also resulted in increasing numbers of 
adult patients with residual loading abnormalities, including RV pressure overload [1]. 
An important determinant of long-term outcome after (surgical) correction for CHD 
is RV function [2]. The initial adaptation of the RV to abnormal loading conditions 
includes remodelling and hypertrophy. At this initial stage the function of the RV is still 
preserved and usually no clinical signs of heart failure are present. This process, referred 
to as compensated RV hypertrophy, will eventually progress to a point where the RV is 
unable to counterbalance the increased loading conditions, and will progress towards 
RV failure. At present not much is known about the underlying protein alterations in the 
process of compensated RV hypertrophy. We previously demonstrated that differential 
proteomic profiling is a valuable tool in detecting alterations in protein expression in 
the hypertrophic rat RV [3]. In that study we demonstrated, after 6 weeks exposure 
of the RV to pressure overload, altered expression of several metabolic proteins 
consistent with the well known shift from fatty acid to carbohydrates as a substrate for 
energy supply. We also found the upregulation of three (post-translationally modified) 
HSP-27s which are indicative for a compensatory response to altered (oxidative) stress. 
The aim of the present study was to determine changes in protein composition over 
time in relation to RV function during prolonged pressure overload. For this purpose 
we extended the duration of pressure overload to a maximum of 20 weeks in the same 
rat model of RV hypertrophy caused by pulmonary artery banding (PAB). The various 
phases of compensated RV hypertrophy were hemodynamically characterized by 
measuring biventricular pressure-volume loops and proteomic analysis was performed 
on the RV (6, 12 and 20 weeks) and left ventricle (LV; 20 weeks). The cytoplasmic proteins 
were separated from the myofilaments and differentially displayed and quantified 
using two-dimensional gel electrophoresis (2-DE). The proteins that were found to 
be significantly up-or down-regulated in the hypertrophic RV were subsequently 
analyzed by mass spectrometry (MS) for identification. 
Materials and Methods
All experimental procedures and protocols used in this investigation were reviewed and 
approved by the institutional animal care and use committee and are in accordance 
with the National Institutes of Health “Guide for the care and use of laboratory animals” 
(NIH publication No. 85-23, revised 1996).
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Male Wistar rats (190-220 g, Harlan, Zeist, The Netherlands) underwent PAB or sham 
operation. The animals were housed after the initial operation (ie. sham or PAB), prior 
to the hemodynamic studies, in groups of 2 or 3 animals, on a 12/12-h light/dark cycle 
with standard rat chow and water ad libitum. Three different periods of housing were 
applied: 6, 12 and 20 weeks (resp. n=6 vs. 6, n=8 vs. 9, n=11 vs. 12 (sham vs. PAB)).
pulmonary artery banding procedure
In order to produce RV pressure overload, the pulmonary artery was banded as 
described previously [3]. Briefly, after induction of anesthesia (pentobarbital) the rats 
were intubated and mechanically ventilated. A left thoracotomy was performed and 
a silk thread was positioned under the pulmonary artery. A suture was tied tightly 
around an 18 gauge needle that was placed alongside the pulmonary artery. Next, 
the needle was rapidly removed in order to produce a fixed constricted opening in the 
lumen equal to the diameter of the needle. The sham animals underwent the same 
procedure except for the banding of the pulmonary artery.
Hemodynamic measurements
After the housing period of either 6, 12 or 20 weeks, hemodynamic measurements 
were performed as described previously [4]. The study protocol was the same for both 
sham and PAB animals. In brief, after induction of anesthesia, the heart was exposed 
by thoracotomy and pressure- and conductance catheters were inserted into both 
ventricles to measure ventricular pressures and volumes simultaneously. From these 
measurements, pressure-volume loops of RV and LV were constructed out of which 
the following parameters were derived: heart rate, cardiac output,  ventricular end-
systolic and end-diastolic pressures, dP/dt-max. The end-systolic elastance was used as 
a parameter of systolic function [4, 5]. At the end of the hemodynamic measurements 
the animals were killed and the heart was rapidly removed and divided into RV, LV, 
right atrium, left atrium and septum. Tissues were weighed and stored at -80°C. 
proteomics
The RV tissues of the individual animals were used for proteomics analysis as previously 
described [3]. In brief, RV tissue was homogenized and subsequently, the homogenate 
(600 μg) was prefractionated using Triton-X-100 into a cytoplasmic and myofilament 
fraction. The cytoplasmic fraction was subjected to 2-DE using nonlinear pI strips (pH 
3-10, Amersham Biosciences, Little Chalfont, Buckinghamshire, UK) and polyacrylamide 
gel (SDS-PAGE, 12%). After 2-DE separation the gels were stained with Coomassie Blue 
and analyzed with PDQUEST (BioRad, Hercules, CA, USA). This analysis leads on the 
one hand to parts per million (ppm) values as a measure of the staining intensity of 
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each protein spot relative to the total of the 2-DE gel and on the other hand the fold 
change of the mean ppm value of a spot due to pressure overload. Significantly up- 
or downregulated spots as well as several unchanged (landmark) spots were excised, 
destained and trypsinized prior to protein identification by MALDI-TOF MS (Bruker 
Daltonics, Billerica, MA, USA) or QTOF MS/MS (Waters, Milford, MA, USA). In addition, for 
database profiling purposes, several other spots were excised and ultimately identified. 
The reproducibility of the subfractionation and the 2-DE technique has been shown 
previously [3]. No technical replicates were used.
Western blotting
Western blotting was used to study the phosphorylation state of HSP-27 at Ser-15 
and Ser-86 and to study the p38 MAPK signaling pathway upstream to HSP-27. In 
brief, proteins were separated by 2D-PAGE ( HSP-27) or 1D-PAGE, using 15% gels. The 
samples were heated for 5 min. at 95º C and 20 μg of protein was applied per sample. 
The following primary antibodies were used: total HSP-27 (cat. #sc-9012, Santa Cruz 
Biotechnology, Santa Cruz, Ca, USA) , P-HSP-27 (Ser-15) (cat. #sc-12359-R, Santa Cruz 
Biotechnology), and P-HSP-27 (Ser86) (cat. #ab17938, Abcam, Cambridge, UK) each 
1:1000 diluted, and p38-MAPK 1:4000 diluted (cat. #9212, Cell Signaling Technology, 
Beverly, MA, USA), p-p38-MAPK (Thr180/Tyr182) 1:2000 diluted (cat. #9211, Cell 
Signaling Technology). After washing with TBS/Tween, the blots were incubated with 
1:5000 (HSP-27s) or 1:2000 (p38 MAPK) diluted goat antirabbit conjugated horseradish 
peroxidase (Pierce Biotechnology, Rockford, IL, USA)). The results were visualized by 
recording the ECL signal (Pierce Biotechnology) on film (Hyperfilm™ ECL, Amersham 
Biosciences) and quantitated with a GS-800 calibrated densitometer (Biorad). The 1D 
gels were analyzed with QuantityOne software (BioRad). 
phosphopeptide analysis by mass spectrometry
In addition to western blotting, MS was used to study HSP-27 phosphorylation. 2-DE 
gel plugs were destained and digested overnight with trypsin (Promega, sequencing 
grade). NanoLC-MS/MS was performed on an Agilent 1100 coupled to an LTQ-Orbitrap 
mass spectrometer (Thermo Scientific, Waltham, MA, USA), operating in positive 
mode. Peptide mixtures were trapped on a Jupiter™ C18 reversed phase column 
(Phenomenex; column dimensions 1.5 cm × 100 µm, packed in-house) at a flow rate of 
8 µl/min. Peptide separation was performed on a Reprosil-Pur C18-AQ  reversed phase 
column (Dr Maisch GmbH column dimensions 20 cm × 50 µm, packed in-house) using 
a linear gradient from 0 to 30% B (A = 0.1 M acetic acid; B = 80% (v/v) acetonitrile, 0.1 
M acetic acid) in 70 min and at a constant flow rate of 200 nl/min using a splitter. The 
column eluent was sprayed directly into the ESI source of the mass spectrometer, which 
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was operated in the data-dependent mode to automatically switch between MS, MS2, 
and MS3 acquisition. Full MS scans were performed in the Orbitrap and the three most 
intense ions were fragmented in the linear ion trap by collision induced dissociation. 
The MS3 event was triggered upon detection of the neutral loss of phosphoric acid 
(m/z difference of  -98, -49, or -32.7 , for charge states 1+, 2+, and 3+, respectively). 
MS2 and MS3 spectra were searched using the Mascot protein identification software 
(MatrixScience) against the publicly available NCBRnr database (taxonomy: Rattus) 
with carbamidomethyl cysteine set as fixed modification and oxidized methionine 
and  phosphorylation (serine, threonine, and tyrosine) set as variable modifications. 
Searches were done with tryptic specificity allowing two missed cleavages, a precursor 
mass tolerance of 10 ppm and MS2 and MS3 fragment ion tolerance of 0.8 Da.
Statistics
The statistical comparison software within PDQUEST (Mann-Whitney) was used for 
identification of significantly up-or downregulated spots when comparing sham gels 
to PAB gels within one time group. The statistical software program SPSS (version 10.1 
for Windows, Microsoft) was used to re-evaluate the Mann-Whitney statistics and to 
calculate exact p-values. Statview  (version 5.0, SAS Institute, Cary, NC, USA) software 
was used to calculate differences in protein expression over time using repeated 
measures Anova followed by Bonferoni correction. The differences in hemodynamic 
parameters between the control group and the PAB group at baseline were analyzed 
using a Student’s T-test. A two-sided p-value < 0.05 was considered statistically 
significant. Data are presented as mean ± SEM.
Results
Degree of hypertrophy
During the banding periods, the rats did not show overt signs of heart failure and/or 
cyanosis. There were no differences in body mass between sham and PAB animals in 
each time group. After 6, 12 and 20 weeks of PAB the RV and right atrium mass, relative 
to body mass, were significantly increased (Table 1).
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Table 1: Heart and bodyweight characteristics of the study groups per time point.
Time group
  6 wk 12 wk 20 wk
BW start sham 212 ± 5 211 ± 6 196 ± 4
pab 206 ± 9 199 ± 4 190 ± 5
BW end sham 376 ± 16 435 ± 11 521 ± 19
pab 374 ± 13 448 ± 8 531 ± 12
RV/BW sham 0.58 ± 0.02 0.51 ± 0.01 0.46 ± 0.02
pab 1.03 ± 0.05 * 0.97 ± 0.04 * 0.84 ± 0.02 *
RA/BW sham 0.13 ± 0.01 0.12 ± 0.01 0.14 ± 0.01
pab 0.21 ± 0.03 * 0.22 ± 0.02 * 0.24 ± 0.02 *
LV/BW sham 1.38 ± 0.03 1.34 ± 0.04 1.29 ± 0.04
pab 1.43 ± 0.05 1.43 ± 0.03 1.32 ± 0.04
LA/BW sham 0.05 ± 0.00 0.05 ± 0.00 0.05 ± 0.00
pab 0.05 ± 0.00 0.04 ± 0.01 0.05 ± 0.00
Septum/BW sham 0.66 ± 0.02 0.63 ± 0.03 0.58 ± 0.02
 pab 0.71 ± 0.03 0.67 ± 0.02 0.61 ± 0.02
Data presented as mean ± SEM. BW = body weight, RV = right ventricle, RA = right atrium, LV = left ventricle, 
LA = left atrium. 
* p<0.05 versus corresponding control 
Hemodynamics (Table 2) 
RV end-systolic pressure in the PAB group was increased to approximately 60% of LV 
end-systolic pressure in all three time groups. Heart rate decreased in PAB at 12 and 20 
weeks and in conjunction, cardiac output tended to be lower in PAB. Parameters of RV 
contractility, dP/dt-max and end-systolic elastance, were increased in PAB to a similar 
extent at 6,12, and 20 weeks, indicating preserved systolic RV function. These results 
in the 12 and 20 week PAB group are similar to our previous results obtained after 6 
weeks of PAB and indicate a state of compensated RV hypertrophy up to 20 weeks [4]. 
In the LV the end-systolic and end-diastolic pressures, dP/dt-max and the end-systolic 
elastance were similar in both groups.
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Table 2: Hemodynamic characterization of the study groups per time point.
   6 wk 12 wk 20 wk
HR sham 310 ± 8 305 ± 7 306 ± 8
PAB 297 ± 12 283 ± 4* 286 ± 6*
Co sham 51 ± 4 51 ± 3 41 ± 3
PAB 49 ± 5 38 ± 3* 36 ± 2
Sv sham 164 ± 11 168 ± 10 137 ± 10
PAB 164 ± 13 135 ± 9* 128 ± 6
Right ventricle           
pes sham 29 ± 1 29 ± 3 32 ± 3
PAB 63 ± 8* 57 ± 5* 68 ± 5*
ped sham 5 ± 1 4 ± 1 6 ± 1
PAB 7 ± 1 6 ± 2 7 ± 1
dp/dtmax sham 1429 ± 94 1542 ± 68 1261 ± 75
PAB 3435 ± 359* 2500 ± 214* 2854 ± 136*
Ees sham 0.126 ± 0.034 0.134 ± 0.024 0.168 ± 0.036
PAB 0.34 ± 0.042* 0.375 ± 0.074* 0.486 ± 0.061*
Left ventricle           
pes sham 93 ± 6 112 ± 8 92 ± 4
PAB 107 ± 7 91 ± 7 92 ± 6
ped sham 10 ± 2 9 ± 1 8 ± 1
PAB 10 ± 3 8 ± 1 10 ± 1
dp/dtmax sham 6331 ± 503 5351 ± 488 5008 ± 294
PAB 5559 ± 795 4542 ± 300 4291 ± 217
Ees sham 0.992 ± 0.255 0.81 ± 0.16 0.921 ± 0.157
  PAB 0.667 ± 0.185 0.886 ± 0.116 0.839 ± 0.105
Values are mean ± SEM. HR=heart rate, CO=cardiac output (mL/min), SV=stroke volume (µL), Pes=end-
systolic pressure (mmHg), Ped=end-diastolic pressure (mmHg), dP/dt
max
=maximum first time derivative of 
pressure vs. time (mmHg·s-1), Ees=end-systolic elastance (mmHg· µL-1).
* p<0.05 versus corresponding control
Differential proteomic profiles over time 
From all the sham and PAB 2-DE gels in all time groups, approximately 350 spots 
were matched. Spots that were differentially regulated and spots that were used for 
efficient matching of the gels were selected for further analysis (179 spots). From 
these 179 spots, 119 spots were identified by MS (66%). As a supplement we include 
a representative 2-DE map of the 179 spots, including a table with the protein names 
and identification details (Fig 1S and Table 1S).
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After comparing and analyzing the 2-DE gels across all time groups and within each 
time group, we identified a group of 72 spots that were present and matched in all gels 
of each time group and were different in intensity in at least one group. Of these 72 
spots, 12 were significantly up- or down regulated in all three time groups, 22 spots in 
only two time groups, and 38 in only one time group (Table 3). No spots unique to either 
sham or PAB rats or time group were observed. The protein alterations were grossly 
divided into four categories: (1) metabolic proteins, (2) stress- and antioxidant proteins, 
(3) miscellaneous (including signal transduction and apoptosis related proteins), and 
(4) not identified. A comprehensive list of RV (and LV) proteins changes, together with 
identification details and degree of up- or downregulation is provided in Table 3. More 
technical MS and identification data is provided in Table 1 of the supplement.
Metabolic proteins (Table 3; Figure 1)
About 50-60% of the spots that changed throughout all time groups, were identified 
as metabolic proteins. 
From table 3 we can conclude that already in the early phase of compensated RV 
hypertrophy (6 weeks), there is a general upregulation of proteins involved in the 
glycolytic pathway. The enzymes related to the mitochondrial oxidation tended to 
change mainly at 12 and 20 weeks of RV hypertrophy. In contrast to the carbohydrate 
metabolism, proteins related to fatty acid oxidation and amino acid metabolism were 
all downregulated. Overall, these changes suggest a shift towards carbohydrates as 
energy fuel for the hypertrophied RV at the expense of fatty acids and amino acids.  
Among the 12 spots that were significantly altered in all time groups (RV), 7 spots were 
related to metabolism (Table 3). Two of these spots were identified as β-enolase, spot 
#17 and #20, and were downregulated in all three time groups (p<0.05). The α-enolase 
(spot #79) did not change at 6 and 12 weeks but was only significantly increased 
after 20 weeks of PAB (increase 30%, p<0.05) (Figure 1). The extent of downregulation 
of both β-enolase spots tended to increase gradually with the duration of pressure 
overload (Figure 1; Table 3).Two other spots were identified as creatine kinase B-chain 
(#9 and #45), which were both increased throughout the study. 
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Figure 1: Composition of the heterodimeric enolase in relation to the duration of Rv 
pressure overload.
Panel A shows the relative intensity as expressed by a ppm value for both beta-enolase isoforms (spot #17 
and #20) and alpha-enolase (spot #79) over time. The relative change (%) over time, is given in panel B.
* p<0.05 sham vs. PAB 
Stress- and antioxidant proteins
Phosphorylated HSP-27s and p38 MAPK pathway activation
Five of the 12 spots that were significantly altered in the RV throughout the 3 time 
groups were stress related, including HSP-27, Hsc-73,  α-B-Crystallin (CryAB) and 
selenium binding protein 2 (Table 3). HSP-27 was identified in three spots that were all 
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Figure 1: Composition of the heterodimeric enolase in relation to the duration of Rv 
pressure overload.
Panel A shows the relative intensity as expressed by a ppm value for both beta-enolase isoforms (spot #17 
and #20) and alpha-enolase (spot #79) over time. The relative change (%) over time, is given in panel B.
* p<0.05 sham vs. PAB 
Stress- and antioxidant proteins
Phosphorylated HSP-27s and p38 MAPK pathway activation
Five of the 12 spots that were significantly altered in the RV throughout the 3 time 
groups were stress related, including HSP-27, Hsc-73,  α-B-Crystallin (CryAB) and 
selenium binding protein 2 (Table 3). HSP-27 was identified in three spots that were all 
upregulated in all time groups. Interestingly, the extent of upregulation of HSP-27 spots 
#5 and #39 in the RV increased further with the duration of pressure overload (Figure 2 
C). Previously we demonstrated by MS, as well as immunoblotting, that spot #5 and #39 
contain HSP-27s that are phosphorylated at least at Ser-15 [3]. Here, we show that spot 
#5 and #39 also contain HSP-27s phosphorylated at Ser-86 using 2-DE immunoblotting. 
Analysis by LTQ-Orbitrap also demonstrated the presence of peptides phosphorylated 
at Ser-15 and Ser-86 (Figure 2 Supplement). In order to examine whether the increase 
of phosphorylated HSP-27 species in the pressure overloaded RV is caused by the 
activation of p38-MAPK, we measured the phosphorylation degree of p38-MAPK by 
immunoblotting. After 6 weeks of PAB, the signals of the p38-MAPK antibody and its 
phosphorylated form were similar in the RV of sham and PAB animals. When PAB was 
extended to 20 weeks, both the p38-MAPK and the phosphorylated antibody signal 
were decreased in the RV of PAB animals. As expected, the levels of p38-MAPK and its 
phosphorylated form were not altered in the LV in all time groups (Figure 3). 
Figure 2: Differential expression of HSp-27 during the progression of Rv hypertrophy in 
rats.
Panel A shows the three separate HSP-27 spots (number 5, 11 and 39 respectively) on a section of a 2DE gel 
for both sham and PAB rats. Panel B shows the relative intensity as expressed by a ppm value for each spot 
number over time. The relative change (%) over time, is given in panel C for each spot number.
* p<0.05 sham vs. PAB 
† p<0.05 vs. 6wk group
a p<0.05 sham 6 wk vs. sham 20 wk 
b p=0.068 pab 6 wk vs. pab 20 wk 
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Figure 3: Western blot analysis of p38-MApK activity
Panel A shows bar graphs representing the differences in expression of p38-MAPK and p-p38 MAPK. The 
changes in the PAB animals were related to the sham levels which were set at 100%. Representative 1D 
western blots are given in panel B.
* p<0.05 versus corresponding control
Alterations in the peroxiredoxin system
The subtypes Prx-2, Prx-5, and Prx-6 were significantly altered in the hypertrophic RV. 
Prx-5 was only upregulated in the 12 wk group (spot #59, Table 3).The subtypes Prx-
2 and Prx-6 each were present in two distinct spots, one acidic and one basic. Their 
alterations over time are shown in Figure 4. The acidic Prx-2 decreased over time by 
28% (spot #151, p<0.05) while the basic Prx-2 increased at 12 weeks by 53% (spot 
#38, p<0.05). Conversely, the acidic Prx-6 increased by approximately 50% at 6 and 12 
weeks to return no near baseline levels at 20 weeks of PAB (spot #30, p<0.05). The basic 
Prx-6 decreased by approximately 45% after 12 and 20 weeks (spot # 41, p<0.05).
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Figure 4: Differential expression of prx-2 and prx-6 during the progression of Rv 
hypertrophy in rats.
Panel A shows the Prx-2 and Prx-6 spots on a section of a 2DE gel for both sham and PAB rats. Spot #151 (Prx-
2) and #30 (Prx-6) are the acidic, oxidized forms. Panel B shows the relative intensity as expressed by a ppm 
value for each spot over time. The relative change (%) over time, is given in panel C.
* p<0.05 sham vs. PAB 
† p<0.05 vs. 6wk group
a p<0.05 sham 6 wk vs. sham 12 and 20 wk 
b p=0.068 pab 6 wk vs. pab 12 and 20 wk 
Miscellaneous and not identified proteins
Besides the large and diverse group of metabolism-,  stress-,  and antioxidant proteins, 
also changes in other functional groups can be found.  In our model, several proteins 
related to signal transduction, apoptosis and cell growth were found to be altered in 
response to prolonged RV pressure overload. The majority of these protein changes 
occur after 12 weeks of PAB (Table 3). Further studies are required to determine the 
relevance and functional consequences of these changes.
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Left ventricular protein changes
In addition to studying protein changes in the compensated RV, we also compared the 
proteome of the LV between control and PAB animals. Since invasive hemodynamic 
evaluation showed that the LV of sham and PAB animals behaved functionally similar 
over time, we chose to study the cytoplasmic proteome of the LV only at the 20 wk 
time point. The same proteomic analysis as described above was applied to the LV. In 
contrast to the 56 protein spots that were altered in the RV after 20 weeks of PAB, only 
11 spots were significantly up- or downregulated in the LV of PAB animals at 20 wks. 
From these spots, 6 were only significantly changed in the LV (4 metabolic proteins, 2 
no identification) while 5 spots were also found to be changed in the RV (2 metabolic, 
2 stress proteins, 1 no identification) for one or two of the time points (Table 3). 
 
Discussion
Here, we present a comprehensive study of the changes in cytoplasmic protein 
expression after a prolonged period of pressure overload of the RV in a hemodynamically 
well-characterized rat model. We demonstrated that the majority of the protein 
expression changes that occur in the cytoplasmic fraction are related to metabolism 
and (oxidative) stress. In general, we observed protein changes consistent with a shift 
towards the glycolytic pathway at the expense of the β-oxidation in the RV of the 
PAB animals. More specifically, the heterodimeric enolase shifted towards a more fetal 
phenotype as the pressure overload progressed. Furthermore, stress-related proteins 
such as phosphorylated HSP-27 were upregulated in the hypertrophic RV and were 
also dependent on the duration of pressure overload. The fact that we also found 
changes in Prx species, in parallel to HSP-27 alterations, can be seen as an indication 
of oxidative stress. In all protein categories, the number of affected proteins increases 
with the duration of PAB. In contrast, the number of affected antioxidant proteins is 
increased at 12 weeks and decreases again at 20 weeks of PAB. This may suggest that 
the RV increasingly adapts to the oxidative and/or mechanical stress during prolonged 
periods of increased workload. We attempted to correlate the temporal changes 
in protein expression with several hemodynamic parameters but no consistent 
correlations were found (data not shown). 
Metabolic protein changes
The majority of the proteins found to be changing during compensated RV hypertrophy 
are related to metabolism (Table 3). Overall, there appears to be a shift in metabolism 
towards carbohydrates as energy fuel for the hypertrophied RV at the expense of fatty 
acids and amino acids. These observations are in accordance with results obtained in 
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various models of LV hypertrophy, and may be the result of increased energy demand 
associated with increased workload [6-12]. In this extended study we observed similar 
qualitative changes (Table 3). In addition, we found that proteins related to the fatty 
acid and amino acid metabolism are all downregulated in the RV of PAB animals. 
Interestingly, the changes in the fatty acid and amino acid oxidation proteins tend to 
occur after 12 and 20 weeks of PAB, whereas several alterations in proteins related to 
the glycolytic pathway already occur after 6 weeks. 
Another metabolic shift was found in the α and β enolase proteins. The glycolytic 
enzyme enolase is composed as a homodimer or heterodimer from α, β, and γ 
subunits with the β subunit being specifically expressed in striated muscle and the 
γ subunit in nervous tissue [13-16]. In our study, we found two different spots most 
likely containing β
1
 and β
2
 -enolase (Table 3) which were both decreased in all three 
time groups which is in accordance with results obtained in studies on LV hypertrophy 
[17, 18]. The α-enolase was not significantly changed after 6 and 12 weeks of PAB but 
increased significantly by 30% in the 20wk group (p<0.05). This suggests that the 
heterodimeric composition of enolase is changing with the duration of RV pressure 
overload (Figure 1). Heterodimeric enolase composed of relatively more a monomers 
has been linked to a better association of the complex of glycolytic enzymes with the 
contractile machinery of hypertrophic cardiac myocytes [18]. 
Interestingly, the alterations in the LV after 20 weeks of PAB were seen in metabolic 
proteins. This is in accordance with observations by Schott et al. [19]. In this study, 
using a monocrotaline model of RV hypertrophy, changes in the LV proteome were 
analyzed. An upregulation of proteins relevant for energy metabolism was observed. 
Since changes in the biomechanical load on the LV were not observed, the changes in 
LV protein expression may be attributed to changes in neurohumoral stimulation [19].
Stress and antioxidant proteins
From table 3 we can appreciate that several stress proteins are upregulated in the early 
phase of compensated RV hypertrophy (6 weeks of PAB). The antioxidant proteins tend 
to be activated after 12 weeks of PAB and these levels subsequently decrease at 20 
weeks. Two of the stress proteins that were significantly altered in this study were HSP-
27 and Hsc-73 (synonym: heat shock 70 kDa protein 8). Both HSP-27 and Hsc-73 were 
present in multiple spots suggesting post-translational modifications (Table 3). Indeed, 
for HSP-27 which is likely to have multiple phosphorylation sites, we have previously 
demonstrated that two out of three spots are at least phosphorylated at the Ser-15 
residue [3]. Here, we show that these two spots contain HSP-27 also phosphorylated at 
Ser-86. This pattern of cardiac HSP-27 phosphorylation induced by stress has also been 
shown by Cullingford et al. [20]. One interpretation may be that the most acidic spot 
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(#39) contains HSP-27 that is double phosphorylated at Ser-15 and Ser-86, and that the 
middle spot (#5) contains HSP-27 phosphorylated at either Ser-15 or Ser-86, whereas 
the most basic spot (#11) contains HSP-27 that is not phosphorylated at these serine 
residues. Alternatively, another modification may discriminate between spots #5 and 
#39. A possible PTM would be an additional phosphorylation of Ser-78. Unfortunately, 
the peptide containing P-Ser-78 could not be found in the MS spectra but this does 
not preclude its presence. A specific antibody is not available. 
One of the signalling pathways for HSP-27 phosphorylation is known to be the MAPK 
pathway. We concordantly studied this pathway using antibodies against p38-MAPK 
and its phosphorylated form (Figure 3) [21, 22]. At 6 wks of PAB the RV levels of p38-
MAPK and p-p38-MAPK were similar in both groups. At 20 wks of PAB these levels 
were not increased in the RV of PAB animals, but even slightly decreased. In a recent 
study by Buermans et al. it was shown in a monocrotaline model of RV hypertrophy 
that compensated RV hypertrophy is characterized by an absence of p38-MAPK 
activation whereas RV failure was associated with an upregulation of p38-MAPK [23]. 
This is in close agreement with the observation that in our model of compensated RV 
hypertrophy there is no activation of the p38-MAPK pathway. 
Our data suggests that throughout the hypertrophic response the transcription of 
total HSP-27 is progressively increasing and that the fraction of phosphorylated HSP-27 
is also progressively increasing. In our study we did not identify the upstream pathway 
for HSP-27 phosphorylation. However, the protein kinase C-δ pathway is known to 
play a role in the development of pathological hypertrophy and has been shown to 
be activated both in RV and LV pressure overload [24-26]. Furthermore, protein kinase 
C-δ has been shown to phosphorylate HSP-27 proteins independent of the p38-MAPK 
pathway [27]. Therefore, it could be speculated that the protein kinase C-δ pathway 
plays a role in the development of compensated RV hypertrophy and that the p38-
MAPK pathway is involved in the transition to decompensated hypertrophy.
In addition to the increased levels of the HSP-27 and Hsc-73 we also observed a 
consistent increased expression of CryAB over time (approximately +40%, p<0.05, 
table 3 #23). Both the HSPs and the CryAB have an important function in the protein 
quality control machinery. It has recently been shown that the formation of desmin 
aggregates, induced by adenoviral mutant-desmin overexpression, impairs the 
proteolytic function of the ubiquitin proteasome system (UPS) in cardiomyocytes 
[28]. Both HSP-27 and CryAB have a critical role in preventing the impairment of the 
proteolytic function of the UPS [28, 29]. The protein quality control and the selective 
protein degradation through the UPS are critical in the cardiac response to stress [30-
32]. Interestingly, the reversibility of the aggregation formation and the subsequent 
UPS impairment offers new opportunities for pharmacological treatment with the 
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protein quality control components as a major target. In our model the RV has to 
deal with increased stress for prolonged period of time. One could speculate that this 
leads to a delicate process of increased protein synthesis and degradation in order 
to adapt to the increased loading conditions. This increased protein handling is also 
subject to the protein quality control machinery, resulting in increased synthesis of 
chaperone proteins. In our model the RV is still capable of dealing with these increased 
loading conditions, suggesting that the protein quality control is still functional. More 
in depth studies are needed to investigate the change in levels or post translational 
modifications of the numerous chaperones in the transition phase to RV failure. 
Several antioxidant proteins, like peroxiredoxin (Prx) and gluthathion peroxidase (glut-
Prx), were also significantly changed during the time course of RV hypertrophy which 
is indicative for increased oxidative stress caused by chronic pressure overload. In a 
recent study by Cullingford et al., cardiomyocytes exposed to H
2
O
2
 showed marked 
changes in the family of Prx proteins in relation to alterations in HSPs and CryAB. 
Among those changes, an increase in the acidic Prx-2 and Prx-6 and a decrease in the 
basic component was found. [20]. In our in vivo study, the Prx subtypes Prx-2 and Prx-6 
were both significantly changed in the hypertrophic RV. Each of these subtypes were 
present in 2 distinct spots. In contrast to the in vitro study by Cullingford, we did not 
observe an acidic shift for the Prx-2. The basic Prx-2 increased with 53% (p<0.05) at 12 
wks and the acidic Prx-2 decreased over time to -28% at 20 wks (p<0.05). However, 
similar to the in vitro study, we did observe an acidic shift for the Prx-6 subtype. The 
acidic Prx-6 increased at 6 and 12 wks with approximately 50% (p<0.05) returning 
to near normal levels at 20 wks. The basic Prx-6 decreased with approximately 45% 
(p<0.05) at 12 and 20 wks (Figure 4) This acidic shift is potentially the result of “over-
oxidation” to Cys-SO
2
H/Cys-SO
3
H [33-36]. It has been speculated that this oxidation 
of Prx proteins, which is reversible, is a mechanism to conserve these proteins and 
may play an important role in long-term defense against oxidative stress [20, 37]. Our 
data suggests that the oxidation of Prx-6 reaches its maximum at 12 weeks. Despite 
the numerous types of Prx, these proteins are nevertheless non-redundant. In a 
recent study by Nagy et al, it was demonstrated that hearts of Prx-6 -/- mice were 
more susceptible to ischemic-reperfusion damage [38]. Another Prx protein, glut-
Prx, is known to be upregulated in the hypertrophied myocardium [39]. Glut-Prx, in 
conjunction with HSP’s, is suggested to have a protective effect on the contractile 
properties of the heart [40]. In our study, the fractional change in glut-Prx levels initially 
increases from 31 to 94% (6 to 12 wks) and subsequently decreases to 67% in 20 wks 
in the RV of PAB animals (Table 3, #52). Again, this suggests that the protective effects 
of glut-Prx reaches its maximum at 12 weeks of PAB. Future studies should include 
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the assessment of the levels of glut-Prx in a more advanced phase of compensated 
hypertrophy, and eventually in hearts that progress to heart failure.
Limitations
It should be noted that our study addresses only the changes in abundant cytoplasmic 
proteins. This is due to the cell fractionation and the proteomics techniques used, 
mainly the choice of IPG strips (pI 3-10) and detection by Coomassie blue staining 
[41, 42]. Further studies are needed to look at, possible related, protein changes with 
a lower abundance, for instance by using 2-DE zoom gels and more sensitive protein 
stains, or proteins that are present in other cell fractions, such as membrane proteins, 
cytoskeletal and myofibrillar proteins.  
Conclusions
In conclusion, we present for the first time, a longitudinal proteomic analysis of 
hemodynamically characterized compensated RV hypertrophy. We have identified 
and grouped several protein changes that occur over time and show similar shifts 
in energy metabolism similar to what has been described for LV hypertrophy [6-12]. 
We have shown that the expression of (phosphorylated) HSP-27s increases with the 
duration of PAB despite the absence of an increase in expression of p38-MAPK. Since 
the RV is still in a state of compensated hypertrophy, the results of the differentially 
displayed proteome suggests that the increase in stress chaperone and antioxidant 
proteins is involved in the protection of the RV against development of failure. Further 
research is needed to study the exact role of these low molecular weight proteins in 
protein quality control machinery as well as the potential role of these proteins as 
therapeutic target. 
The supplementary data (Figure 1S and 2S and Table1S) associated with this chapter 
can be found under the Appendix at the end of this chapter
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matching of the gels. The numbers correspond with the numbers used in Table 1S.
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Figure 2S
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Figure 2 Supplement
Panel A: LTQ-Orbitrap spectra of HSP-27 peptides. Top spectrum is 
showing a phosphorylation at Ser-15 residue. The bottom spectrum is 
showing a phosphorylation at Ser-86. 
Panel B shows the amino acid sequence of HSP-27 with the 
phosphopeptides in bold. 
Panel C shows 2-DE westernblots using specific antibodies against total 
HSP-27 (top), HSP-27 phosphorylated at Ser-15 (middle), and HSP-27 
phosphorylated at Ser-86 (bottom).
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Table 1S
Location ratio (max/min) NCBI Theoretical
MOW-
SE
% seq. Matched Mann-Whitney*                               Parts per million (ppm) values ± SEM 
# Map Protein ID Cat.
6 wk RV
*
12 wk RV
*
20 wk RV
*
20 wk LV 
*
Acc.nr. Mr pI score cover-age peptides 06R 12R 20R 20L sham 06 RV pab 06 RV sham 12 RV pab 12 RV sham 20 RV pab 20 RV sham 20 LV pab 20 LV
1 @ 3a no ID No ID 2,0 down $ - - - - - - - - - n/a n/a n/a n/a n/a n/a $ - - - 587 38 288 58 - - - - - - - - - - - -
2 @ 3a no ID No ID 1,8 up ns - - - - - - - - - n/a n/a n/a n/a n/a n/a ns - - - 183 55 325 29 - - - - - - - - - - - -
3 @ 2a no ID No ID 2,4 up $ - - - - - - - - - n/a n/a n/a n/a n/a n/a $ - - - 214 39 512 90 - - - - - - - - - - - -
4 @ 1a Tubulin B-chain Misc. 1,6 up $ 1,1 up ns 1,7 up $ 1,1 down ns gi|92930 49905 4,79 $ ns $ ns 652 90 1046 145 459 41 524 120 517 75 860 108 183 23 171 24
5 @ 3b HSP-27 Stress 1,9 up $ 3,0 up $ 3,9 up $ 1,1 down ns gi|1170367 22808 6,12 $ $ $ ns 258 41 497 71 285 45 867 182 261 28 1025 121 495 52 466 35
6 @ 2b
L-lactate dehydroge-
nase B-chain
Metab. 1,2 up $ 1,4 up $ 1,0 up ns 1,0 down ns gi|1170739 36458 5,70 $ $ ns ns 12867 663 15796 618 11189 1301 15597 1573 27656 1311 27720 1915 28290 1938 27756 2284
7 @ 2b
L-lactate dehydroge-
nase B-chain
Metab. 1,9 up $ - - ns 1,2 up ns 1,2 up ns gi|1170739 36458 5,70 $ ns ns ns 591 89 1095 108 - - - - 1379 151 1613 423 1617 129 1931 238
8 @ 2b no ID No ID 1,9 up ns - - - - - - - - - n/a n/a n/a n/a n/a n/a ns - - - 267 66 512 87 - - - - - - - - - - - -
9 @ 2b
Creatine-kinase 
chain B
Metab. 1,7 up $ 2,4 up $ 2,0 up $ 1,0 up ns gi|125296 42685 5,33 $ $ $ ns 1018 92 1733 269 1337 127 3150 251 1829 152 3616 196 2375 220 2426 155
10 @ 1b
dnaK-type molecular 
chaperone hsc-73
Stress 1,5 up $ 1,5 up $ 1,5 up $ 1,1 down ns gi|51702275 71112 5,37 $ $ $ ns 338 32 511 47 395 28 587 50 417 61 608 51 521 40 479 36
11 @ 3b HSP-27 Stress 3,5 up $ 3,1 up ns 4,2 up $ 1,1 down ns gi|1170367 22808 6,12 $ ns $ ns 138 21 486 161 188 41 575 166 194 25 823 112 453 63 420 61
12 @ 1c no ID No ID 2,2 up $ - - - 2,1 up $ - - - n/a n/a n/a n/a n/a n/a $ - $ - 489 66 1068 130 - - - - 537 60 1117 99 - - - -
13 @ 3c
P20 protein = HSP-
beta-6
Stress 2,5 up ns - - - - - - 1,1 down ns gi|6016271 17494 6,05 ns - - ns 512 106 1267 371 - - - - - - - - 840 118 734 130
14 @ 2c no ID No ID 1,6 down $ - - - - - - - - - n/a n/a n/a n/a n/a n/a $ - - - 640 61 396 58 - - - - - - - - - - - -
15 @ 3c
2-enolyl CoA hy-
dratase (A/B chain) 
Metab. 1,5 down $ 1,1 down ns 1,2 down ns 1,3 down $ gi|2392292 28141 6,41 $ ns ns $ 2720 295 1873 111 3776 131 3357 451 2694 138 2289 149 3667 229 2924 250
16 @ 3c
Phosphoglycerate 
mutase B-chain
Metab. 1,6 up $ 1,4 up ns 1,2 down ns 1,3 up ns gi|112128 28814 6,67 $ ns ns ns 1582 70 2468 181 1145 178 1551 291 2628 175 2249 132 1607 161 2065 313
17 @ 1c
Enolase 3 = Beta-
enolase
Metab. 2,0 down $ 2,2 down $ 2,7 down $ 1,1 down ns gi|119346 46800 7,74 $ $ $ ns 793 164 398 58 646 64 299 33 518 40 192 16 427 27 405 29
18 @ 3d no ID No ID 1,9 down $ - - - - - - - - - n/a n/a n/a n/a n/a n/a $ - - - 701 65 371 99 - - - - - - - - - - - -
19 @ 2d Bcat2 protein Misc. 1,7 down $ 1,5 down $ 1,5 down $ 1,0 up ns gi|81885326 44138 8,62 $ $ $ ns 619 84 358 41 569 64 374 34 496 26 333 20 433 39 451 48
20 @ 1d
Enolase 3 = Beta-
enolase
Metab. 2,0 down $ 2,0 down $ 2,8 down $ 1,1 down ns gi|119346 46800 7,74 $ $ $ ns 4664 400 2317 300 4955 289 2451 324 4725 256 1680 111 4102 224 3683 400
21 @ 1d
Pyruvate kinase, 
isozymes M1/M2
Metab. 1,5 up $ 1,3 up ns 2,2 up $ 1,1 up ns gi|125601 57613 7,40 $ ns $ ns 358 44 555 38 250 52 338 46 141 18 316 29 205 14 223 11
22 @ 2d no ID No ID 2,1 up $ - - - - - - - - - n/a n/a n/a n/a n/a n/a $ - - - 539 95 1109 160 - - - - - - - - - - - -
23 @ 3d Alpha-B-crystallin Stress 1,5 up $ 1,3 up $ 1,4 up $ 1,0 up ns gi|117388 19945 6,67 $ $ $ ns 8111 417 11784 988 10974 376 14749 1392 12912 557 18406 640 13943 393 14439 799
24 @ 2a
Tropomyosin 1 alpha 
chain
Misc. - - - - - - - - - 1,5 down ns gi|92090646 32693 4,69 - - - ns - - - - - - - - - - - - 7176 708 4809 577
25 @ 2a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
26 @ 2b Actin alpha  - - - - - - - - - - - - gi|54036697 41992 5,30 - - - - - - - - - - - - - - - - - - - -
27 @ 2b no ID No ID - - - - - - 1,7 down $ - - - n/a n/a n/a n/a n/a n/a - - $ - - - - - - - - - 1433 138 861 91 - - - -
28 @ 2c
Malate dehydroge-
nase (cytosolic)
 - - - - - - - - - - - - gi|81861572 36460 6,16 - - - - - - - - - - - - - - - - - - - -
29 @ 3a MLC-2  - - - - - - - - - - - - gi|127167 18737 4,86 - - - - - - - - - - - - - - - - - - - -
30 @ 3b
Peroxiredoxin 6 = 
Anti-oxidant protein 2
Stress 1,5 up $ 1,5 up $ 1,2 up ns 1,0 up ns gi|5902791 24672 5,65 $ $ ns ns 814 42 1227 224 1353 124 2023 251 1628 117 1957 198 2008 134 2009 206
31 @ 3b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
32 @ 1c
Serum Albumin 
(precursor)
 - - - - - - - - - - - - gi|113580 68674 6,09 - - - - - - - - - - - - - - - - - - - -
33 @ 3a
14-3-3 protein 
gamma
Misc. 1,4 up ns 1,7 up $ 1,6 up $ 1,1 up ns gi|48428718 28325 4,80 ns $ $ ns 939 198 1325 110 306 29 526 75 292 15 455 32 360 38 396 26
34 @ 2a
Annexin V = Lipo-
cortin V 
Misc. 1,2 up ns 2,4 up $ 1,9 up $ 1,1 up ns gi|4033508 35648 4,93 ns $ $ ns 753 96 906 238 379 44 925 126 541 45 1025 69 517 69 569 60
35 @ 2a
Annexin V = Lipo-
cortin V 
Misc. 1,1 down ns 1,2 down $ 1,4 down $ 1,1 down ns gi|4033508 35533 4,93 ns $ $ ns 1427 109 1326 194 1186 57 1015 44 1105 82 764 73 1033 69 964 83
36 @ 2a 14-3-3 protein epsilon Misc. 1,2 down ns 2,2 up $ 1,1 up ns 1,0 down ns gi|61216932 29326 4,63 ns $ ns ns 460 58 398 77 158 25 347 84 311 29 357 32 259 28 253 36
37 @ 3a MLC-1 Misc. 1,2 up ns 1,3 up $ 1,1 up ns 1,1 up ns gi|127151 22125 5,03 ns $ ns ns 3107 280 3608 119 3182 208 4284 311 3702 155 3931 308 3488 173 3698 180
38 @ 3b
Peroxiredoxin 2 = 
Thioredoxin per-
oxidase
Stress 1,1 up ns 1,5 up $ 1,0 up ns 1,2 up ns gi|549132 21941 5,34 ns $ ns ns 1664 249 1754 270 1217 130 1866 122 1521 117 1559 137 1369 107 1651 91
39 @ 3b HSP-27 Stress 1,7 up $ 2,8 up $ 2,9 up $ 1,3 down ns gi|1170367 22808 6,12 $ $ $ ns 326 18 541 56 200 49 553 107 200 19 571 61 247 41 190 26
40 @ 2b no ID No ID - - - 1,7 up $ - - - - - - n/a n/a n/a n/a n/a n/a - $ - - - - - - 308 29 522 19 - - - - - - - -
41 @ 3c
Peroxiredoxin 6 = 
Anti-oxidant protein 2
Stress 1,1 down ns 1,8 down $ 1,8 down $ 1,4 down $ gi|5902791 24729 5,65 ns $ $ $ 672 64 633 88 845 87 459 62 724 60 410 57 1085 78 768 75
42 @ 3b no ID No ID - - - - - $ 2,4 down $ 1,3 down - n/a n/a n/a n/a n/a n/a - $ $ - - - - - - - - - 494 34 207 34 356 33 285 38
43 @ 2b
NAD+ specific isoci-
trate dehydrogenase. 
a-subunit
Metab. 1,2 down ns 1,3 up $ 1,1 up ns 1,1 down ns gi|68565369 40044 6,47 ns $ ns ns 502 30 434 33 684 44 878 59 1110 65 1239 82 1202 110 1078 123
44 @ 2b
ATP-specific succinyl-
CoA synthetase 
subunit beta
Metab. 1,4 down ns 1,4 down $ 2,0 down $ 1,2 down ns gi|52788305 50424 6,57 ns $ $ ns 451 78 326 28 572 79 400 31 839 48 423 41 748 75 645 82
45 @ 2b
Creatine-kinase 
chain B
Metab. 2,8 up $ 3,5 up $ 2,3 up $ 1,2 up ns gi|125296 42685 5,33 $ $ $ ns 75 10 210 50 75 7 263 32 102 8 232 21 138 18 165 19
46 @ 1b no ID No ID - - - 1,4 up $ - - - - - - n/a n/a n/a n/a n/a n/a - $ - - - - - - 611 35 856 62 - - - - - - - -
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Table 1S
Location ratio (max/min) NCBI Theoretical
MOW-
SE
% seq. Matched Mann-Whitney*                               Parts per million (ppm) values ± SEM 
# Map Protein ID Cat.
6 wk RV
*
12 wk RV
*
20 wk RV
*
20 wk LV 
*
Acc.nr. Mr pI score cover-age peptides 06R 12R 20R 20L sham 06 RV pab 06 RV sham 12 RV pab 12 RV sham 20 RV pab 20 RV sham 20 LV pab 20 LV
1 @ 3a no ID No ID 2,0 down $ - - - - - - - - - n/a n/a n/a n/a n/a n/a $ - - - 587 38 288 58 - - - - - - - - - - - -
2 @ 3a no ID No ID 1,8 up ns - - - - - - - - - n/a n/a n/a n/a n/a n/a ns - - - 183 55 325 29 - - - - - - - - - - - -
3 @ 2a no ID No ID 2,4 up $ - - - - - - - - - n/a n/a n/a n/a n/a n/a $ - - - 214 39 512 90 - - - - - - - - - - - -
4 @ 1a Tubulin B-chain Misc. 1,6 up $ 1,1 up ns 1,7 up $ 1,1 down ns gi|92930 49905 4,79 $ ns $ ns 652 90 1046 145 459 41 524 120 517 75 860 108 183 23 171 24
5 @ 3b HSP-27 Stress 1,9 up $ 3,0 up $ 3,9 up $ 1,1 down ns gi|1170367 22808 6,12 $ $ $ ns 258 41 497 71 285 45 867 182 261 28 1025 121 495 52 466 35
6 @ 2b
L-lactate dehydroge-
nase B-chain
Metab. 1,2 up $ 1,4 up $ 1,0 up ns 1,0 down ns gi|1170739 36458 5,70 $ $ ns ns 12867 663 15796 618 11189 1301 15597 1573 27656 1311 27720 1915 28290 1938 27756 2284
7 @ 2b
L-lactate dehydroge-
nase B-chain
Metab. 1,9 up $ - - ns 1,2 up ns 1,2 up ns gi|1170739 36458 5,70 $ ns ns ns 591 89 1095 108 - - - - 1379 151 1613 423 1617 129 1931 238
8 @ 2b no ID No ID 1,9 up ns - - - - - - - - - n/a n/a n/a n/a n/a n/a ns - - - 267 66 512 87 - - - - - - - - - - - -
9 @ 2b
Creatine-kinase 
chain B
Metab. 1,7 up $ 2,4 up $ 2,0 up $ 1,0 up ns gi|125296 42685 5,33 $ $ $ ns 1018 92 1733 269 1337 127 3150 251 1829 152 3616 196 2375 220 2426 155
10 @ 1b
dnaK-type molecular 
chaperone hsc-73
Stress 1,5 up $ 1,5 up $ 1,5 up $ 1,1 down ns gi|51702275 71112 5,37 $ $ $ ns 338 32 511 47 395 28 587 50 417 61 608 51 521 40 479 36
11 @ 3b HSP-27 Stress 3,5 up $ 3,1 up ns 4,2 up $ 1,1 down ns gi|1170367 22808 6,12 $ ns $ ns 138 21 486 161 188 41 575 166 194 25 823 112 453 63 420 61
12 @ 1c no ID No ID 2,2 up $ - - - 2,1 up $ - - - n/a n/a n/a n/a n/a n/a $ - $ - 489 66 1068 130 - - - - 537 60 1117 99 - - - -
13 @ 3c
P20 protein = HSP-
beta-6
Stress 2,5 up ns - - - - - - 1,1 down ns gi|6016271 17494 6,05 ns - - ns 512 106 1267 371 - - - - - - - - 840 118 734 130
14 @ 2c no ID No ID 1,6 down $ - - - - - - - - - n/a n/a n/a n/a n/a n/a $ - - - 640 61 396 58 - - - - - - - - - - - -
15 @ 3c
2-enolyl CoA hy-
dratase (A/B chain) 
Metab. 1,5 down $ 1,1 down ns 1,2 down ns 1,3 down $ gi|2392292 28141 6,41 $ ns ns $ 2720 295 1873 111 3776 131 3357 451 2694 138 2289 149 3667 229 2924 250
16 @ 3c
Phosphoglycerate 
mutase B-chain
Metab. 1,6 up $ 1,4 up ns 1,2 down ns 1,3 up ns gi|112128 28814 6,67 $ ns ns ns 1582 70 2468 181 1145 178 1551 291 2628 175 2249 132 1607 161 2065 313
17 @ 1c
Enolase 3 = Beta-
enolase
Metab. 2,0 down $ 2,2 down $ 2,7 down $ 1,1 down ns gi|119346 46800 7,74 $ $ $ ns 793 164 398 58 646 64 299 33 518 40 192 16 427 27 405 29
18 @ 3d no ID No ID 1,9 down $ - - - - - - - - - n/a n/a n/a n/a n/a n/a $ - - - 701 65 371 99 - - - - - - - - - - - -
19 @ 2d Bcat2 protein Misc. 1,7 down $ 1,5 down $ 1,5 down $ 1,0 up ns gi|81885326 44138 8,62 $ $ $ ns 619 84 358 41 569 64 374 34 496 26 333 20 433 39 451 48
20 @ 1d
Enolase 3 = Beta-
enolase
Metab. 2,0 down $ 2,0 down $ 2,8 down $ 1,1 down ns gi|119346 46800 7,74 $ $ $ ns 4664 400 2317 300 4955 289 2451 324 4725 256 1680 111 4102 224 3683 400
21 @ 1d
Pyruvate kinase, 
isozymes M1/M2
Metab. 1,5 up $ 1,3 up ns 2,2 up $ 1,1 up ns gi|125601 57613 7,40 $ ns $ ns 358 44 555 38 250 52 338 46 141 18 316 29 205 14 223 11
22 @ 2d no ID No ID 2,1 up $ - - - - - - - - - n/a n/a n/a n/a n/a n/a $ - - - 539 95 1109 160 - - - - - - - - - - - -
23 @ 3d Alpha-B-crystallin Stress 1,5 up $ 1,3 up $ 1,4 up $ 1,0 up ns gi|117388 19945 6,67 $ $ $ ns 8111 417 11784 988 10974 376 14749 1392 12912 557 18406 640 13943 393 14439 799
24 @ 2a
Tropomyosin 1 alpha 
chain
Misc. - - - - - - - - - 1,5 down ns gi|92090646 32693 4,69 - - - ns - - - - - - - - - - - - 7176 708 4809 577
25 @ 2a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
26 @ 2b Actin alpha  - - - - - - - - - - - - gi|54036697 41992 5,30 - - - - - - - - - - - - - - - - - - - -
27 @ 2b no ID No ID - - - - - - 1,7 down $ - - - n/a n/a n/a n/a n/a n/a - - $ - - - - - - - - - 1433 138 861 91 - - - -
28 @ 2c
Malate dehydroge-
nase (cytosolic)
 - - - - - - - - - - - - gi|81861572 36460 6,16 - - - - - - - - - - - - - - - - - - - -
29 @ 3a MLC-2  - - - - - - - - - - - - gi|127167 18737 4,86 - - - - - - - - - - - - - - - - - - - -
30 @ 3b
Peroxiredoxin 6 = 
Anti-oxidant protein 2
Stress 1,5 up $ 1,5 up $ 1,2 up ns 1,0 up ns gi|5902791 24672 5,65 $ $ ns ns 814 42 1227 224 1353 124 2023 251 1628 117 1957 198 2008 134 2009 206
31 @ 3b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
32 @ 1c
Serum Albumin 
(precursor)
 - - - - - - - - - - - - gi|113580 68674 6,09 - - - - - - - - - - - - - - - - - - - -
33 @ 3a
14-3-3 protein 
gamma
Misc. 1,4 up ns 1,7 up $ 1,6 up $ 1,1 up ns gi|48428718 28325 4,80 ns $ $ ns 939 198 1325 110 306 29 526 75 292 15 455 32 360 38 396 26
34 @ 2a
Annexin V = Lipo-
cortin V 
Misc. 1,2 up ns 2,4 up $ 1,9 up $ 1,1 up ns gi|4033508 35648 4,93 ns $ $ ns 753 96 906 238 379 44 925 126 541 45 1025 69 517 69 569 60
35 @ 2a
Annexin V = Lipo-
cortin V 
Misc. 1,1 down ns 1,2 down $ 1,4 down $ 1,1 down ns gi|4033508 35533 4,93 ns $ $ ns 1427 109 1326 194 1186 57 1015 44 1105 82 764 73 1033 69 964 83
36 @ 2a 14-3-3 protein epsilon Misc. 1,2 down ns 2,2 up $ 1,1 up ns 1,0 down ns gi|61216932 29326 4,63 ns $ ns ns 460 58 398 77 158 25 347 84 311 29 357 32 259 28 253 36
37 @ 3a MLC-1 Misc. 1,2 up ns 1,3 up $ 1,1 up ns 1,1 up ns gi|127151 22125 5,03 ns $ ns ns 3107 280 3608 119 3182 208 4284 311 3702 155 3931 308 3488 173 3698 180
38 @ 3b
Peroxiredoxin 2 = 
Thioredoxin per-
oxidase
Stress 1,1 up ns 1,5 up $ 1,0 up ns 1,2 up ns gi|549132 21941 5,34 ns $ ns ns 1664 249 1754 270 1217 130 1866 122 1521 117 1559 137 1369 107 1651 91
39 @ 3b HSP-27 Stress 1,7 up $ 2,8 up $ 2,9 up $ 1,3 down ns gi|1170367 22808 6,12 $ $ $ ns 326 18 541 56 200 49 553 107 200 19 571 61 247 41 190 26
40 @ 2b no ID No ID - - - 1,7 up $ - - - - - - n/a n/a n/a n/a n/a n/a - $ - - - - - - 308 29 522 19 - - - - - - - -
41 @ 3c
Peroxiredoxin 6 = 
Anti-oxidant protein 2
Stress 1,1 down ns 1,8 down $ 1,8 down $ 1,4 down $ gi|5902791 24729 5,65 ns $ $ $ 672 64 633 88 845 87 459 62 724 60 410 57 1085 78 768 75
42 @ 3b no ID No ID - - - - - $ 2,4 down $ 1,3 down - n/a n/a n/a n/a n/a n/a - $ $ - - - - - - - - - 494 34 207 34 356 33 285 38
43 @ 2b
NAD+ specific isoci-
trate dehydrogenase. 
a-subunit
Metab. 1,2 down ns 1,3 up $ 1,1 up ns 1,1 down ns gi|68565369 40044 6,47 ns $ ns ns 502 30 434 33 684 44 878 59 1110 65 1239 82 1202 110 1078 123
44 @ 2b
ATP-specific succinyl-
CoA synthetase 
subunit beta
Metab. 1,4 down ns 1,4 down $ 2,0 down $ 1,2 down ns gi|52788305 50424 6,57 ns $ $ ns 451 78 326 28 572 79 400 31 839 48 423 41 748 75 645 82
45 @ 2b
Creatine-kinase 
chain B
Metab. 2,8 up $ 3,5 up $ 2,3 up $ 1,2 up ns gi|125296 42685 5,33 $ $ $ ns 75 10 210 50 75 7 263 32 102 8 232 21 138 18 165 19
46 @ 1b no ID No ID - - - 1,4 up $ - - - - - - n/a n/a n/a n/a n/a n/a - $ - - - - - - 611 35 856 62 - - - - - - - -
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47 @ 1b
Dihydrolipoamide 
S-acetyltransferase 
(fragment)
Metab. 1,2 down ns 1,8 up $ 1,3 up ns 1,2 down ns gi|220838 57645 5,53 ns $ ns ns 210 20 172 23 276 32 501 35 488 33 622 62 679 88 563 70
48 @ 2c no ID No ID 1,2 down ns 1,5 down ns 1,2 down ns 1,1 up ns n/a n/a n/a n/a n/a n/a ns ns ns ns 162 28 135 34 208 23 138 20 176 10 144 15 196 19 213 18
49 @ 1c
Propionyl-CoA car-
boxylase alpha-chain 
prec.
Metab. 1,1 down ns 1,3 down ns 1,2 down $ 1,0 down ns gi|92654 78190 6,33 ns ns $ ns 1396 125 1238 102 1683 159 1296 90 1554 62 1267 62 1487 128 1420 103
50 @ 4c
Histidine triad nucleo-
tide-binding protein 1 
= PKC-inhibitor
Misc. - - xx 1,8 up $ 1,3 up ns - - xx gi|2495231 13751 6,39 xx $ ns xx - - 285 46 508 80 267 22 341 34 - -
51 @ 1c
Selenium binding 
protein 2
Misc. 1,4 down $ 1,4 down $ 1,5 down $ 1,1 down ns gi|81879451 52498 6,10 $ $ $ ns 838 68 604 14 915 85 656 62 761 29 517 23 711 41 620 42
52 @ 3c
Gluthathione per-
oxidase
Stress 1,3 up ns 1,9 up $ 1,7 up $ 1,1 down ns gi|121668 22486 7,66 ns $ $ ns 545 29 717 95 383 25 743 107 438 24 734 48 630 26 590 55
53 @ 1c Phosphoglucomutase Metab. 1,3 up ns 1,6 up $ 1,7 up $ 1,0 down ns gi|730311 61519 6,32 ns $ $ ns 682 94 875 157 641 70 1037 99 673 40 1117 70 809 47 788 23
54 @ 1c
Dihydrolipoamide 
dehydrogenase 
Metab. 1,1 up ns 1,3 up $ 1,3 up $ 1,0 down ns gi|81885266 54004 7,96 ns $ $ ns 1237 92 1385 109 1319 87 1660 110 1051 32 1358 50 1186 59 1177 56
55 @ 4d
Nucleoside diphos-
phate kinase (B?)
Metab. 1,0 down ns 1,3 up $ 1,1 up ns 1,0 up ns gi|127984 17386 6,92 ns $ ns ns 1962 67 1962 157 1967 69 2623 115 2169 90 2400 96 2223 67 2240 137
56 @ 2c
Annexin I = Lipo-
cortin I
Misc. 1,5 up $ 1,6 up ns 1,5 up $ 1,1 down ns gi|113947 39016 7,14 $ ns $ ns 513 74 790 52 432 57 692 95 512 44 746 60 403 36 364 48
57 @ 1d Catalase Stress 1,2 down ns 1,7 down $ 1,2 down ns 1,1 down ns gi|115707 59931 7,15 ns $ ns ns 356 59 306 24 439 61 263 22 452 112 393 58 1330 83 1240 120
58 @ 1d
Carnitine O-
palmitolyltransferase 
II (prec)
Metab. 1,1 down ns 1,4 down ns 1,1 down ns 1,0 down ns gi|117289 74634 6,89 ns ns ns ns 558 39 497 54 544 64 392 28 300 25 269 20 342 23 327 55
59 @ 4d
Peroxiredoxin 5, mit 
prec
Stress 1,3 down ns 1,2 up $ 1,1 down ns 1,0 up ns gi|20138819 22507 8,94 ns $ ns ns 636 48 499 59 377 22 469 27 375 26 344 24 510 44 520 48
60 @ 4d
Nucleoside diphos-
phate kinase
Metab. 1,2 up ns 1,8 up $ 2,0 up $ 1,0 up ns gi|127984 17386 6,92 ns $ $ ns 762 97 943 178 618 67 1118 103 472 40 937 34 602 39 625 43
61 @ 3d
Triosephosphate 
isomerase (fragment)
Metab. 1,1 down ns 1,2 up $ 1,2 up $ 1,0 up ns gi|1351280 26773 6,51 ns $ $ ns 2869 168 2570 75 2897 153 3490 157 2489 142 3069 125 3073 123 3086 220
62 @ 2d no ID No ID 1,0 down ns 1,4 down $ 1,4 down $ 1,2 down ns n/a n/a n/a n/a n/a n/a ns $ $ ns 876 51 844 37 739 59 544 31 626 39 452 18 803 130 655 61
63 @ 3d
Adenylate kinase 
isozyme 2 (mit?)
Metab. 1,4 down ns 1,3 down ns 1,1 up ns 1,2 down ns gi|266401 26232 6,36 ns ns ns ns 657 60 464 101 441 41 328 29 356 41 377 36 497 30 416 44
64 @ 2d Bcat2 protein Misc. 1,5 down $ 1,7 down $ 1,4 down $ 1,0 up ns gi|81885326 44138 8,62 $ $ $ ns 1239 120 851 88 1312 146 780 88 1018 56 704 43 1027 71 1038 101
65 @ 2b
Pyruvate dehydro-
genase (lipoamide), 
B-chain
 - - - - - - - - - - - - gi|1352624 38823 5,94 - - - - - - - - - - - - - - - - - - - -
66 @ 1b Desmin  - - - - - - - - - - - - gi|1352241 53293 5,21 - - - - - - - - - - - - - - - - - - - -
67 @ 1a Desmin  - - - - - - - - - - - - gi|11968118 53424 5,21 - - - - - - - - - - - - - - - - - - - -
68 @ 1b
dnaK-type molecular 
chaperone GRP75, 
prec
 - - - - - - - - - - - - gi|55584140 73699 5,87 - - - - - - - - - - - - - - - - - - - -
69 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
70 @ 3c Alpha-B-crystallin  - - - - - - - - - - - - gi|2119189 20076 6,76 - - - - - - - - - - - - - - - - - - - -
71 @ 4a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
72 @ 4c
Superoxide dismutase 
[Cu-Zn]
 - - - - - - - - - - - - gi|818029 15569 5,89 - - - - - - - - - - - - - - - - - - - -
73 @ 4d Myoglobin  - - - - - - - - - - - - gi|78099013 17146 7,83 - - - - - - - - - - - - - - - - - - - -
74 @ 4d Myoglobin  - - - - - - - - - - - - gi|78099013 17146 7,83 - - - - - - - - - - - - - - - - - - - -
75 @ 4d Myoglobin  - - - - - - - - - - - - gi|78099013 17146 7,83 - - - - - - - - - - - - - - - - - - - -
76 @ 2d Aldolase A  - - - - - - - - - - - - gi|6978487 39327 8,31 - - - - - - - - - - - - - - - - - - - -
77 @ 2c
Peroxisomal dienoyl 
CoA isomerase
Metab. 1,4 down ns 1,5 down $ 2,1 down $ 1,1 down ns gi|6015047 36148 8,13 ns $ $ ns 3120 330 2184 172 3727 315 2561 288 3410 120 1624 101 3235 99 3034 160
78 @ 1d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
79 @ 1c
Enolase 1 = Alpha 
Enolase
Metab. 1,2 up ns 1,1 up ns 1,3 up $ 1,0 down ns gi|56757324 46955 6,16 ns ns $ ns 4427 340 5463 475 4507 237 5078 507 4887 299 6361 521 5633 119 5493 277
80 @ 3c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
81 @ 2b
Troponin T, cardiac 
muscle isoforms
 - - - - - - - - - - - - gi|1717772 34431 5,19 - - - - - - - - - - - - - - - - - - - -
82 @ 2c Aldose reductase Metab. 1,0 up ns 1,1 up ns 1,2 up $ 1,1 down ns gi|1168407 35643 6,28 ns ns $ ns 2899 89 2938 158 3351 145 3768 147 3454 103 3997 138 3392 120 3148 141
83 @ 2c
NADH dehydroge-
nase 1 alpha-subcom-
plex 10-like protein
Metab. 1,0 up ns 1,1 down ns 1,2 down ns 1,4 down $ gi|81885291 31681 5,44 ns ns ns $ 608 151 617 103 633 140 588 109 374 73 299 52 563 48 406 42
84 @ 2c
Acyl CoA dehydroge-
nase, short chain spec 
mito prec
Metab. 1,0 up ns 1,1 down ns 1,2 down $ 1,1 down ns gi|1168286 44737 8,47 ns ns $ ns 712 70 722 62 812 65 762 67 627 34 522 31 773 51 705 46
85 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
86 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
87 @ 3c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
88 @ 3c
Proteasome endo-
peptidase complex, 
iota chain
 - - - - - - - - - - - - gi|46397659 27382 6,34 - - - - - - - - - - - - - - - - - - - -
89 @ 3c
Hypoxanthine phos-
phoribosyltransferase
 - - - - - - - - - - - - gi|2117729 24462 6,07 - - - - - - - - - - - - - - - - - - - -
90 @ 2d
Creatine-kinase 
M-chain
Metab. 1,0 up ns 1,4 down ns 1,5 down $ 1,0 down ns gi|125308 42992 6,58 ns ns $ ns 13684 3017 14259 1697 15541 1781 11378 1593 26994 1265 18596 1772 22883 1372 21845 1146
91 @ 1c Transferrin  - - - - - - - - - - - - gi|6175089 75809 7,57 - - - - - - - - - - - - - - - - - - - -
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47 @ 1b
Dihydrolipoamide 
S-acetyltransferase 
(fragment)
Metab. 1,2 down ns 1,8 up $ 1,3 up ns 1,2 down ns gi|220838 57645 5,53 ns $ ns ns 210 20 172 23 276 32 501 35 488 33 622 62 679 88 563 70
48 @ 2c no ID No ID 1,2 down ns 1,5 down ns 1,2 down ns 1,1 up ns n/a n/a n/a n/a n/a n/a ns ns ns ns 162 28 135 34 208 23 138 20 176 10 144 15 196 19 213 18
49 @ 1c
Propionyl-CoA car-
boxylase alpha-chain 
prec.
Metab. 1,1 down ns 1,3 down ns 1,2 down $ 1,0 down ns gi|92654 78190 6,33 ns ns $ ns 1396 125 1238 102 1683 159 1296 90 1554 62 1267 62 1487 128 1420 103
50 @ 4c
Histidine triad nucleo-
tide-binding protein 1 
= PKC-inhibitor
Misc. - - xx 1,8 up $ 1,3 up ns - - xx gi|2495231 13751 6,39 xx $ ns xx - - 285 46 508 80 267 22 341 34 - -
51 @ 1c
Selenium binding 
protein 2
Misc. 1,4 down $ 1,4 down $ 1,5 down $ 1,1 down ns gi|81879451 52498 6,10 $ $ $ ns 838 68 604 14 915 85 656 62 761 29 517 23 711 41 620 42
52 @ 3c
Gluthathione per-
oxidase
Stress 1,3 up ns 1,9 up $ 1,7 up $ 1,1 down ns gi|121668 22486 7,66 ns $ $ ns 545 29 717 95 383 25 743 107 438 24 734 48 630 26 590 55
53 @ 1c Phosphoglucomutase Metab. 1,3 up ns 1,6 up $ 1,7 up $ 1,0 down ns gi|730311 61519 6,32 ns $ $ ns 682 94 875 157 641 70 1037 99 673 40 1117 70 809 47 788 23
54 @ 1c
Dihydrolipoamide 
dehydrogenase 
Metab. 1,1 up ns 1,3 up $ 1,3 up $ 1,0 down ns gi|81885266 54004 7,96 ns $ $ ns 1237 92 1385 109 1319 87 1660 110 1051 32 1358 50 1186 59 1177 56
55 @ 4d
Nucleoside diphos-
phate kinase (B?)
Metab. 1,0 down ns 1,3 up $ 1,1 up ns 1,0 up ns gi|127984 17386 6,92 ns $ ns ns 1962 67 1962 157 1967 69 2623 115 2169 90 2400 96 2223 67 2240 137
56 @ 2c
Annexin I = Lipo-
cortin I
Misc. 1,5 up $ 1,6 up ns 1,5 up $ 1,1 down ns gi|113947 39016 7,14 $ ns $ ns 513 74 790 52 432 57 692 95 512 44 746 60 403 36 364 48
57 @ 1d Catalase Stress 1,2 down ns 1,7 down $ 1,2 down ns 1,1 down ns gi|115707 59931 7,15 ns $ ns ns 356 59 306 24 439 61 263 22 452 112 393 58 1330 83 1240 120
58 @ 1d
Carnitine O-
palmitolyltransferase 
II (prec)
Metab. 1,1 down ns 1,4 down ns 1,1 down ns 1,0 down ns gi|117289 74634 6,89 ns ns ns ns 558 39 497 54 544 64 392 28 300 25 269 20 342 23 327 55
59 @ 4d
Peroxiredoxin 5, mit 
prec
Stress 1,3 down ns 1,2 up $ 1,1 down ns 1,0 up ns gi|20138819 22507 8,94 ns $ ns ns 636 48 499 59 377 22 469 27 375 26 344 24 510 44 520 48
60 @ 4d
Nucleoside diphos-
phate kinase
Metab. 1,2 up ns 1,8 up $ 2,0 up $ 1,0 up ns gi|127984 17386 6,92 ns $ $ ns 762 97 943 178 618 67 1118 103 472 40 937 34 602 39 625 43
61 @ 3d
Triosephosphate 
isomerase (fragment)
Metab. 1,1 down ns 1,2 up $ 1,2 up $ 1,0 up ns gi|1351280 26773 6,51 ns $ $ ns 2869 168 2570 75 2897 153 3490 157 2489 142 3069 125 3073 123 3086 220
62 @ 2d no ID No ID 1,0 down ns 1,4 down $ 1,4 down $ 1,2 down ns n/a n/a n/a n/a n/a n/a ns $ $ ns 876 51 844 37 739 59 544 31 626 39 452 18 803 130 655 61
63 @ 3d
Adenylate kinase 
isozyme 2 (mit?)
Metab. 1,4 down ns 1,3 down ns 1,1 up ns 1,2 down ns gi|266401 26232 6,36 ns ns ns ns 657 60 464 101 441 41 328 29 356 41 377 36 497 30 416 44
64 @ 2d Bcat2 protein Misc. 1,5 down $ 1,7 down $ 1,4 down $ 1,0 up ns gi|81885326 44138 8,62 $ $ $ ns 1239 120 851 88 1312 146 780 88 1018 56 704 43 1027 71 1038 101
65 @ 2b
Pyruvate dehydro-
genase (lipoamide), 
B-chain
 - - - - - - - - - - - - gi|1352624 38823 5,94 - - - - - - - - - - - - - - - - - - - -
66 @ 1b Desmin  - - - - - - - - - - - - gi|1352241 53293 5,21 - - - - - - - - - - - - - - - - - - - -
67 @ 1a Desmin  - - - - - - - - - - - - gi|11968118 53424 5,21 - - - - - - - - - - - - - - - - - - - -
68 @ 1b
dnaK-type molecular 
chaperone GRP75, 
prec
 - - - - - - - - - - - - gi|55584140 73699 5,87 - - - - - - - - - - - - - - - - - - - -
69 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
70 @ 3c Alpha-B-crystallin  - - - - - - - - - - - - gi|2119189 20076 6,76 - - - - - - - - - - - - - - - - - - - -
71 @ 4a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
72 @ 4c
Superoxide dismutase 
[Cu-Zn]
 - - - - - - - - - - - - gi|818029 15569 5,89 - - - - - - - - - - - - - - - - - - - -
73 @ 4d Myoglobin  - - - - - - - - - - - - gi|78099013 17146 7,83 - - - - - - - - - - - - - - - - - - - -
74 @ 4d Myoglobin  - - - - - - - - - - - - gi|78099013 17146 7,83 - - - - - - - - - - - - - - - - - - - -
75 @ 4d Myoglobin  - - - - - - - - - - - - gi|78099013 17146 7,83 - - - - - - - - - - - - - - - - - - - -
76 @ 2d Aldolase A  - - - - - - - - - - - - gi|6978487 39327 8,31 - - - - - - - - - - - - - - - - - - - -
77 @ 2c
Peroxisomal dienoyl 
CoA isomerase
Metab. 1,4 down ns 1,5 down $ 2,1 down $ 1,1 down ns gi|6015047 36148 8,13 ns $ $ ns 3120 330 2184 172 3727 315 2561 288 3410 120 1624 101 3235 99 3034 160
78 @ 1d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
79 @ 1c
Enolase 1 = Alpha 
Enolase
Metab. 1,2 up ns 1,1 up ns 1,3 up $ 1,0 down ns gi|56757324 46955 6,16 ns ns $ ns 4427 340 5463 475 4507 237 5078 507 4887 299 6361 521 5633 119 5493 277
80 @ 3c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
81 @ 2b
Troponin T, cardiac 
muscle isoforms
 - - - - - - - - - - - - gi|1717772 34431 5,19 - - - - - - - - - - - - - - - - - - - -
82 @ 2c Aldose reductase Metab. 1,0 up ns 1,1 up ns 1,2 up $ 1,1 down ns gi|1168407 35643 6,28 ns ns $ ns 2899 89 2938 158 3351 145 3768 147 3454 103 3997 138 3392 120 3148 141
83 @ 2c
NADH dehydroge-
nase 1 alpha-subcom-
plex 10-like protein
Metab. 1,0 up ns 1,1 down ns 1,2 down ns 1,4 down $ gi|81885291 31681 5,44 ns ns ns $ 608 151 617 103 633 140 588 109 374 73 299 52 563 48 406 42
84 @ 2c
Acyl CoA dehydroge-
nase, short chain spec 
mito prec
Metab. 1,0 up ns 1,1 down ns 1,2 down $ 1,1 down ns gi|1168286 44737 8,47 ns ns $ ns 712 70 722 62 812 65 762 67 627 34 522 31 773 51 705 46
85 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
86 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
87 @ 3c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
88 @ 3c
Proteasome endo-
peptidase complex, 
iota chain
 - - - - - - - - - - - - gi|46397659 27382 6,34 - - - - - - - - - - - - - - - - - - - -
89 @ 3c
Hypoxanthine phos-
phoribosyltransferase
 - - - - - - - - - - - - gi|2117729 24462 6,07 - - - - - - - - - - - - - - - - - - - -
90 @ 2d
Creatine-kinase 
M-chain
Metab. 1,0 up ns 1,4 down ns 1,5 down $ 1,0 down ns gi|125308 42992 6,58 ns ns $ ns 13684 3017 14259 1697 15541 1781 11378 1593 26994 1265 18596 1772 22883 1372 21845 1146
91 @ 1c Transferrin  - - - - - - - - - - - - gi|6175089 75809 7,57 - - - - - - - - - - - - - - - - - - - -
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92 @ 1d Aconitase, mit, prec  - - - - - - - - - - - - gi|13242312 85421 7,87 - - - - - - - - - - - - - - - - - - - -
93 @ 1b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
94 @ 1c
Aldehyde dehydro-
genase / ALDH , mit, 
prec.
 - - - - - - - - - - - - gi|16073616 48239 6,06 - - - - - - - - - - - - - - - - - - - -
95 @ 1c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
96 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
97 @ 3d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
98 @ 1b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
99 @ 2b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
100 @ 2b Actin alpha  - - - - - - - - - - - - gi|54036698 41758 5,30 - - - - - - - - - - - - - - - - - - - -
101 @ 2c
Acyl-CoA dehydroge-
nase, long chain, prec
 - - - - - - - - - - - - gi|113016 47842 7,63 - - - - - - - - - - - - - - - - - - - -
102 @ 3b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
103 @ 3b
Adenine phosphori-
bosyltransferase
 - - - - - - - - - - - - gi|202964 19533 6,17 - - - - - - - - - - - - - - - - - - - -
104 @ 3c
Hypoxantine phos-
phoribosyltransferase
 - - - - - - - - - - - - gi|2117729 24462 6,07 - - - - - - - - - - - - - - - - - - - -
105 @ 1c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
106 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
107 @ 1d
Methylmalonate-
semialdehyde 
dehydrogenase 
(acylating)
 - - - - - - - - - - - - gi|400269 57771 8,47 - - - - - - - - - - - - - - - - - - - -
108 @ 1c Transferrin  - - - - - - - - - - - - gi|1854476 76314 6,94 - - - - - - - - - - - - - - - - - - - -
109 @ 2d
Creatine kinase, sarco-
meric mitochondrial, 
prec ?
 - - - - - - - - - - - - gi|125313 47355 8,76 - - - - - - - - - - - - - - - - - - - -
110 @ 2d
Alcohol dehydroge-
nase [NADP+]
 - - - - - - - - - - - - gi|1703237 36352 6,81 - - - - - - - - - - - - - - - - - - - -
111 @ 2d
Carbonyl reductase 
[NADPH] 1
Metab. 1,1 down ns 1,1 down ns 1,2 down $ 1,1 down ns gi|1352258 30428 8,21 ns ns $ ns 6421 356 5597 153 7237 420 6438 483 7658 260 6462 171 7612 191 6934 415
112 @ 3c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
113 @ 3d
Glutathion S-
transferase YB2
 - - - - - - - - - - - - gi|121719 25555 7,30 - - - - - - - - - - - - - - - - - - - -
114 @ 3d
Adenylate kinase 
isozyme 1
 - - - - - - - - - - - - gi|23831184 21588 7,71 - - - - - - - - - - - - - - - - - - - -
115 @ 3d
Superoxide dismutase 
[Mn], mit, prec
 - - - - - - - - - - - - gi|134678 24659 8,96 - - - - - - - - - - - - - - - - - - - -
116 @ 2b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
117 @ 1c
Dihydropyrimidinase 
related protein-2
Misc. 1,2 up ns 1,5 down ns 1,3 up ns - - - gi|1351260 62239 5,95 ns ns ns - 102 5 119 16 268 60 181 38 125 16 160 27 - - - -
118 @ 2d
Fumarate hydratase, 
mit prec.
Metab. 1,1 down ns 1,2 down ns 1,4 up $ 1,2 up ns gi|120605 54429 9,06 ns ns $ ns 1110 170 975 129 1159 55 945 99 726 33 989 62 1196 70 1396 65
119 @ 1d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
120 @ 1d no ID No ID 1,4 up ns 1,0 up ns 2,3 up $ 1,1 down ns n/a n/a n/a n/a n/a n/a ns ns $ ns 3933 437 5622 955 4524 815 4533 560 4962 475 11197 762 6854 258 6176 524
121 @ 1c
Propionyl-CoA car-
boxylase, beta chain 
mit prec
Metab. 1,1 up ns 1,3 up ns - - - - - - gi|129686| 58589 7,19 ns ns - - 250 18 264 17 262 37 329 33 - - - - - - - -
122 @ 1c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
123 @ 1d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
124 @ 1d Aconitase, mit, prec  - - - - - - - - - - - - gi|13242312 85421 7,87 - - - - - - - - - - - - - - - - - - - -
125 @ 1a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
126 @ 2a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
127 @ 2a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
128 @ 2a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
129 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
130 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
131 @ 3d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
132 @ 3d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
133 @ 1a Vimentin Misc. - - - - - - - - - - - - gi|14389299 53700 5,06 - - - - - - - - - - - - - - - - - - - -
134 @ 1b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
135 @ 2d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
136 @ 1d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
137 @ 1c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
138 @ 3a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
139 @ 3b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
140 @ 3a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
141 @ 3a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
142 @ 1b
Protein disulphide 
isomerase A3, prec.
Misc. 1,3 up $ 1,4 up ns 1,4 up $ 1,1 down ns gi|1352384 56588 5,88 $ ns $ ns 317 15 409 37 348 48 475 65 493 30 671 55 472 31 420 35
143 @ 1c
T-complex protein 1, 
gamma subunit 
Misc. 1,2 up $ 1,1 up ns 1,2 up ns 1,1 up ns gi|549059 60450 6,23 $ ns ns ns 263 17 321 14 176 22 195 15 128 7 147 9 140 6 154 27
144 @ 1c
Propionyl-CoA car-
boxylase, beta chain 
mit prec
Metab. 1,4 down $ 1,2 down ns 1,2 down ns 1,0 down ns gi|129686 58589 7,19 $ ns ns ns 1218 69 842 35 1084 105 876 37 926 56 791 62 951 44 918 46
145 @ 1c
Adenylyl cyclase-
associated protein
Misc. 1,3 up $ 1,2 up ns 1,6 up $ 1,3 up ns gi|1705586 52879 6,69 $ ns $ ns 158 10 203 14 88 23 104 9 75 9 122 19 102 10 137 21
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92 @ 1d Aconitase, mit, prec  - - - - - - - - - - - - gi|13242312 85421 7,87 - - - - - - - - - - - - - - - - - - - -
93 @ 1b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
94 @ 1c
Aldehyde dehydro-
genase / ALDH , mit, 
prec.
 - - - - - - - - - - - - gi|16073616 48239 6,06 - - - - - - - - - - - - - - - - - - - -
95 @ 1c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
96 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
97 @ 3d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
98 @ 1b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
99 @ 2b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
100 @ 2b Actin alpha  - - - - - - - - - - - - gi|54036698 41758 5,30 - - - - - - - - - - - - - - - - - - - -
101 @ 2c
Acyl-CoA dehydroge-
nase, long chain, prec
 - - - - - - - - - - - - gi|113016 47842 7,63 - - - - - - - - - - - - - - - - - - - -
102 @ 3b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
103 @ 3b
Adenine phosphori-
bosyltransferase
 - - - - - - - - - - - - gi|202964 19533 6,17 - - - - - - - - - - - - - - - - - - - -
104 @ 3c
Hypoxantine phos-
phoribosyltransferase
 - - - - - - - - - - - - gi|2117729 24462 6,07 - - - - - - - - - - - - - - - - - - - -
105 @ 1c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
106 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
107 @ 1d
Methylmalonate-
semialdehyde 
dehydrogenase 
(acylating)
 - - - - - - - - - - - - gi|400269 57771 8,47 - - - - - - - - - - - - - - - - - - - -
108 @ 1c Transferrin  - - - - - - - - - - - - gi|1854476 76314 6,94 - - - - - - - - - - - - - - - - - - - -
109 @ 2d
Creatine kinase, sarco-
meric mitochondrial, 
prec ?
 - - - - - - - - - - - - gi|125313 47355 8,76 - - - - - - - - - - - - - - - - - - - -
110 @ 2d
Alcohol dehydroge-
nase [NADP+]
 - - - - - - - - - - - - gi|1703237 36352 6,81 - - - - - - - - - - - - - - - - - - - -
111 @ 2d
Carbonyl reductase 
[NADPH] 1
Metab. 1,1 down ns 1,1 down ns 1,2 down $ 1,1 down ns gi|1352258 30428 8,21 ns ns $ ns 6421 356 5597 153 7237 420 6438 483 7658 260 6462 171 7612 191 6934 415
112 @ 3c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
113 @ 3d
Glutathion S-
transferase YB2
 - - - - - - - - - - - - gi|121719 25555 7,30 - - - - - - - - - - - - - - - - - - - -
114 @ 3d
Adenylate kinase 
isozyme 1
 - - - - - - - - - - - - gi|23831184 21588 7,71 - - - - - - - - - - - - - - - - - - - -
115 @ 3d
Superoxide dismutase 
[Mn], mit, prec
 - - - - - - - - - - - - gi|134678 24659 8,96 - - - - - - - - - - - - - - - - - - - -
116 @ 2b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
117 @ 1c
Dihydropyrimidinase 
related protein-2
Misc. 1,2 up ns 1,5 down ns 1,3 up ns - - - gi|1351260 62239 5,95 ns ns ns - 102 5 119 16 268 60 181 38 125 16 160 27 - - - -
118 @ 2d
Fumarate hydratase, 
mit prec.
Metab. 1,1 down ns 1,2 down ns 1,4 up $ 1,2 up ns gi|120605 54429 9,06 ns ns $ ns 1110 170 975 129 1159 55 945 99 726 33 989 62 1196 70 1396 65
119 @ 1d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
120 @ 1d no ID No ID 1,4 up ns 1,0 up ns 2,3 up $ 1,1 down ns n/a n/a n/a n/a n/a n/a ns ns $ ns 3933 437 5622 955 4524 815 4533 560 4962 475 11197 762 6854 258 6176 524
121 @ 1c
Propionyl-CoA car-
boxylase, beta chain 
mit prec
Metab. 1,1 up ns 1,3 up ns - - - - - - gi|129686| 58589 7,19 ns ns - - 250 18 264 17 262 37 329 33 - - - - - - - -
122 @ 1c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
123 @ 1d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
124 @ 1d Aconitase, mit, prec  - - - - - - - - - - - - gi|13242312 85421 7,87 - - - - - - - - - - - - - - - - - - - -
125 @ 1a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
126 @ 2a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
127 @ 2a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
128 @ 2a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
129 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
130 @ 2c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
131 @ 3d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
132 @ 3d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
133 @ 1a Vimentin Misc. - - - - - - - - - - - - gi|14389299 53700 5,06 - - - - - - - - - - - - - - - - - - - -
134 @ 1b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
135 @ 2d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
136 @ 1d no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
137 @ 1c no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
138 @ 3a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
139 @ 3b no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
140 @ 3a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
141 @ 3a no ID  - - - - - - - - - - - - n/a n/a n/a n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
142 @ 1b
Protein disulphide 
isomerase A3, prec.
Misc. 1,3 up $ 1,4 up ns 1,4 up $ 1,1 down ns gi|1352384 56588 5,88 $ ns $ ns 317 15 409 37 348 48 475 65 493 30 671 55 472 31 420 35
143 @ 1c
T-complex protein 1, 
gamma subunit 
Misc. 1,2 up $ 1,1 up ns 1,2 up ns 1,1 up ns gi|549059 60450 6,23 $ ns ns ns 263 17 321 14 176 22 195 15 128 7 147 9 140 6 154 27
144 @ 1c
Propionyl-CoA car-
boxylase, beta chain 
mit prec
Metab. 1,4 down $ 1,2 down ns 1,2 down ns 1,0 down ns gi|129686 58589 7,19 $ ns ns ns 1218 69 842 35 1084 105 876 37 926 56 791 62 951 44 918 46
145 @ 1c
Adenylyl cyclase-
associated protein
Misc. 1,3 up $ 1,2 up ns 1,6 up $ 1,3 up ns gi|1705586 52879 6,69 $ ns $ ns 158 10 203 14 88 23 104 9 75 9 122 19 102 10 137 21
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146 @ 4b
Fatty acid binding 
protein
Metab. - - - - - - - - - - - - n/a n/a n/a
literature com-
parison
- - - - - - - - - - - - - - - - - - - -
147 @ 4c
Transthyretin prec 
(prealbumin)
Misc. - - - - - - - - - - - - n/a n/a n/a
literature com-
parison
literature com-
parison
literature com-
parison
literature com-
parison
- - - - - - - - - - - - - - - - - - - -
148 @ 1a
ATP synthase beta-
subunit, mit prec
Metab. - - - - - - - - - - - - n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
149 @ 4d Hemoglobin B-chain Misc. - - - - - - - - - - - - n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
150 @ 3b Endothelin 3 prec Misc. - - - - - - - - - - - - n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
151 @ 3a
Peroxiredoxin 2 = 
Thioredoxin per-
oxidase
Stress 1,0 down ns 1,1 down ns 1,4 down $ 1,2 down $ gi|549132 21770 5,34 ns ns $ $ 991 47 985 65 605 28 553 48 505 40 362 33 860 60 727 41
152 @ 2a no ID No ID - - - - - - 1,2 up $ 1,0 up ns n/a n/a n/a n/a n/a n/a - - $ ns - - - - - - - - 919 40 1067 27 965 45 1001 39
153 @ 1a Calreticulin prec Stress 1,0 up ns 1,4 up ns 1,6 up $ 1,1 up ns gi|117505 47966 4,33 ns ns $ ns 1188 159 1193 229 888 96 1222 143 921 77 1506 85 536 56 595 34
154 @ 1a
dnaK-type molecular 
chaperone prec
Stress 1,1 down ns 1,1 up ns 1,4 up $ 1,0 down ns gi|121574 72302 5,07 ns ns $ ns 1441 124 1363 147 1278 156 1434 72 1237 48 1764 99 1378 81 1324 60
155 @ 1b
dnaK-type molecular 
chaperone hsc-73
Stress 1,0 up ns 1,2 up ns 1,4 up $ 1,2 down ns gi|347019 70884 5,43 ns ns $ ns 2585 235 2637 381 3145 231 3800 419 3865 277 5307 321 4051 360 3514 285
156 @ 2b
3-methyl-2-oxob-
utanoate dehydro-
genase (lipoamide) 
alpha-chain prec
Metab. 1,3 down ns 1,1 down ns 1,7 down $ 1,2 down ns gi|129032 50133 7,68 ns ns $ ns 429 64 333 36 594 40 531 46 811 80 490 37 741 107 606 117
157 @ 1b Guanine deaminase Misc. 1,0 up ns 2,0 up ns 2,0 up $ 1,1 up ns gi|81868670 50869 5,48 ns ns $ ns 153 36 160 20 151 32 300 79 218 19 435 44 205 12 215 18
158 @ 1b
Dihydrolipoamide 
S-acetyltransferase 
(fragment)
Metab. 1,0 down ns 1,3 up $ 1,2 up $ 1,1 down ns gi|266685 58727 5,70 ns $ $ ns 1901 139 1854 108 2312 126 2982 185 3976 230 4866 292 4543 399 4280 353
159 @ 1c
Aldehyde dehydroge-
nase, mit (fragment)
Metab. 1,2 up ns 1,3 up ns 1,6 up $ 1,0 down ns gi|81892738 55566 6,69 ns ns $ ns 3591 346 4154 413 3658 485 4580 312 3681 113 5897 417 4317 289 4217 270
160 @1c
TNF receptor-associ-
ated protein 1
Misc. 1,4 down ns 1,3 down ns 1,4 down $ 1,0 up ns gi|81910345 80411 6,56 ns ns $ ns 1675 194 1226 112 1890 212 1404 120 1229 74 892 37 1370 131 1397 114
161 @ 1c
Dihydropyrimidinase 
related protein-2
Misc. 1,2 up ns 1,1 up ns 1,3 up $ 1,0 down ns gi|1351260 62239 5,95 ns ns $ ns 541 51 630 77 555 90 624 57 413 17 548 33 431 25 428 28
162 @ 1c no ID No ID - - - - - - 2,4 down $ 1,0 up ns n/a n/a n/a n/a n/a n/a - - $ ns - - - - - - - - 807 91 334 28 539 68 560 53
163 @ 2c
Acyl-CoA dehydro-
genase, short chain 
specific, mit prec
Metab. 1,1 up ns 1,1 down ns 1,4 down $ 1,1 down ns gi|1168286 44737 8,47 ns ns $ ns 3305 364 3614 361 4259 289 4006 345 4172 248 3068 215 4641 287 4162 304
164 @ 1c
ATP synthase, H+ 
transporting, mito-
chondrial F1 complex, 
alpha subunit, 
isoform 1
Metab. 1,2 up ns 1,2 up ns 1,3 up $ 1,0 down ns gi|83300587 59717 9,22 ns ns $ ns 533 36 633 33 468 43 561 77 467 23 618 29 458 32 442 21
165 @ 1c
Electron-transferring-
flavoprotein dehydro-
genase
Misc. 1,1 down ns 1,2 down ns 1,2 down $ 1,0 down ns gi|52000614 68155 7,33 ns ns $ ns 1376 128 1285 49 1551 249 1326 112 1906 106 1608 68 1690 85 1634 112
166 @ 2c no ID No ID - - - - - - 1,1 down $ 1,1 down ns n/a n/a n/a n/a n/a n/a - - $ ns - - - - - - - - 912 30 821 26 802 45 710 51
167 @ 2c
Acyl coA thioesterase, 
mit prec.
Metab. 1,3 down ns 1,2 down ns 1,7 down $ 1,0 down ns gi|6166586 49670 7,68 ns ns $ ns 2378 315 1888 145 2988 296 2402 188 3648 158 2178 118 3412 164 3317 195
168 @ 1d
Glutamate dehydro-
genase 1
Metab. 1,0 up ns 1,2 down ns 1,2 down $ 1,1 down ns gi|92090591 61377 8,05 ns ns $ ns 1994 171 2058 287 2710 220 2261 215 3067 163 2525 134 2500 126 2227 156
169 @ 4d
Fatty acid binding 
protein, adiposite 
(AFABP)
Metab. - - - 1,2 down ns 2,0 down $ - - - gi|2494405 14568 7,93 xx ns $ xx - - 2691 248 2232 155 3097 212 1580 92 - -
170 @2d
Aspartate transami-
nase
Metab. 1,2 down ns 1,1 down ns 1,2 down $ 1,1 up ns gi|91997 46399 6,73 ns ns $ ns 3954 217 3434 283 4645 383 4087 196 5254 241 4224 176 4959 299 5273 273
171 @ 1d
3-oxoacid CoA-
transferase  
Metab. 1,4 up $ 1,4 up $ 1,5 up $ 1,3 up ns gi|2492999 56371 8,47 $ $ $ ns 2233 270 3051 235 3008 274 4356 266 2812 327 4265 283 2635 109 3408 519
172 @ 1d
Fumarate hydratase, 
mit prec.
Metab. 1,0 up ns 1,1 down ns 1,2 up $ 1,1 up ns gi|120605 54429 9,06 ns ns $ ns 2088 179 2175 320 3408 142 2991 178 2359 155 2938 183 3538 170 3775 178
173 @ 1b no ID No ID 1,9 down $ 1,7 down ns 2,2 down $ 1,6 down $ n/a n/a n/a n/a n/a n/a $ ns $ $ 92 13 48 13 131 34 79 15 161 19 73 14 252 31 158 33
174 @ 1c
Succinate dehydro-
genase [ubiquinone] 
flavoprotein subunit, 
mit, prec
Metab. 1,1 up $ 1,1 down ns 1,2 down ns 1,2 down $ gi|52782765 71570 6,75 $ ns ns $ 1241 62 1417 88 1155 161 1096 112 1060 167 921 51 1289 64 1052 58
175 @ 1c no ID No ID 1,1 up ns 1,2 up ns 1,0 down ns 1,3 down $ n/a n/a n/a n/a n/a n/a ns ns ns $ 263 24 298 14 186 28 216 15 154 8 148 14 198 15 154 6
176 @ 1c
Succinate dehydro-
genase [ubiquinone] 
flavoprotein subunit, 
mit, prec
Metab. 1,1 up ns 1,0 up ns 1,1 down ns 1,3 down $ gi|52782765 71570 6,75 ns ns ns $ 3674 383 3936 410 2617 207 2688 188 2950 317 2771 146 3504 167 2765 234
177 @ 2c no ID No ID 1,0 down ns 1,2 down ns 1,1 down ns 1,7 down $ n/a n/a n/a n/a n/a n/a ns ns ns $ 600 161 591 125 453 109 378 53 319 76 284 40 507 60 298 35
178 @ 1c
Dihydrolipoamide 
dehydrogenase 
Metab. 1,3 up ns 1,2 up ns 1,1 up ns 1,1 down $ gi|81885266 54004 7,96 ns ns ns $ 511 75 642 51 722 68 833 82 700 42 775 31 617 25 542 19
179 @ 3d
Ubiquinol-cyto-
chrome c reductase 
iron-sulfur subunit, 
mit, prec.
Metab. 1,0 up ns 1,1 down ns 1,3 down ns 1,6 down $ gi|52001457 29427 9,04 ns ns ns $ 2229 633 2238 343 3044 662 2681 428 1813 216 1403 187 2346 187 1499 239
Protein database corresponding to 2-DE map presented in Figure 1S.                   * Mann-Whitney statistics were used to compare sham vs. PAB within one time group.                           
$= p<0.05 and ns=non-significant.
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146 @ 4b
Fatty acid binding 
protein
Metab. - - - - - - - - - - - - n/a n/a n/a
literature com-
parison
- - - - - - - - - - - - - - - - - - - -
147 @ 4c
Transthyretin prec 
(prealbumin)
Misc. - - - - - - - - - - - - n/a n/a n/a
literature com-
parison
literature com-
parison
literature com-
parison
literature com-
parison
- - - - - - - - - - - - - - - - - - - -
148 @ 1a
ATP synthase beta-
subunit, mit prec
Metab. - - - - - - - - - - - - n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
149 @ 4d Hemoglobin B-chain Misc. - - - - - - - - - - - - n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
150 @ 3b Endothelin 3 prec Misc. - - - - - - - - - - - - n/a n/a n/a - - - - - - - - - - - - - - - - - - - -
151 @ 3a
Peroxiredoxin 2 = 
Thioredoxin per-
oxidase
Stress 1,0 down ns 1,1 down ns 1,4 down $ 1,2 down $ gi|549132 21770 5,34 ns ns $ $ 991 47 985 65 605 28 553 48 505 40 362 33 860 60 727 41
152 @ 2a no ID No ID - - - - - - 1,2 up $ 1,0 up ns n/a n/a n/a n/a n/a n/a - - $ ns - - - - - - - - 919 40 1067 27 965 45 1001 39
153 @ 1a Calreticulin prec Stress 1,0 up ns 1,4 up ns 1,6 up $ 1,1 up ns gi|117505 47966 4,33 ns ns $ ns 1188 159 1193 229 888 96 1222 143 921 77 1506 85 536 56 595 34
154 @ 1a
dnaK-type molecular 
chaperone prec
Stress 1,1 down ns 1,1 up ns 1,4 up $ 1,0 down ns gi|121574 72302 5,07 ns ns $ ns 1441 124 1363 147 1278 156 1434 72 1237 48 1764 99 1378 81 1324 60
155 @ 1b
dnaK-type molecular 
chaperone hsc-73
Stress 1,0 up ns 1,2 up ns 1,4 up $ 1,2 down ns gi|347019 70884 5,43 ns ns $ ns 2585 235 2637 381 3145 231 3800 419 3865 277 5307 321 4051 360 3514 285
156 @ 2b
3-methyl-2-oxob-
utanoate dehydro-
genase (lipoamide) 
alpha-chain prec
Metab. 1,3 down ns 1,1 down ns 1,7 down $ 1,2 down ns gi|129032 50133 7,68 ns ns $ ns 429 64 333 36 594 40 531 46 811 80 490 37 741 107 606 117
157 @ 1b Guanine deaminase Misc. 1,0 up ns 2,0 up ns 2,0 up $ 1,1 up ns gi|81868670 50869 5,48 ns ns $ ns 153 36 160 20 151 32 300 79 218 19 435 44 205 12 215 18
158 @ 1b
Dihydrolipoamide 
S-acetyltransferase 
(fragment)
Metab. 1,0 down ns 1,3 up $ 1,2 up $ 1,1 down ns gi|266685 58727 5,70 ns $ $ ns 1901 139 1854 108 2312 126 2982 185 3976 230 4866 292 4543 399 4280 353
159 @ 1c
Aldehyde dehydroge-
nase, mit (fragment)
Metab. 1,2 up ns 1,3 up ns 1,6 up $ 1,0 down ns gi|81892738 55566 6,69 ns ns $ ns 3591 346 4154 413 3658 485 4580 312 3681 113 5897 417 4317 289 4217 270
160 @1c
TNF receptor-associ-
ated protein 1
Misc. 1,4 down ns 1,3 down ns 1,4 down $ 1,0 up ns gi|81910345 80411 6,56 ns ns $ ns 1675 194 1226 112 1890 212 1404 120 1229 74 892 37 1370 131 1397 114
161 @ 1c
Dihydropyrimidinase 
related protein-2
Misc. 1,2 up ns 1,1 up ns 1,3 up $ 1,0 down ns gi|1351260 62239 5,95 ns ns $ ns 541 51 630 77 555 90 624 57 413 17 548 33 431 25 428 28
162 @ 1c no ID No ID - - - - - - 2,4 down $ 1,0 up ns n/a n/a n/a n/a n/a n/a - - $ ns - - - - - - - - 807 91 334 28 539 68 560 53
163 @ 2c
Acyl-CoA dehydro-
genase, short chain 
specific, mit prec
Metab. 1,1 up ns 1,1 down ns 1,4 down $ 1,1 down ns gi|1168286 44737 8,47 ns ns $ ns 3305 364 3614 361 4259 289 4006 345 4172 248 3068 215 4641 287 4162 304
164 @ 1c
ATP synthase, H+ 
transporting, mito-
chondrial F1 complex, 
alpha subunit, 
isoform 1
Metab. 1,2 up ns 1,2 up ns 1,3 up $ 1,0 down ns gi|83300587 59717 9,22 ns ns $ ns 533 36 633 33 468 43 561 77 467 23 618 29 458 32 442 21
165 @ 1c
Electron-transferring-
flavoprotein dehydro-
genase
Misc. 1,1 down ns 1,2 down ns 1,2 down $ 1,0 down ns gi|52000614 68155 7,33 ns ns $ ns 1376 128 1285 49 1551 249 1326 112 1906 106 1608 68 1690 85 1634 112
166 @ 2c no ID No ID - - - - - - 1,1 down $ 1,1 down ns n/a n/a n/a n/a n/a n/a - - $ ns - - - - - - - - 912 30 821 26 802 45 710 51
167 @ 2c
Acyl coA thioesterase, 
mit prec.
Metab. 1,3 down ns 1,2 down ns 1,7 down $ 1,0 down ns gi|6166586 49670 7,68 ns ns $ ns 2378 315 1888 145 2988 296 2402 188 3648 158 2178 118 3412 164 3317 195
168 @ 1d
Glutamate dehydro-
genase 1
Metab. 1,0 up ns 1,2 down ns 1,2 down $ 1,1 down ns gi|92090591 61377 8,05 ns ns $ ns 1994 171 2058 287 2710 220 2261 215 3067 163 2525 134 2500 126 2227 156
169 @ 4d
Fatty acid binding 
protein, adiposite 
(AFABP)
Metab. - - - 1,2 down ns 2,0 down $ - - - gi|2494405 14568 7,93 xx ns $ xx - - 2691 248 2232 155 3097 212 1580 92 - -
170 @2d
Aspartate transami-
nase
Metab. 1,2 down ns 1,1 down ns 1,2 down $ 1,1 up ns gi|91997 46399 6,73 ns ns $ ns 3954 217 3434 283 4645 383 4087 196 5254 241 4224 176 4959 299 5273 273
171 @ 1d
3-oxoacid CoA-
transferase  
Metab. 1,4 up $ 1,4 up $ 1,5 up $ 1,3 up ns gi|2492999 56371 8,47 $ $ $ ns 2233 270 3051 235 3008 274 4356 266 2812 327 4265 283 2635 109 3408 519
172 @ 1d
Fumarate hydratase, 
mit prec.
Metab. 1,0 up ns 1,1 down ns 1,2 up $ 1,1 up ns gi|120605 54429 9,06 ns ns $ ns 2088 179 2175 320 3408 142 2991 178 2359 155 2938 183 3538 170 3775 178
173 @ 1b no ID No ID 1,9 down $ 1,7 down ns 2,2 down $ 1,6 down $ n/a n/a n/a n/a n/a n/a $ ns $ $ 92 13 48 13 131 34 79 15 161 19 73 14 252 31 158 33
174 @ 1c
Succinate dehydro-
genase [ubiquinone] 
flavoprotein subunit, 
mit, prec
Metab. 1,1 up $ 1,1 down ns 1,2 down ns 1,2 down $ gi|52782765 71570 6,75 $ ns ns $ 1241 62 1417 88 1155 161 1096 112 1060 167 921 51 1289 64 1052 58
175 @ 1c no ID No ID 1,1 up ns 1,2 up ns 1,0 down ns 1,3 down $ n/a n/a n/a n/a n/a n/a ns ns ns $ 263 24 298 14 186 28 216 15 154 8 148 14 198 15 154 6
176 @ 1c
Succinate dehydro-
genase [ubiquinone] 
flavoprotein subunit, 
mit, prec
Metab. 1,1 up ns 1,0 up ns 1,1 down ns 1,3 down $ gi|52782765 71570 6,75 ns ns ns $ 3674 383 3936 410 2617 207 2688 188 2950 317 2771 146 3504 167 2765 234
177 @ 2c no ID No ID 1,0 down ns 1,2 down ns 1,1 down ns 1,7 down $ n/a n/a n/a n/a n/a n/a ns ns ns $ 600 161 591 125 453 109 378 53 319 76 284 40 507 60 298 35
178 @ 1c
Dihydrolipoamide 
dehydrogenase 
Metab. 1,3 up ns 1,2 up ns 1,1 up ns 1,1 down $ gi|81885266 54004 7,96 ns ns ns $ 511 75 642 51 722 68 833 82 700 42 775 31 617 25 542 19
179 @ 3d
Ubiquinol-cyto-
chrome c reductase 
iron-sulfur subunit, 
mit, prec.
Metab. 1,0 up ns 1,1 down ns 1,3 down ns 1,6 down $ gi|52001457 29427 9,04 ns ns ns $ 2229 633 2238 343 3044 662 2681 428 1813 216 1403 187 2346 187 1499 239
Protein database corresponding to 2-DE map presented in Figure 1S.                   * Mann-Whitney statistics were used to compare sham vs. PAB within one time group.                           
$= p<0.05 and ns=non-significant.
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Abstract
Aims: In several types of congenital heart disease, as well as in pulmonary hypertension, 
RV hypertrophy may develop that could ultimately progress to RV failure. In this study 
we sought to determine hemodynamic signs of imminent RV failure in a model of 
pulmonary artery banding (PAB).
Methods: Rats received sham (n=28) or PAB (n=27) surgery and were housed for 6, 
12 and 20 weeks respectively. After the housing period, baseline diastolic function 
was measured using pressure-volume loops and dobutamine infusions were used to 
test systolic and diastolic reserve. In addition, molecular determinants of β-adrenergic 
signalling, Ca2+-cycling and the degree of fibrosis were measured.
Results: In PAB rats RV systolic function was 3-fold increased in all three time groups 
(p<0.01) and dobutamine response was unimpaired. RV diastolic function parameters 
indicated both impaired early (p<0.01) and late (p<0.01) diastolic function, with similar 
response to dobutamine in PAB and sham. LV systolic and diastolic function was 
unaffected. The RV β-ARs decreased at 20 weeks, while GRK-2 decreased at 6  and 20 
weeks (p<0.05). At 6 and 20 weeks the NCX1/SERCA2 ratio was increased (p<0.05). 
There were no signs of increased RV fibrosis in PAB. 
Conclusions: Prolonged PAB resulted in compensated RV hypertrophy, with maintained 
RV systolic function and impaired diastolic function. LV function was not affected. The 
decrease in β-ARs and SERCA2, commonly found in heart failure, were compensated 
for by decreases in GRK-2 and PLB, respectively, and an increase in NCX1. These 
molecular alterations are compatible with our hemodynamic findings of compensated 
hypertrophy.
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Introduction
In several types of (corrected) congenital heart disease, as well as in pulmonary 
hypertension, the right ventricle (RV) can be subjected to (residual) pressure overload 
[1]. As a result, compensated RV hypertrophy will develop, that may progress to a 
decompensated state of hypertrophy (ie. RV failure). This impaired cardiac function is 
not strictly limited to the RV. The left ventricle (LV) can be involved as well either through 
neurohumoral pathways or by direct mechanical interaction [2,3]. As the survival of 
patients with congenital heart disease has improved, a better understanding of the 
biventricular response to RV pressure overload over time is mandatory enabling us to 
design preventive strategies and to time surgical (re)intervention.
At present, most studies have addressed the effects of RV pressure overload at one 
point in time. However, little is known about the time-related changes that occur in 
the RV and LV during prolonged RV pressure overload. Previously, we reported that RV 
systolic function after 6 weeks of pulmonary artery banding (PAB) in rats was increased 
and that RV contractile reserve was maintained [4].  Subsequently, we demonstrated 
progressive alterations in cytoplasmic metabolic and anti-oxidant proteins after 6, 12 
and 20 weeks of RV pressure overload [5]. Despite these molecular changes baseline 
RV systolic function was unaffected, suggesting compensated RV hypertrophy up to 
20 weeks of RV pressure overload. However, early signs of systolic impairment may 
only be demonstrable during increased systolic demands.
Furthermore, clinical signs of heart failure in the face of prolonged ventricular 
hypertrophy may also develop secondary to diastolic impairment, as has extensively 
been demonstrated for the LV. Diastolic dysfunction in these circumstances may 
be related to alterations in active relaxation as well as alterations in passive diastolic 
properties due to increased ventricular mass and/or fibrosis. At the molecular level 
changes in both diastolic as well as systolic function, may be intimately related with 
alterations in Ca2+ cycling and in β-adrenergic signalling.  
In this present study, we therefore aim to analyze RV (systolic) contractile reserve 
as well as biventricular diastolic function after prolonged PAB. Here, we tested the 
hypothesis that prolonged RV pressure overload up to 20 weeks in rats will eventually 
result in impaired RV contractile reserve and impaired diastolic function. Furthermore 
we suspect that LV diastolic function will be preserved. For this purpose, we performed 
biventricular pressure-volume (PV) loops to assess systolic and diastolic function in rest 
and under dobutamine stimulation [4-8]. In order to link these potential hemodynamic 
changes to molecular mechanisms, several components of the Ca2+ storage/release 
system and β
1
-adrenergic signaling were studied, as well as the degree of fibrosis.    
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Methods
Ethical Approval
All experimental procedures and protocols used in this investigation were reviewed 
and approved by the institutional animal care and use committee of the Erasmus MC 
and are in accordance with the National Institutes of Health “Guide for the care and use 
of laboratory animals” (NIH publication No. 85-23, revised 1996).
Male Wistar rats (190-220 g, Harlan, Zeist, The Netherlands) underwent PAB or sham 
operation. The animals were housed after the initial operation (i.e. sham or PAB), prior 
to the hemodynamic studies, in groups of 2 or 3 animals, on a 12/12-h light/dark cycle 
with standard rat chow and water ad libitum. Three different periods of housing were 
applied: 6, 12 and 20 weeks (resp. n=9 vs. 6, n=8 vs. 9, n=11 vs. 12 (sham vs. PAB)). 
The instrumentation of the animals as well as the hemodynamic measurements that 
we used, were exactly the same as previously reported [4] and will only be described 
briefly.
pulmonary artery banding procedure
After induction of anesthesia a left thoracotomy was performed and a silk thread was 
positioned under the pulmonary artery. A suture was tied tightly around an 18 gauge 
needle that was placed alongside the pulmonary artery. Next, the needle was rapidly 
removed in order to produce a fixed constricted opening in the lumen equal to the 
diameter of the needle. The sham animals underwent the same procedure except for 
the banding of the pulmonary artery.
Hemodynamic instrumentation
Six, 12 or 20 weeks after sham or PAB operations animals were instrumented for 
hemodynamic measurements. After induction of anesthesia a right thoracotomy was 
performed and an ultrasonic flow-probe (Transonics Systems Inc., Ithaca, NY), was 
placed around the aorta. A left thoracotomy was performed for maximal exposure of 
the left side of the heart. For preload reduction, required to obtain systolic and diastolic 
PV-relations, a silk thread was placed around the vena cava inferior. Conductance 
catheters (CD Leycom, Zoetermeer, The Netherlands) and pressure-tip catheters (Millar 
Instruments, Houston, TX) were inserted in the RV and LV. Signals were recorded at a 
sample rate of 500Hz using the Conduct 2000 data-acquisition hard- and software (CD 
Leycom). Conductance catheters were calibrated as previously described [9].
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Hemodynamic study protocol 
When hemodynamic stability was reached, a set of measurements was performed 
to calibrate the conductance catheter and to assess hemodynamics and contractile 
performance in baseline conditions and during dobutamine stimulation (2.5 μg/kg/min 
(dobu-2.5) and 5 μg/kg/min (dobu-5)). Data were recorded with open chest at steady-
state baseline conditions and during transient preload reduction. All measurements 
were made during short suspension of the ventilation at end-expiration. 
Hemodynamic measurements and calculations
The biventricular signals were analyzed by custom made software (Circlab (P.S.)). From 
the steady state data the following parameters were calculated: heart rate, cardiac 
output, stroke volume, end-systolic pressure, end-diastolic pressure, end-systolic 
volume, end-diastolic volume, as reported previously [5].
The following parameters were obtained: end-systolic pressure-volume relation 
(ESPVR), dP/dt
max 
–end-diastolic volume (dPdt
max
-Ved) relation, and preload recruitable 
stroke work relation (PRSW) [6-8]. The end-systolic point was defined as the point in 
the cardiac cycle of maximal elastance. Elastance was defined as P(t)/[V(t)-V
0
], where 
P(t) is the instantaneous pressure, V(t) instantaneous volume, and V
0
 the theoretical 
volume at zero pressure [10]. V
0
 was determined by an iterative algorithm as previously 
described by Kono et al [11]. 
The diastolic function was described with the following three parameters: dP/dt
min
, 
tau and chamber stiffness constant derived from the end-diastolic pressure volume 
relation (EDPVR) [12,13]. The dP/dt
min
 and tau were calculated from the baseline PV 
loops whereas the EDPVR was constructed during transient preload reduction. The 
tau was calculated as time constant of mono-exponential pressure decay during 
isovolumic relaxation. The isovolumic period was defined as the period between dP/
dt
min
 and the point where the dP/dt reached 10% of the dP/dt
min  
[14]. The late-phase 
of diastole is characterized by passive chamber properties which is reflected by the 
EDPVR. This EDPVR was constructed by integrating the end-diastolic pressures and 
volumes in a linear fashion. The slope of this relationship was used as the chamber 
stiffness constant. 
Western blotting
Western blotting was used to study, in RV and LV after 6 and 20 weeks, the levels of β
1
-
adrenergic receptor (β
1
-AR) and its regulator β-adrenergic receptor kinase (GRK-2). In 
addition, several Ca2+ handling proteins were studied. These included the sarcoplasmic 
reticulum Ca2+ ATPase (SERCA2), phospholamban (PLB), and the Na+/Ca2+ exchanger 
(NCX1). In brief, proteins were extracted from homogenized RV and LV tissues as 
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described before [15]. Next, proteins were separated by 1D-PAGE, using 10% (β
1
-AR, 
GRK-2, NCX1) or 12% (SERCA2, PLB) gels. The samples were heated for 5 min. at 95º 
C (β
1
-AR, GRK-2) or 37º C (SERCA2, PLB, NCX1). Subsequently 20 μg of protein was 
applied per sample. The following primary antibodies were used: β
1
-AR 1:4000 diluted 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), GRK-2 1:4000 diluted (Santa Cruz 
Biotechnology), SERCA2 1:30000 diluted (Abcam, Cambridge, MA, USA), PLB 1:100000 
diluted (Affinity BioReagents, Golden, CO, USA) and NCX1 1:1000 diluted (Abcam). The 
blots were incubated with either GARPO (β
1
-AR, GRK-2, SERCA2, resp. 1:4000, 1:4000, 
1:30.000) or GAMPO (PLB, NCX1, resp. 1:10.000, 1:100.000). The results were visualized 
on film (Hyperfilm™ ECL, Amersham Biosciences) and quantitated and analyzed with a 
GS-800 calibrated densitometer and QuantityOne software (Biorad, Hercules, CA, USA). 
Histology
Following the hemodynamic measurements, the heart was dissected and a slice of 
the RV was fixed in 10% formaldehyde and subsequently dehydrated in several steps 
of ethanol and xylene followed by embedding in paraffin. Sections of 4.5 µm were 
deparaffinated in several steps of xylene and ethanol. A routine Heamatoxylin-Eosin 
staining was performed to assess the orientation of the cardiomyocytes and other 
structures. A Gomori negative staining was used to assess myocytes cross sectional 
area, a lectin staining was used for assessing capillary density, and a Picro Sirius red 
staining was used for quantification of myocardial fibrosis. 
Data and statistical analysis
To test contractile reserve in rats after 12 and 20 weeks of PAB we used the following 
approach. Data on baseline systolic function, that we previously reported [4], as well as 
the responses to dobutamine after 6 weeks of PAB [4] were all analysed together with 
dobutamine responses after 12 and 20 weeks of PAB that we report here. We took this 
approach in order to detect alterations in contractile reserve throughout 6 to 20 weeks 
of PAB. For the purpose of clarity some of those previously reported data are reiterated 
here in tables and figures.
Similarly, the diastolic function data (not previously reported) were analysed for all 
three time groups.
The differences in hemodynamic parameters between the control group and the 
PAB group at baseline were analyzed using a Student’s T-test. Repeated measures 
3-way ANOVA was used to study the various interactions between 1) type (ie. sham 
and PAB), 2) time (ie. 6, 12, and 20 weeks), and 3) dobutamine (i.e. baseline, dobu-2.5, 
dobu-5). Interactions studied were: type*time, type*dobutamine, time*dobutamine, 
and type*time*dobutamine. If following the 3-way ANOVA any of these interactions 
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was found to have a p-value <0.05, subsequent testing was performed using (2-way) 
ANOVA. Post hoc testing, when appropriate, was performed using the Bonferroni 
correction. The software package Statview (version 5.0, SAS Institute, Cary, NC, USA) 
was used for data analysis. For the histological measurements, the data was analyzed 
using a 2-way ANOVA and when appropriate post hoc testing using the Bonferroni 
correction. A two-sided p-value < 0.05 was considered statistically significant. Data are 
presented as mean ± SEM
Results
There were no differences in body mass between sham and PAB animals in each time 
group and PAB rats did not show any signs of heart failure and/or cyanosis. RV and 
right atrium weights, relative to body weight, were significantly increased [5].
Table 1: Baseline hemodynamic response to various durations of Rv pressure overload.
Baseline Conditions
General  6 wk 12 wk 20 wk
HR sham 310 ± 8 305 ± 7 306 ± 8
PAB 297 ± 12 283 ± 4* 286 ± 6
CO sham 51 ± 4 51 ± 3 41 ± 3
PAB 49 ± 5 38 ± 3* 36 ± 2
SV sham 164 ± 11 168 ± 10 137 ± 10
PAB 164 ± 13 135 ± 9 128 ± 6
Right Ventricle          
Pes sham 29 ± 1 29 ± 3 32 ± 3
PAB 63 ± 8* 57 ± 5* 68 ± 5*
Ped sham 4.6 ± 0.8 4.4 ± 1.1 6.3 ± 0.8
PAB 6.8 ± 0.5 6.1 ± 1.7 7.2 ± 0.9
Ved sham 315 ± 44 351 ± 31 295 ± 21
PAB 259 ± 32 195 ± 18* 233 ± 14*
Values are mean ± SEM. HR=heart rate (beats/min), CO=cardiac output (mL/min), SV=stroke volume (µL), 
Pes=end-systolic pressure (mmHg), Ped=end-diastolic pressure (mmHg), Ved=end-diastolic volume (µL). 
*p<0.05 versus corresponding control
Global hemodynamic function and Rv (systolic) contractile reserve
In all three time groups RV end-systolic pressures were increased in PAB animals to 
approximately 60% of LV end-systolic pressures. Heart rate and cardiac output were 
slightly lower in the PAB animals, but stroke volumes were similar (Table 1). Indices of 
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baseline RV systolic performance were increased in PAB in all time groups to a similar 
extent (Figure 1) 
In response to dobutamine heart rate increased, cardiac output tended to increase, 
whereas stroke volume tended to decrease in all sham and PAB animals. These responses 
were independent of the presence and duration of PAB (Table 2). Furthermore, RV end-
systolic pressure increased in both sham and PAB and the increase tended to be higher 
in PAB. In the animals that had PAB in place for 12 and 20 weeks the three indices 
of systolic performance all increased in response to dobutamine (Figure 1). These 
responses were similar to those previously reported after 6 weeks of PAB. These results 
indicate that up to 20 weeks of PAB the animals in our study demonstrated increased 
baseline RV systolic performance and maintained contractile reserve.
Similarly, indices of  LV systolic performance increased in response to dobutamine 
stimulation after 12 and 20 weeks in a similar fashion as previously reported after 6 
weeks of PAB (data not shown).  
Table 2: Hemodynamic response to dobutamine infusion after various durations of Rv 
pressure overload.
Values are presented as percent change ± SEM. HR=heart rate (beats/min), CO=cardiac output (mL/min), 
SV=stroke volume (µL), Pes=end-systolic pressure (mmHg), Ped=end-diastolic pressure (mmHg), Ved=end-
diastolic volume (µL).
*p<0.05 versus baseline 
†p<0.05 versus dobu-2.5
#p<0.05 effect of banding baseline versus dobu-2.5 
$p<0.05 effect of banding dobu-2.5 versus dobu-5
∆p<0.05 effect of banding baseline versus dobu-5
                                       6 weeks       12 weeks 20 weeks     
General dobu-2.5 dobu-5 dobu-2.5 dobu-5 dobu-2.5 dobu-5 
HR sham 28± 4* 36± 4 28± 3* 38± 4*† 30± 4* 41± 4*† 
PAB 28± 5* 38± 6*† 32± 4* 43± 4*† 24± 2* 36± 3*† 
Co sham 3± 5 20± 7*† 10± 9 16± 11 18± 4* 33± 7*† 
PAB 6± 7 12± 10 33± 21 52± 21* 24± 5* 35± 5*† 
Sv sham -20± 4* -12± 6† -14± 6 -17± 7 -9± 3 -5± 5 
PAB -17± 3* -19± 5* 0± 15 6± 13 -1± 5 -2± 4 
Right ventricle
pes sham 15± 6 23± 12* -1± 8 22± 12*† 39± 6* 57± 6*† 
PAB 19± 14 45± 16*†$ 38± 7*# 84± 8*†$ 36± 6* 58± 11*†$ 
ped sham -31± 19 4± 54 -17± 32 -24± 35 49± 17 28± 17 
PAB 36± 18 47± 24 10± 31 63± 46 33± 25 79± 43 
ved sham -22± 15* -14± 20* -31± 6* -41± 8* -29± 5* -31± 6* 
PAB -11± 7 15± 19 -9± 6# -1± 8$ -9± 5# -6± 6 
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Figure 1: Alterations in Rv systolic function parameters at baseline and during 
dobutamine infusion. 
Ees=end-systolic elastance (mmHg·µL-1), PRSW=preload recruitable stroke work (mmHg), dP/dt
max
-
Ved=maximum first time derivative of pressure divided by end-diastolic volume (mmHg·s-1·µL-1)
*p<0.05 versus corresponding control in baseline
†p<0.05 versus baseline and ‡ p<0.05 versus dobu-2.5 
ap<0.05 6 wk dobutamine response versus response at 12 and 20 wks 
bp<0.05 banding effect baseline – dobu-2.5
cp<0.05 banding effect baseline – dobu-5
Faber.indd   135 28-02-12   12:48
Chapter 6 Preserved biventricular function after long-term pulmonary artery banding despite progressive molecular alterations
136
Figure 2: Alterations in diastolic function parameters at baseline and during dobutamine 
infusion for the Rv (A; squares) and Lv (B; circles).
Tau=time constant of isovolumic relaxation (ms), dPdt
min
=minimum first time derivative of pressure vs. time 
(mmHg·s-1), b=chamber stiffness constant derived from end-diastolic pressure-volume relation (µL-1).
*p<0.05 versus corresponding control in baseline 
†p<0.05 versus baseline and ‡ p<0.05 versus dobu-2.5 
ap<0.05 6 wk dobutamine response versus response at 12 and 20 wks 
bp<0.05 banding effect baseline – dobu-2.5
cp<0.05 banding effect dobu-2.5 – dobu-5
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Diastolic properties of the Rv and Lv
Baseline (Table 1; Figure 2)
For all time groups, the RV end-diastolic pressures were similar between PAB and sham. 
The end-diastolic volume was similar for sham and PAB in after 6 wk banding, but lower 
after  12 and 20 weeks of PAB (Table 1). At baseline RV dP/dt
min
 was decreased and tau 
was increased in PAB animals, both indicating a decrease in early diastolic function. 
Over time (6-20 wk), these parameters did not change in sham and PAB animals 
(Fig. 2). The chamber stiffness constant b, derived from the EDPVR, was increased in 
PAB, indicating an impaired late diastolic function (passive stiffness). However, when 
corrected for RV mass, this passive stiffness of the RV of PAB animals was not increased. 
Over time the chamber stiffness constant did not change in sham nor PAB animals. 
In the LV, the end-diastolic pressures and the end-diastolic volumes were similar for 
sham and PAB animals. The baseline indices of diastolic function were similar for sham 
and PAB in all three time groups, except for a minor increase in LV tau at 20 weeks PAB. 
Response to dobutamine (Figure 3)
In response to dobutamine, both RV dP/dt
min 
and tau decreased in sham and PAB rats 
to a similar extent. Furthermore, no consistent changes in the RV chamber stiffness 
constant were observed. Since the tau is not entirely load-indepent, we corrected the 
changes in tau during dobutamine stimulation for the Pes. For the RV the slope of the 
tau-Pes relation was significantly less steep (slope -0.313 ± 0.080 vs. -0.116 ± 0.001 
sham vs. PAB RV 20 wk), indicating a true decrease in active relaxation.
The LV dP/dt
min
 and tau responded similar to dobutamine in sham and PAB animals in 
all three time groups. The slopes of the tau-Pes relation for the LV were not significantly 
altered (slope -0.087 ± 0.003 vs. -0.060 ± 0.005 sham vs. PAB LV 20 wk). The LV chamber 
stiffness constant was similar between sham and PAB in response to dobutamine. 
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Figure 3: dpdtmin-pes and Tau-pes corrected relations in the Rv and Lv after 20 weeks 
of pAB
The left panel shows the alterations in dPdtmin and Tau during dobutamine stimulation (from left to right: 
baseline, dobu-2.5 and dobu-5) for the RV after 20 weeks of PAB corrected for end systolic pressure (Pes). 
After 20 weeks the slope of the Tau-Pes relation is significantly less steep for the PAB animals (p<0.05, see 
Results). The right panel shows the dPdtmin-Pes and Tau-Pes relation for the LV after 20 weeks of PAB with 
no difference in slope between sham and PAB.
Western blots (Figure 4)
Since the hemodynamics are relatively constant over time we only performed western 
blotting in the 6 and 20 weeks. The RV β
1
-AR levels were similar after 6 weeks of PAB, 
but deceased after 20-week PAB-animals by 32% (p<0.05, Figure 4A). The RV GRK-2 
was decreased by 27% (p<0.05) in 6-week PAB animals and decreased even further 
(-48%, p<0.05) after 20-weeks. Over time, changes were found in several Ca2+ handling 
proteins. RV SERCA2 (Figure 4B) was decreased in 6- and 20-week PAB animals by 
30% and 41%, respectively (both p<0.05). The regulator of SERCA2, PLB, was also 
downregulated in 6- and 20-week PAB by 14% and 32%, respectively (both p<0.05). 
The levels of RV NCX1 (Fig 4C) were significantly increased in both 6- and 20-week PAB 
(41% and 90% respectively, both p<0.05).
In the LV, the β
1
-AR levels were approximately 30% higher in PAB animals after 6 and 
20 weeks (p<0.05). The LV levels of GRK-2 did not change significantly over time. 
LV SERCA2 levels were decreased in 6- and 20-week PAB animals (-17% and -14%, 
respectively, both p<0.05). No changes were found in LV PLB levels. The level of LV 
NCX1 was unaltered after 6 weeks of PAB but was increased by 31% (p<0.05) after 20 
wk of PAB.
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Figure 4: Time-related changes in several Ca2+-handling proteins and components of the 
β1-adrenergic signalling system.
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Panel A shows bar graphs representing the differences in expression of the β
1
-adrenergic receptor (β
1
-
AR) and G-protein coupled receptor kinase 2 (GRK-2) in RV and LV after 6 and 20 weeks of RV pressure 
overload. The changes in the PAB animals were related to the sham levels which were set at 100%. Similar 
data presentation was used for Panel B which shows changes in the sarcoplasmic reticulum Ca2+-ATPase 
(SERCA2) and phospholamban (PLB). Panel C shows alterations in the sodium-calcium exchanger (NCX1).
*p<0.05 versus corresponding control
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Histology (Figure 5)
The RV myocytes size increased significantly in the PAB animals in all three time groups. 
Furthermore, the myocyte size increased over time in only the PAB animals. The 
capillary density after 6 weeks of PAB was similar in sham and PAB animals. When the 
period of PAB was extended to 12 and 20 weeks, the capillary density was decreased in 
the PAB animals. The degree of interstitial fibrosis was similar in sham and PAB animals 
for all three time groups.
Figure 5. Morphological changes in the Rv after various durations of Rv pressure 
overload.
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Discussion
This present study, together with previous observations, shows that prolonged PAB 
up to 20 weeks resulted in compensated RV hypertrophy, characterized by enhanced 
RV systolic function and maintained contractile reserve [5]. Baseline RV diastolic 
function was impaired but the response to dobutamine stimulation was unaffected. 
Furthermore, LV systolic function and contractile reserve in general were unaffected. 
Despite the limited hemodynamic consequences of prolonged PAB, temporal changes 
were found in several molecular components, potentially compensatory in nature, to 
preserve systolic and diastolic function of both RV and LV.
Rv - Systolic function
In our studies we used relatively load-insensitive measures of contractility to 
characterize the response of RV and LV to prolonged RV pressure overload induced 
by PAB. As shown previously, the three indices of systolic function (Figure 1) indicated 
a similar increase in systolic performance of the RV of PAB animals at baseline [5]. So 
far, only few investigators have used models of prolonged PAB (>12 weeks) and the 
extensive hemodynamic analyses, such as presented in this paper, have not previously 
been performed at different time points after prolonged PAB [16,17].
Several studies have addressed the adaptation of the RV to acute or chronic pressure 
overload. In acute RV pressure overload, cardiac output was maintained by enhanced 
RV contractile performance while end-diastolic volumes remained stable [10]. 
Observations in chronic RV pressure overload are, in general, in line with our study. For 
example, after 12 weeks of PAB in dogs, cardiac output was maintained and the slope of 
the ESPVR was three-fold increased [18]. In lambs, after 6 weeks of PAB, RV contractility 
was enhanced even after correction for RV mass, indicating a hypercontractile state of 
the RV [19]. In our study, however, RV contractility corrected for mass was increased 
only after 20 weeks of PAB. The response to dobutamine was unaffected, indicating 
maintained contractile reserve of the RV up to 20 weeks of PAB. In contrast to our 
findings, in a study in rats with similar degree of PAB as in our study, LekanneDeprez 
et al. found heart failure developing after 12 weeks based on clinical signs [17]. Based 
on those results we extended the PAB up to 20 weeks, but we could not replicate their 
observations. 
Other investigators have used monocrotaline-induced pulmonary hypertension to 
study the development of (de)compensated RV hypertrophy [20,21]. In many of these 
studies (severe) RV failure develops after a few weeks [20,22]. Recently, in monocrotaline 
treated rats developing compensated RV hypertrophy, Hessel et al, found increased 
RV volumes and unchanged parameters of contractility [21]. The differences in RV 
contractile performance in the PAB as compared to the monocrotaline model might 
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be explained by differences in β-adrenergic signalling [21,23,24]. In our study, the RV 
β
1
-AR level as well as the GRK-2 level was decreased after 20 weeks of PAB. In contrast, 
in monocrotaline induced RV failure in rats, decreased β
1
-AR levels and increased GRK-
2 levels have been found [23,24]. A simultaneous decrease of β
1
-AR and increase of 
GRK-2 levels, has been implicated in the decreased β-adrenergic signalling in heart 
failure [25]. In the hypertrophic or senescent heart β-adrenergic signalling could be 
improved by interventions that reduced the level of GRK-2, while β-adrenergic levels 
were unaffected [26,27]. Thus, decreasing the level of GRK-2 seems a favourable 
adaptation to maintain β-adrenergic signalling. We suspect that this is an important 
compensatory mechanism in our PAB rats, as the responses to adrenergic stimulation 
were unaffected up to 20 weeks of PAB.
Rv - Diastolic function
Early relaxation was prolonged and RV stiffness was increased, indicating an 
impairment of diastolic function. We used dP/dtmin and tau as early diastolic function 
parameters and both pointed in the same direction. However, interpretation of these 
parameters should be done carefully as the dP/dtmin is load-dependent. Similarly, tau 
is not entirely load-independent and the period of isovolumic relaxation in the RV is 
less well defined [14,28]. Nevertheless, tau has been used frequently to describe early 
RV relaxation in animal models, as well as in patients [14,29-31]. In acute RV pressure 
overload it was shown that RV tau was prolonged and it was suggested that this might 
be related to the decreased expression of NCX1 [31]. In chronic RV pressure overload 
a similar impairment of early relaxation, as found in our study, has been shown. For 
example, after 8 weeks of monocrotaline-induced pulmonary hypertension in dogs 
a prolonged tau in the RV was found [29]. Similarly, PAB-induced chronic RV pressure 
overload in lambs also resulted in a prolonged tau [14]. In line with this latter study, 
we have also analyzed the Tau-Pes (end-systolic pressure) relation at baseline and 
during dobutamine infusions for the RV and LV, showing that tau decreases less in 
response to higher end-systolic pressures in the RV of PAB animals (Figure 3). Although 
catecholaminergic stimulation by dobutamine infusion itself enhances the calcium 
cycling and hence contributes to increased active relaxation, the differences in 
response between PAB and sham occurred at same dosages. Therefore, the decreased 
active relaxation in response to an alteration in load, reflects a true difference in active 
relaxation in the RV of PAB animals.
Our study further adds to these observations by demonstrating a stable impairment 
of early relaxation over the entire observation of 20 weeks, but simultaneously 
demonstrating progressive changes at the molecular level. The expression levels of 
SERCA2 and PLB in the RV were progressively decreasing, while NCX1 expression 
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levels progressively increased. The alterations in PLB and NCX1 may be interpreted as a 
compensatory mechanism to maintain Ca2+-cycling, in the face of a decreased SERCA2 
expression. A similar decrease in SERCA2 in combination with signs of impaired 
relaxation, has been reported in rats with monocrotaline-induced RV hypertrophy 
[22]. An increase of NCX1 may improve early relaxation, but may also negatively affect 
contractile function by virtue of underloading of the sarcoplasmic reticulum with Ca2+ 
[32]. However, in small mammals like rats the contribution of NCX1 to the decrease in 
intracellular [Ca2+] in early diastole is only small and an increase in NCX1 expression 
therefore may not have such profound effects as in larger mammals [33]. The effects 
of these changes on Ca2+-transients in our PAB rats are unknown. We interpret the 
alterations in the Ca2+-handling proteins in our PAB rats as being compensatory and 
compatible with compensated RV hypertrophy. 
Late diastolic function was impaired in PAB animals as reflected by an increased 
chamber stiffness constant. As a result the RV end-diastolic volume was lower in RV 
pressure overload. Other studies on chronic RV pressure overload have found similar 
increases in RV stiffness [14,18]. The results from the morphometric analysis of RV 
tissues do not indicate significant fibrosis in PAB rats, suggesting that the increased 
RV mass per se explains the impaired late diastolic function. This is also supported by 
the observation that the RV EDPVR, when corrected for RV mass, was not increased in 
PAB animals. 
This present study is the first to provide an in-depth analysis of biventricular 
function over an extended range of durations of PAB. Despite the relatively stable 
hemodynamics during prolonged RV pressure overload, alterations occur at the 
molecular level, as shown for β-adrenergic signalling and Ca2+-handling proteins. In 
addition, we previously demonstrated a time-dependent increase in components of 
the protein quality control machinery, such as (phosphorylated) heat shock protein 27, 
as well as alterations in several anti-oxidant enzymes [5]. In rats with monocrotaline-
induced RV hypertrophy, the development of congestive heart failure has been 
specifically associated with the activation of the p38 MAPK pathway [20]. Previously, 
we demonstrated the p38 MAPK pathway not to be activated in our PAB rats [5]. We 
speculate that the development of decompensated RV hypertrophy (RV failure) may 
ensue with a further disruption of, for example, the Ca2+-cycling pathway, the protein 
quality control machinery, the oxidant/anti-oxidant balance, or activation of the p38-
MAPK pathway.
Lv - Diastolic function
LV diastolic function remained stable over time. Only after 20 weeks of PAB there 
was an increase in tau, suggesting impaired early relaxation. At the molecular level, 
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an increase was found in the NCX1/SERCA2 ratio, which could be related to the 
prolonged relaxation [34]. However, our hemodynamic data are compatible with only 
a minor impaired diastolic function and maintained systolic function. Furthermore, 
during stimulation with catecholamines both diastolic and systolic function further 
improved in both sham and PAB rats in a similar fashion, suggesting intact Ca2+-
cycling. The passive stiffness of the LV was unaltered in our model. This is different from 
observations by Lamberts et al. who showed an increased stiffness of the LV together 
with increased collagen depositions in a monocrotaline model of RV hypertrophy [35]. 
These differences may be related to the degree of hypertrophy, since the LV/body 
weight and the RV/body weight were approximately 2-fold higher as compared to 
our study.
Conclusions
This study demonstrates that prolonged RV pressure overload, induced by PAB in rats, 
leads to compensated hypertrophy, characterized by maintained RV (and LV) systolic 
function and a slight impairment of diastolic function, that are stable throughout the 
observation period of 20 weeks. Concurrently, time-dependent alterations occur at the 
molecular level, for example in the β-adrenergic signalling, Ca2+-handling, the protein 
quality control machinery, the oxidant/anti-oxidant balance, and the absence of p38-
MAPK pathway activation [5]. We suggest that these alterations are necessary for the 
heart to maintain its function. The progressive nature of these alterations underlines 
the concept that compensated hypertrophy is not a static situation, but rather is a 
dynamic, slowly progressive process in which the heart is able to maintain its function 
by employing compensatory mechanisms. We speculate that the disruption of these 
compensatory changes at the molecular level may herald the onset of RV failure. 
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Abstract
Nowadays cardiovascular disease are along the most common causes of morbidity 
and mortality in the Western world. Increased understanding of the underlying protein 
changes can be achieved using proteomic technologies. The main component of 
the cardiomyocyte is the myofilament machinery, responsible for the contractile 
properties of the heart. Proteomic analysis of the myofilaments is difficult due to 
intrinsic proterties of these proteins. In this study reverse-phase HPLC was used to 
determine the myofilament proteome. 
First, optimization of the RP-HPLC technique was achieved by testing several solvents 
and gradients. Second, using HPLC techniques the myofilament proteins were separated 
from prefractionated rat heart samples and analysed using mass spectrometry. Finally, 
122 non-redundant proteins were found including 24 myofilament proteins. 
In conclusion, RP-HPLC can be used to separate the myofilament proteins from rat 
hearts with high reproducibility. Using this method a myofilament subproteome was 
described.  Complementary proteomic techniques are necessary to further increase 
the protein coverage of the myofilament subproteome. 
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Introduction
Cardiovascular disease is an important determinant of morbidity and mortality in 
developed countries. The cardiac proteome is dominated by the myofilaments, which 
are responsible for the contractile properties of the heart and consists of sarcomeric as 
well as sarcomere-associated proteins. The thick filaments consist of the myosin heavy 
and light chains and myosin binding protein C, and the thin filaments are comprised 
of alpha-actin, F-actin capping protein, tropomyosin (alpha or beta) and the cardiac 
specific troponin complex (TnI, TnT and TnC) [1-3]. The sarcomere further consists of 
Z-line proteins, including α-actinin, myozenin, filamin and spectrin,M-line proteins, 
including M-protein, myomesin and skelemin, and additional proteins responsible 
for structural integrity of the filaments, including titin and nebulin. Among the 
sarcomere-associated proteins are the intermediate filaments (e.g. desmins), which 
link the myofilaments to the plasma membrane and the nucleus [4]. However, a full 
complement of the myofilamental subproteome has not yet been established.
Analysis of the myofilamental subproteome is notoriously difficult, mainly due to the 
intrinsic properties of the constituent proteins. Separation on the basis of pI and size by 
classical two-dimensional electrophoresis (2-DE) has long been the method of choice. 
However, 2-DE analysis is hampered by the extreme pI values and high molecular 
weights of many of these proteins. Associated proteins are difficult to identify due to 
their relatively low abundance. Moreover, many myofilamental proteins do not stain 
well with the general protein stains used in 2-DE [5, 6]. Nevertheless, several studies 
have shown changes of myofilamental proteins during heart hypertrophy and heart 
failure using classical 2-DE analysis [7-10]. 
Separation of proteins on the basis of hydrophobicity by reverse-phase high performance 
liquid chromatography (RP-HPLC) has been shown to be a good alternative for 2-DE in 
determining subcellular proteomes, including the myofilamental proteins from swine 
hearts [6, 11-13]. In addition RP-HPLC has been shown to be a useful tool in studying 
troponin crosslinking and identifying a competitive protein antagonist for F-actin [14, 
15]  . In our study into the effect of pulmonal hypertension on cardiac function in rats, we 
decided to determine the complement of myofilamental proteins of right ventricular 
heart tissue. We chose to separate the myofilamental proteins by RP-HPLC before their 
identification by mass spectrometry. Here, we present an optimized RP-HPLC protocol 
for rat myofilament proteins, and the detailed myofilament subproteome of the right 
ventricle generated with this technique.
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Methods and Results
Right ventricle (RV) tissue from 28-weeks old male Wistar rats (Harlan, Zeist, The 
Netherlands) was frozen in liquid N
2
 immediately after dissection, and stored at –80ºC 
until use. The myofilament subproteome was extracted using the “IN Sequence” 
protocol [6, 16]. In brief, individual RV tissues were homogenized in 20mM HEPES (pH 
7.4) and 0.5 mM EDTA, 1 µM leupeptin, 1 µM pepstatin, 0.26 µM aprotinin, 50 mM NaF, 
0.2 mM Na
3
VO
4
, and 0.5 mM PMSF at 4º C at a 1:4 ratio of tissue weight:buffer volume. 
The whole-tissue homogenate was centrifuged at 4º C for 15 min at 18000g. The pellet 
was resuspended in 1% aqueous TFA v/v and 0.1% Tris(2-carboxyethyl)-phosphine 
hydrochloride (initial tissue weight:buffer volume = 1:3) at 4º C. The sample was 
centrifuged (15 min at 18000g), and the pellet was reextracted with the same buffer. 
Both supernatants were combined and taken as the myofilament extract. Protein 
concentrations were determined by BCA protein assay (Pierce). The extracts were 
stored at -80º C until analysis. Myofilament proteins (0.1mg) were separated on a C8 
reverse-phase column (4.6mm id x 76mm, 80 Å pore size, particle size 3µm, Beckman 
Coulter , Fullerton, CA, USA) with a flow rate of 0.5 mL/min. Protein elution profiles 
were monitored by extinction at 214 nm. The 32Karat software package (Beckman 
Coulter) was used to analyse data on an IBM compatible computer.
The reproducibility of column performance was tested by running a mixture of standard 
proteins (SDS-7, Sigma-Aldrich, St. Louis, MO, USA). The coefficient of variation for the 
4 most prominent protein peaks in 6 runs was 0.750.20 % for elution time and 1715% 
for peak height. To optimize protein separation, a number of different solvent gradient 
conditions were tested (Table 1 and Figure 1) using the elution profile developed by 
Neverova as starting point [6]. This consists of a linear 1% per min gradient of B in A 
followed by C in A at a flow rate of 1.0 mL/min, in which solvent A was 0.05% aqueous 
TFA, solvent B was 0.05% TFA in isopropanol:ACN (1:9 v/v) and solvent C was 0.05% TFA 
in acetonitrile. This resulted in poor separation as most of the proteins eluted as a broad 
peak between 55 and 60 min (Figure 1-A). In addition, the elution profile deteriorated 
after a few runs and the columns were difficult to recover even by extensive rinsing. 
The optimal separation was achieved using a linear 0-70 % B gradient in A and a flow 
rate of 0.5 mL/min, in which solvent A consisted of 0.6% aqueous TFA and solvent B 
was 0.45 % TFA in ACN (Figure 1-D). To prevent clogging of the column, an extensive 
column-wash prior to re-equilibration was performed using a 70-100 % linear gradient 
of solvent C (2% TFA in isopropanol:ACN (1:4 v/v)) in A over 7 min. After each fourth run 
an additional column rinsing step was performed using a linear 0-70% B in A gradient 
in 30 min. Using this protocol we separated the myofilament proteins extracted from 
rat RV tissue (Figure 1).
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Table 1:  optimization of reverse-phase HpLC elution profiles
a: profiles 1 to 4 correspond to elution profiles in Figure 1 A to D, respectively
b: resolution was judged from protein profiles, ranging from poor (- -) to good (++)
In three separate runs, the coefficient of variation of 15 major peaks in the elution 
profile was 0.10  0.05% for retention time, and 13  5% for peak height . Fractions (0.5 
ml) were collected and stored at -80ºC until processing. After protein quantitation, 
the reverse phase fractions (150 L) were concentrated using a SpeedVac (Thermo 
Scientific, Waltham, MA, USA) to 5-10 L. NH
4
HCO
3
 (1 M) was added to the residue to 
pH 8.0. After addition of sequencing grade modified trypsin (Promega, Madison, WI) 
at a 1:50  enzyme to substrate ratio,  the sample was incubated overnight at 37 ºC. 
The digestion was stopped by addition of TFA [13]. Subsequently, the digests were 
analyzed using a LTQ ion trap MS/MS instrument (Thermo Finnigan, San Jose, CA, USA) 
at the Johns Hopkins Proteomics Core Facility. The data obtained from the MS spectra 
were searched using the NCBI database using the Mascot Deamon search engine 
(Matrix Science Mascot Daemon, V2.2.0; maximal 2 missed cleavages; peptide and MS/
MS tolerance 1.5 Da and 0.8 Da, respectively; common posttranslational modifications; 
p < 0.05). In addition, for Mascot result validation, the raw datafiles were uploaded to 
the Proteomics Analyzer Software System (PASS, Integrated Analysis Inc). 
In three independent runs, 124 non redundant proteins were identified (supplement 
Table 1). Of these proteins, roughly 20 % belongs to the functional category of 
myofilament- and cytoskeleton-associated proteins (Figure 2). More than 50 % of the 
proteins were of mitochondrial and nuclear origin, which may reflect contamination 
of the myofilament extracts or may be due to the interaction of these organelles 
with myofilaments, either directly or via the intermediate filaments [17].  Yet, this 
method of separation allowed coverage of many of the sarcomere proteins (Table 2) 
Profilea     Solvent Gradient
Flow 
characteristics
Resolu-
tion b
A B C A-B A-C
rate
(mL/min)
duration
(min)
1
0.05% TFA 
(aq)
0.05% TFA in 
isopropanol:
ACN  1:9 v/v
0.05% 
TFA in 
ACN 
0-42% 40-80% 10 90 +/-
2 2% TFA (aq)
2% TFA in 
ACN
- 0-100% - 5 30 - -
3 1% TFA (aq)
1% TFA in 
ACN
- 0-100% - 5 30. -
4
0.6% TFA 
(aq)
0.45% TFA in 
ACN 
- 0-70% - 5 80 ++
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including proteins which are difficult to separate by 2DE because of their high MW, 
such as titin. Of the major sarcomere proteins, notably of actin and myosin light chain, 
several isoforms exists with a high degree of sequence similarity (Table 2). For each 
of these proteins at least two unique peptides were identified in the tryptic digest. In 
addition, post-translational modifications were found at several peptides for most of 
the identified proteins ( supplement Table 1).  
Figure 1: optimization of reverse-phase HpLC myofilament protein separation
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The elution profiles A-D were achieved by using the gradients described in Table 1, profile 1-4 respectively.
Discussion
In this study, we have first separated the myofilamental from the cytoplasmic proteins 
according to the “IN sequence” protocol. This extraction procedure dramatically 
reduced complexity of the myofilament extract relative to the whole RV proteome. 
The subsequent HPLC analysis not only revealed many abundant sarcomeric proteins, 
but also relatively low abundant proteins such as PDZ and LIM domain 5 and nesprin 
isoforms. Besides sarcomere proteins, intermediate filaments were found together 
with mitochondrial proteins. The presence of this latter group of proteins might be 
explained by the linkage of intermediate filaments such as desmin and vimentin 
with the mitochondrial apparatus [4, 18, 19]. Previously, we have reported on the rat 
RV myofilament subproteome based on 2-DE analysis but with a slightly different 
prefractionation protocol [7]. Many proteins identified with the 2-DE analysis were also 
found by HPLC, but the latter technique led to the identification of  many additional 
proteins. Interestingly, the desmin proteins identified with the 2-DE method were not 
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found with HPLC. McDonald et al. previously showed a strikingly low overlap between 
subproteomes derived by 2-DE and HPLC separation, and concluded that both 
techniques are complementary in achieving full protein coverage of subproteomes 
[13]. In addition, other studies also showed that parallel proteomics is needed to 
improve coverage of the proteome [20, 21].  
In conclusion, we have shown that RP-HPLC can be used to fractionate the myofila-
mental proteins from rat hearts with high reproducibility and is suitable for subsequent 
mass spectrometry analysis. With this method, we have described the myofilamental 
subproteome of right ventricles from adult rats. However, complementary proteomic 
techniques are necessary to further increase the protein coverage of the myofilament 
subproteome. This method may prove useful in the detection and quantification of 
protein changes in various forms of cardiac disease.
The supplementary data (Table1S) associated with this chapter can be found under 
the Appendix at the end of this chapter
Figure 2: Number of non-redundant proteins identified in the rat Rv myofilamental 
extract.
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Discussion
RV pressure overload may be the clinical consequence of (repaired or palliated) 
congenital heart disease, pulmonary hypertension or chronic pulmonary disease. 
The RV differs from the LV with regard to embryology, genetics, anatomy, coronary 
circulation, contraction pattern and the basic role in the circulation [1-4]. In this thesis we 
have described the hemodynamic alterations that occur after prolonged RV pressure 
overload. We have used biventricular PV-loops to describe baseline hemodynamics, 
such as ventricular pressure and volume, as well as contractile function using 
several parameters. Combined with dobutamine stimulation this allowed relatively 
load-independent assessment of ventricular function and reserve [5-7]. In addition, 
proteomic technologies were used to study concomitant protein alterations.
Our results indicate that in response to prolonged pressure overload, the RV 
hypertrophies by increasing the mass of the RV free wall. Systolic RV function at baseline 
is increased as measured by end-systolic elastance (Ees) and is further enhanced during 
catecholaminergic stimulation. Furthermore, both early and late diastolic RV function 
is affected. This is demonstrated by prolongation of early relaxation, as measured by 
tau and dP/dt
min
, as well as an increased passive stiffness, as measured by the late 
phase of the end-diastolic pressure-volume relationship.
In addition, LV mass and both its systolic and diastolic function are unimpaired after 
prolonged RV pressure overload. Finally, throughout the observation of 20 weeks of 
pressure overload, the hemodynamic responses did not change much. At the protein 
level, distinct changes were found, including alterations in metabolic- and stress 
related proteins.
Hemodynamic response to prolonged Rv pressure overload
The effect of increased RV afterload on the development of RV hypertrophy and RV 
failure has been studied under various experimental conditions.
The first approach that has been used is banding of the pulmonary artery, similar to 
the approach described in this thesis [7-10]. From these studies we have learned that 
an acute increase of afterload on the RV is tolerated as long as RV systolic pressure 
is not increased to more than approximately 60% of systemic pressure [11]. Higher 
pressure loads have led to acute ventricular failure and unacceptably high mortality 
[12]. Interestingly, this is quite compatible with observations in patients with congenital 
heart disease, where acutely increasing the pressure load upon the subpulmonary 
ventricle (either with right or left ventricular morphology) to higher levels leads to 
ventricular failure and /or the need for debanding [13, 14]. 
The adaptation to an acute increase of RV afterload is through homeometric 
autoregulation, with an increase in end-diastolic and end-systolic volume [15, 16].
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Prolonged pressure overload induced by pulmonary artery banding (PAB) leads to a 
hypertrophic response of the RV. In the studies that have used a similar approach as 
described in this thesis, i.e. one-time banding and allowing animals “to grow into their 
banding”, have generally led to RV peak systolic pressure at subsystemic levels. Other 
investigators, that have used adjustable bands around the pulmonary artery, allowing 
the RV systolic pressure to be gradually increased over time, have generally reached 
near-systemic peak-systolic pressures in the RV. Irrespective of the approach used, the 
data from these banding studies are all compatible with our results. There is a vigorous 
hypertrophic response from the RV, almost exclusively by an increased mass of the 
free wall of the RV, while the interventricular septum and the LV free wall mass are 
unaffected [17, 18]. The contractile function of the RV is generally well maintained with 
a 3-4-fold increase of Ees in baseline conditions when PAB was maintained for up to 
12 weeks using various animal models including rats, lambs and dogs [7, 9, 18, 19]. In 
those instances where contractile reserve was studied, all studies have demonstrated 
a further (modest) increase of Ees [7, 18]. Collectively these responses, which we also 
demonstrated in our studies, indicate that in most instances of prolonged RV pressure 
overload compensated RV hypertrophy will develop. In some cases the increase 
in Ees was out of proportion in relation to the increase in RV mass, suggesting a 
hypercontractile state of the RV, but this has not been a consistent finding in all studies 
[7]. Only few studies have described the clinical signs of heart failure after PA banding. 
In one such study in rats clinical signs of heart failure developed after 20 weeks of PA 
banding, but invasive hemodynamic measurements were not obtained [10]. Based on 
that study we included the group with 20 weeks of PA banding, expecting to obtain 
failure and to characterise hemodynamic and protein changes that accompany the 
transition from compensated hypertrophy to failure. However, we were unable to 
replicate these findings.
The effects of the increased RV afterload on RV and LV volumes differ somewhat in 
the various studies. In some studies, like ours, a decrease in RV and LV end-diastolic 
volumes has been found, while other studies described an moderate increase in these 
volumes [7, 20]. However, severe dilatation of either RV of LV is not a normal finding 
after PA banding.
A second approach that has been widely used by investigators, primarily interested 
in pulmonary arterial hypertension, is monocrotaline induced pulmonary arterial 
hypertension. In general, two different responses have been described in these 
studies. The first is an increase in pulmonary arterial pressure with the development 
of a compensated state of right ventricular hypertrophy. The second response is a 
progressive increase in pulmonary artery pressure with the development of severe 
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right heart failure and death within a few weeks. The differential responses seem to 
be dose-related with dosages up to 30-40 mg/kg leading to a compensated state and 
higher dosages, generally 60-80 mg/kg leading to a decompensated state and RV 
failure [21-24]. 
In all studies there is a vigorous RV hypertrophic response with an increase RV free wall 
mass, while the interventricular septum and LV free wall are unaffected. The increase in 
RV mass is higher in animals developing RV failure.  
In most studies RV peak-systolic pressure remains at subsystemic level, irrespective 
of the development of compensated or decompensated RV hypertrophy. Only a 
few studies addressed the hemodynamic adjustments in this model in some more 
detail. In contrast to the results of our studies, Hessel et al. demonstrated that in 
monocrotaline-treated rats, end-systolic and end-diastolic volumes progressively 
increased, as compared to controls, dependant on whether compensated or 
decompensated RV hypertrophy developed [24]. Furthermore, baseline Ees of the RV, 
both in the compensated as well as in the decompensated state, was not increased as 
compared to controls, whereas this is normally found in all banding studies. In isolated 
RV myocardial trabeculae from rats showing clinical signs of heart failure the force 
generated at baseline was increased, but the force frequency response was grossly 
abnormal. Furthermore, the contractile response to catecholaminergic stimulation 
was decreased [22].
The third approach that has been used is (simulated) high-altitude to induce pulmonary 
arterial hypertension. This not only exposes the right ventricle to an increased 
afterload, but also to the effects of arterial hypoxemia [25-30]. In many of these studies 
the differential effects of hypoxemia alone (upon the LV) and of hypoxemia and 
pressure load (upon the RV) have been studied. Many studies have addressed research 
questions regarding capillary density and biochemical or molecular adaptations. 
However, extensive hemodynamic characterization has usually not been performed, 
apart from characterization of the RV pressure response.  
Prolonged pressure overload upon the RV also induced alterations in diastolic 
function, indicating that the RV became less compliant. In our study early relaxation, a 
process dependant on Ca2+ re-uptake in the sarcoplasmatic reticulum, was prolonged 
in the pressure overloaded RV. Even though early relaxation improved during 
catecholaminergic stimulation, suggesting that Ca2+-cycling was enhanced in these 
conditions, it was still slower than in normal RV under catecholaminergic stimulation. A 
decrease in early relaxation has also been observed after PA banding in lambs [31] and 
after monocrotaline-induced RV hypertrophy in dogs [32]. Global diastolic function 
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was impaired in RV trabeculae from rats with RV failure after monocrotaline treatment 
[22]. Similarly, late diastolic function was impaired in these studies as well as in the rats 
in our study. In our study fibrosis was excluded as an important cause of late diastolic 
impairment, but our analysis suggested the increased RV mass as an important cause 
for the diastolic dysfunction.
The effect of RV hypertrophy on LV mass, volumes and function seem to be negligible. 
Most studies using one of the three above-mentioned approaches have failed to 
demonstrate significant interference with LV behaviour. 
Molecular alterations following prolonged Rv pressure overload
As presented in this thesis, many protein alterations occur over time when the RV is 
subjected to increased afterload [19, 33]. The majority of these changes were related to 
cardiac metabolism. In general, a shift of proteins related to carbohydrate metabolism 
and away from fatty acid was observed suggesting a shift towards carbohydrates 
as preferred energy source. This shift in energy metabolism has already been well 
documented in LV hypertrophy [34-38]. Earlier, Takeyama reported that glucose uptake 
is increased in the RV in a model of acute (4 weeks PAB) RV pressure overload [39]. 
This shift may be the result of an increased energy demand associated with increased 
workload. 
A second set of protein changes in RV hypertrophy included the stress- and antioxidant 
proteins. These heat shock proteins are known to play a role in adaptation processes 
to various forms of stress and have a cytoprotective function [40]. We have shown 
that several stress proteins are upregulated in the early phase of RV hypertrophy (ie. 6 
weeks PAB) [33]. This enhanced expression continued throughout the study period of 
20 weeks PAB and included the presence of multiple posttranslational modifications 
[19]. These posttranslational modifications, such as phosphorylation, are thought to be 
essential for their protective roles [41-43]. For instance, the phosphorylation of HSP-
27 has been suggested to play an important role in maintaining the microfilament 
integrity in response to oxidative stress. In our studies, HSP-27 was found to be 
upregulated in the hypertrophied RV. In addition, the HSP-27 was found to be 
phosphorylated at different residues [19].  Several studies have shown the activation 
of heat shock proteins in the stressed RV. Rafiee et al. studied the expression of the 
inducible heat shock protein 70 (Hsp-70) in cardiac (right atrium) tissue of children 
undergoing corrective surgery for cardiac birth defects [44]. One of the main results 
was the 4-5 fold elevation of Hsp-70 levels in the hearts of children with cyanotic heart 
disease, while the levels of constitutive Hsp70 were unaffected. Similar results were 
obtained in their hypoxic animal model, where rabbits were exposed to hypoxia after 
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birth for a period of 10 days. The presence of selective regulation of HSP levels in the 
adaptive response to hypoxia-induced stress was also shown in cultured myocytes 
[42]. Brar et al. showed that selective over expression of HSP by transfection of plasmid 
constructs in vitro and in vivo resulted in protection against apoptosis-inducing stimuli 
as well as hypoxic stress [45]. 
The upstream signalling pathway for HSP-27 phosphorylation includes the MAPK 
pathway [42, 46]. In our study we found that after 6 wk of RV pressure overload, the 
levels of p-38 MAPK and its phosphorylated form were similar between controls and 
PAB animals [19]. After 20 weeks of PAB these levels were slightly decreased, despite 
the increased HSP-27 transcription, suggesting that another pathway is also involved 
in HSP-27 transcription and phosphorylation. In addition, the absence of p-38 MAPK 
activation in our model correlates with the observations done by Buermans et al. 
[23]. Their study involved prolonged RV pressure overload induced by monocrotaline 
in rats. The RV with compensated hypertrophy did not show p-38 MAPK activation 
whereas the RV with signs of hemodynamic failure did. On the other hand, studies 
on p-38 MAPK signalling in hypoxic hearts revealed early activation of this pathway 
[42, 47]. Together with our observations, these data suggest that other pathways are 
involved in HSP-27 phosphorylation. For instance, the protein kinase C-δ pathway has 
been known to play a role in the development of pathological hypertrophy and has 
been shown to be activated both in RV and LV pressure overload [48-50]. Furthermore, 
protein kinase C-δ has been shown to phosphorylate HSP-27 proteins independent of 
the p38-MAPK pathway [51]. Additional studies are needed to determine the role of 
the different upstream signalling pathways in (pathological) RV hypertrophy.
Furthermore, changes in cardiac myofilament proteome can be an important part of 
adaptation to prolonged increased afterload. Conventional proteomic techniques, 
such as 2-DE protein separation, may not be able to study these changes properly 
[52]. New techniques, including reversed phase protein separation may be useful 
techniques for this purpose.
Development of compensated Rv hypertrophy versus Rv failure.
In order to understand how RV failure develops, one may wonder what the difference 
between the various experimental approaches is. Why does RV failure almost never 
develop in PA banding and why is it so common after exposure to high-dose 
monocrotaline? One possible explanation is that investigators are just not patient 
enough to await RV failure to develop. In both PA banding and (simulated) high altitude 
studies, some reports can be identified where failure developed after prolonged 
exposure to increased RV afterload [8, 10].
In monocrotaline induced pulmonary arterial hypertension and, Buermans et al 
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demonstrated that treatment with high-dose monocrotaline was associated with early 
activation of the p38-MAPK pathway, even before the development of RV failure. In 
contrast, in rats with treated with low-dose monocrotaline, developing compensated 
RV hypertrophy, p38-MAPK was deactivated by MKP-1, a MAPK specific phosphatase 
[53]. These authors suggested the development of pathological hypertrophy was 
predetermined by the activation of the p38-MAPK pathway even before heart failure 
developed.
In monocrotaline-induced pulmonary arterial hypertension it is generally believed that 
the active form of the alkaloid, after hepatic conversion, only reaches the pulmonary 
microvasculature and induces a local vasculitis. However, a recent study demonstrated 
that vascular responses are also observed in the coronary circulation, suggesting that 
a monocrotaline-induced vascular response in the RV myocardium might contribute 
to the development of RV failure [53]. 
Other investigators have suggested that the development of heart failure in response 
to pressure overload may be related to a mismatch between the degree of hypertrophy 
and neo-angiogenesis in the affected myocardium. In this way myocyte oxygen 
demand may exceed oxygen delivery, thus leading to persistent oxidative stress. In 
such circumstances the cellular anti-oxidant mechanisms, that we demonstrated to be 
up-regulated during compensated hypertrophy, may be overwhelmed and activation 
of intracellular pathways leading to pathological hypertrophy and apoptosis may 
ensue [54].
In a recent study van de Bogaard et al. demonstrated that the development of RV 
failure was associated with abnormal capillary formation and with increased RV fibrosis 
[8]. The loss of capillaries in the failing RV myocardium, that was only seen after the 
combined exposure to hypoxia and a VEGF receptor blocker, was associated with 
increased HIF-1α signalling, but decreased VEGF-signalling. These responses were not 
encountered after pulmonary artery banding and capillary density was maintained 
in the RV after PA banding. Their observations after PA banding are similar to the 
results of our study. Furthermore, these authors demonstrated that various dietary 
interventions that interfered with defence mechanisms against oxidative stress could 
induce the development of RV failure. Conversely, interventions that boosted defence 
mechanisms could prevent the development of RV failure [8]. 
Similar observations have been obtained in the pressure overloaded left ventricle. 
In experimentally induced LV hypertrophy the development of pathological LV 
hypertrophy and failure was attenuated or prevented after treatment that enhanced 
angiogenesis [55-58].
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We suspect that RV failure is almost never seen in experimental studies where PA 
banding is applied, because the acute increase in RV pressure that is tolerated 
during the banding procedure, leads to a favourable balance between local oxygen 
demand and supply. This will allow a favourable adjustment at cellular level, like we 
have demonstrated in our studies. In the experimental model we used the potential 
interference with coronary angiogenesis from toxic substances, that may be present in 
other models, is lacking. For the application of our results to many forms of congenital 
heart disease, it must be borne in mind that pressure overload upon the RV often 
has been present from birth on and/or increases only gradually. Cyanosis may be an 
integral part of congenital heart disease and pressure overload upon the RV. Studies in 
infant humans and rabbits have suggested that the presence of cyanosis may induce 
further protective adjustments against oxidative stress in the myocardium [44, 47]. 
Others have suggested that the transcription of pathways of adaptive remodeling was 
lower in the RV compared with the LV in different types of congenital heart disease 
with outflow obstruction [4]. Further studies are needed to clarify the role of different 
mechanisms in the right ventricle related to adaptation to increased afterload and 
hypoxemia.
Clinical implications
RV pressure overload may be the clinical consequence of (repaired or palliated) 
congenital heart disease, pulmonary hypertension or chronic pulmonary disease.
For patients with pure (congenital) pulmonary valve stenosis the long-term outcome 
is generally good, although the natural history of moderate to severe obstruction is 
generally modified by intervention [59]. Residual obstruction in the RV outflow tract 
may be a consequence of repaired or palliated complex congenital heart disease, like 
for example Tetralogy of Fallot, transposition of the great arteries or more complex 
lesions. In many instances residual lesions induce combined pressure and volume 
loads upon the right ventricle. The presence and severity of symptoms of heart failure 
in adults with congenital heart disease correlates with neurohumoral levels, but also 
with signs of abnormal left heart and right heart function [60]. However, isolated RV 
systolic failure as a cause of heart failure is rare in these complex lesions. We suspect, 
therefore, that the alterations in the proteome of the pressure overloaded RV in our 
rats, improving the ability to withstand increased oxidative stress is also relevant for 
patient with residual pressure overload upon their RV. 
Another aspect of the adjustment to RV pressure overload is the effect on diastolic 
function. The decrease in both early and late diastolic function in experimental studies 
of RV pressure overload has been a consistent finding. This may lead to either a 
decrease in RV end-diastolic volume, as in our study, or an increase in diastolic filling 
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pressures. Furthermore, the results of our study indicate that an abnormal structure 
of the RV, for example by increased fibrosis, may not be necessary for the presence of 
the diastolic dysfunction. Rather, our results suggest that the abnormalities in the late 
diastolic function of the RV are a direct consequence of an increased RV mass. This may 
limit the possibility for therapeutical interventions to improve diastolic function, other 
than by reducing RV mass. 
The consequences for the diastolic dysfunction of the RV on systemic output may not 
be so clear at rest, but may become relevant during exercise. In our experimental set-
up, RV end-diastolic volume and stroke volume decreased during catecholaminergic 
stimulation, and cardiac output did not increase. Although effects of dobutamine 
stimulation are not similar to the effects of physical stress in patients, , our experiments 
suggest that limitation of cardiac output in patients with RV hypertrophy may be a 
consequence of the diastolic rather than the systolic dysfunction.
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Summary
This thesis describes studies on the effects of prolonged right ventricular (RV) 
pressure-overload on hemodynamics as well as protein changes. In Chapter 1, the 
rationale for this research project is presented. Congenital heart disease is a common 
birth defect with great impact on morbidity and mortality in children. The ongoing 
improvement in surgical techniques has led to an increased survival of children with 
certain congenital heart anomalies. In addition, death resulting from congenital heart 
disease is shifting from newborns towards (young) adults. In a selected group of these 
patients, such as Tetralogy of Fallot, left hypoplastic heart syndrome or congenitally 
corrected transposition of the great vessels, the RV is subjected to increased loading 
conditions. In addition, other diseases such as pulmonary hypertension or even 
ischemic heart disease can result in increased RV pressure overload. The effects of 
prolonged RV pressure overload on the heart’s function, as well as the effects on 
molecular and cellular level is not yet fully understood.
One way to study changes at molecular level is the use of proteomics technologies. 
Proteomics is  the study of the proteome, ie. the entire set of proteins expressed by 
a genome, cell, tissue or organism. Chapter 2 describes the different proteomics 
technologies and strategies and its implementation in the study of cardiac hypertrophy 
and failure.
In Chapter 3 an animal model of RV hypertrophy as a result of pulmonary artery 
banding (PAB) is presented. Besides basic hemodynamic measurements a proteomics 
approach was used to study the protein alterations in compensated RV hypertrophy 
(after 6 weeks of PAB). Cytoplasmic protein changes were observed including a shift 
in metabolism from fatty acids to glucose as a substrate for energy supply. In addition, 
upregulation of heat-shock protein (HSP) 27 was found in the hypertrophied RV, 
indicating an altered stress response. Proteomic analysis of the myofilament proteins 
showed upregulation of desmin and α-β-crystallin.
In Chapter 4 we report the biventricular adaptation to 6 weeks of PAB. In this study 
biventricular pressure-volume loops were obtained in our rat model. With the help 
of these invasive measurements many hemodynamic parameters could be obtained. 
These include basic parameters such as pressure, volume, and heart rate, as well 
as load-independent measures of contractility, such as the end-systolic pressure-
volume relation. In general, systemic hemodynamic parameters were not altered 
and overt signs of heart failure were absent. RV contractility was enhanced in the PAB 
rats. In addition, dobutamine stimulation revealed preserved RV contractile reserve, 
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supporting the concept that 6 weeks of PAB in our model leads to a compensated 
state of RV hypertrophy. 
As our initial studies focussed on the development of the RV hypertrophy model 
and the use of biventricular pressure-volume loops as well as the application of 
proteomics technologies, the next two studies were aimed at capturing the transition 
from compensated to decompensated RV hypertrophie, ie. heart failure. Therefore we 
extended the duration of PAB to 12 and 20 weeks.
Chapter 5 describes the longitudinal protein alterations in the cytoplasmic fraction. 
Basic hemodynamic measurements however revealed that the RV is still in a 
compensated state after 20 weeks of PAB. Nevertheless, many differentially regulated 
proteins were found including metabolism related proteins as well as stress proteins 
including HSP-27 en peroxiredoxin species. The observed protein changes are likely 
part of a protective mechanism against the development of RV failure.
In parallel to the proteomics studies, hemodynamic characterization was performed. 
Chapter 6 describes changes in systolic and diastolic function during prolonged PAB 
(up to 20 weeks), as well as molecular alterations. In the hypertrophied RV, the systolic 
function of the RV and the left ventricle was maintained. Diastolic (RV) function, which 
was measured using the end-diastolic pressure-volume relation and tau, was impaired 
in the early and late phase of diastole but remained stable throughout the observation 
period. The RV hemodynamic alterations were linked to alterations in several molecular 
components of the Ca2+ cycling and β
1
-adrenergic signalling as well as the degree 
of fibrosis. We suggest that these alterations are necessary for the heart to maintain 
its function. The progressive nature of these alterations underlines the concept that 
compensated hypertrophy is not a static situation, but rather is a dynamic, slowly 
progressive process in which the heart is able to maintain its function by employing 
compensatory mechanisms.
The contractile properties of the heart ultimately are based on the myofilament 
machinery that is present in the cardiomyocyte. Alterations in the myofilaments is 
therefore likely to have its effects on cardiac function. The study of myofilament protein 
alterations using proteomics technologies is difficult due to the intrinsic properties of 
these proteins. In Chapter 7 we present a method for myofilament protein separation 
using reversed-phase high performance liquid chromatography. The optimization and 
reproducibility is presented, as well as myofilament subproteome. 
In Chapter 8 the main findings from the preceding chapters were summarized and 
placed in a broader context. Clinical implications are also discussed.
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Samenvatting 
Dit proefschrift beschrijft studies over de effecten van langdurige rechter hartkamer 
(RV) druk overbelasting op de hemodynamiek alsmede de veranderingen in eiwitten. 
In Hoofdstuk 1 wordt de achtergrond van het onderzoek beschreven. Aangeboren 
hartafwijkingen komen frequent voor en hebben derhalve gevolgen voor de 
morbiditeit en mortaliteit bij kinderen. Dankzij nieuwe en verbeterde chirurgische 
methoden is er sprake van een betere overleving bij kinderen met bepaalde 
aangeboren hartafwijkingen. Daarnaast zien we dat overlijden ten gevolge van een 
aangeboren hartafwijking meer aan het verschuiven is van pas geborenen naar (jonge) 
volwassenen. In een bepaalde groep van deze patiënten, zoals kinderen met een 
Tetralogie van Fallot, hypoplastisch linkerhart syndroom of congenitaal gecorrigeerde 
transpositie van de grote vaten, staat de RV bloot aan hogere drukken dan de normale 
situatie. Ook andere ziekten zoals pulmonale hypertensie of soms zelf ischemische 
hartziekten kunnen leiden tot een hogere drukbelasting van de RV. Wat het precieze 
effect is van de druk overbelasting op de functie van het hart alsmede de effecten op 
cellulair en moleculair niveau is nog niet volledig bekend.
Een methode om veranderingen op moleculair niveau te bestuderen is het 
zogenaamde proteomics onderzoek. Proteomics is de studie van het proteoom, 
dat wil zeggen de studie naar alle eiwitten die voortkomen uit het genoom en die 
aanwezig zijn in een cel, weefsel of organisme. Hoofdstuk 2 beschrijft de verschillende 
proteomics technieken en strategieën en de toepassing daarvan in onderzoek naar 
hart hypertrofie en falen.
In Hoofdstuk 3 presenteren we een diermodel met RV hypertrofie ten gevolge van het 
plaatsen van een bandje om de pulmonaal arterie (PAB). Naast basale hemodynamische 
metingen werden proteomics technieken gebruikt om eiwitveranderingen in 
gecompenseerde RV hypertrofie in kaart te brengen (na 6 weken PAB). Er werden 
veranderingen gevonden in verschillende cytoplasmatische eiwitten waaronder 
veranderingen in eiwitten betrokken bij het metabolisme. Een verschuiving in 
energie substraten, van vetzuren naar glucose, werd gevonden. Daarnaast werden 
er aanwijzingen gezien voor een veranderde stress reactie in de hypertrofische RV 
gezien de verhoogde aanwezigheid van heat-shock proteïne (HSP) 27. De analyse van 
myofilament eiwitten liet een toename zien van desmine en α-β-crystalline.
In Hoofdstuk 4 beschrijven we de adaptatie van beide hartkamers na 6 weken PAB. 
In deze studie werden druk-volume relaties verkregen in ons diermodel. Dankzij deze 
invasieve metingen konden diverse hemodynamische parameters worden verkregen 
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zoals de basale parameters druk, volume en hart frequentie. Ook konden (belasting-
onafhankelijke) parameters geëxtraheerd worden die iets zeggen over de contractilteit 
van het hart, zoals de eind-systolische druk-volume relatie. In het algemeen werden na 
6 weken PAB geen veranderingen gezien in de basale hemodynamische parameters. 
Ook werden geen duidelijke klinische tekenen van hartfalen gezien. De contractiliteit 
was echter verhoogd in de hypertrofische RV. Na stimulatie met dobutamine bleef de 
contractiliteitsreserve gehandhaafd. Dit ondersteunt de gedacht dat 6 weken PAB leidt 
tot een gecompenseerde staat van RV hypertrofie. 
Deze voorgaande studies richtten zich meer op de ontwikkeling van het diermodel 
en het gebruik van druk-volume relaties en de toepassing van proteomics technieken. 
De volgende studies waren meer gericht op het bestuderen van het overgangspunt 
van gecompenseerde hypertrofie naar hart falen. Om dit te bewerkstelligen werd de 
duur van PAB uitgebreid naar 12 en 20 weken. Hoofdstuk 5 beschrijft longitudinale 
veranderingen in eiwitten in de cytoplasmatische fractie. Ondanks de uitbreiding van 
de PAB naar 12 en 20 weken laten basale hemodynamische metingen zien dat de 
RV nog steeds in een gecompenseerde hypertrofische toestand verkeert. Ondanks 
deze observatie zien we toch dat er meerdere eiwitveranderingen optreden welke 
tijdsafhankelijk zijn. Er werden oa. veranderingen gevonden in eiwitten betrokken 
bij het metabolisme alsmede stress eiwitten zoals HSP-27 en peroxiredixine. Deze 
eiwitveranderingen maken mogelijk deel uit van een beschermend mechanisme 
tegen de ontwikkeling van hartfalen. 
Naast de proteomics studies werd ook uitgebreid gekeken naar de hemodynamische 
veranderingen. Hoofdstuk 6 beschrijft veranderingen in systolische en diastolische 
functie ten gevolge van langdurige PAB (tot 20 weken), alsmede veranderingen 
op moleculair niveau. De systolische functie van de RV en de linker hartkamer blijft 
intact na langdurige PAB. De diastolische functie, zoals weergegeven door de eind-
diastolische druk-volume relatie en de tau, is echter afgenomen in zowel de vroege 
als late fase van de diastole. De geobserveerde veranderingen in RV hemodynamiek 
werden gekoppeld aan veranderingen in verschillende componenten van calcium 
huishouding en  β
1
-adrenerge signaaltransductie alsmede de mate van fibrosering 
in het hart. Wij denken dat al deze veranderingen nodig zijn voor het hart om zijn 
functie te waarborgen. Veel van deze veranderingen in eiwitten zijn progressief of 
tijdsafhankelijk. Dit onderstreept het concept dat gecompenseerde hypertrofie niet 
een statische toestand is maar juist een dynamisch, langzaam progressief proces 
waarbij het hart allerlei compensatie mechanismen inzet om zijn functie te behouden. 
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De contractiele eigenschappen van het hart zijn uiteindelijk gebaseerd op de 
myofilament eiwitten welke de basis vormen van het contractiliteitsapparaat in de 
hartspiercellen. Veranderingen in deze eiwitten hebben derhalve dus effect op de 
functie van het hart. Het bestuderen van myofilament eiwitten gebruikmakend 
van de proteomics technieken is lastig vanwege de eigenschappen van deze 
eiwitten. In Hoofdstuk 7 presenteren we een methode waarbij we myofilament 
eiwitten bestuderen gebruikmakend van zogenaamde “reversed-phase” vloeistof 
chromatografie. De optimalisatie en reproduceerbaarheid worden besproken. Ook 
word een myofilament subproteoom gepresenteerd.
In Hoofdstuk 8 zijn de belangrijkste bevindingen uit de voorgaande hoofdstukken 
samengevat en in een bredere context geplaatst. Daarnaast wordt er aandacht 
gegeven aan de klinische implicatie van dit onderzoek.
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Het aloude adagium “promoveren doe je niet alleen” is zonder meer waar. Graag zou ik 
op deze plek een aantal mensen willen bedanken voor hun bijdrage.
Allereerst Prof.dr. W.A. Helbing, beste Wim, hartelijk dank dat je mij de mogelijkheid 
hebt gegeven om te werken aan dit fantastische project. Ik denk een mooi begin van 
het basale wetenschappelijk onderzoek binnen de kindercardiologie in Rotterdam. De 
discussies over de onderzoeksopzet, de resultaten en ook klinische implicatie heb ik 
erg kunnen waarderen. Fijn dat je me altijd de mogelijkheid hebt geboden om ons 
werk (inter)nationaal te presenteren.
Prof.dr. J.M.J. Lamers, beste Jos, hartelijk dank dat ik de mogelijkheid heb gekregen om 
in jouw lab te mogen werken aan het proteomics gedeelte. Na je trainingsrondje van 
10-tallen kilometers in de ochtend was je immer bereidt om samen te discussiëren over 
ons werk. Je inspiratie en motivatie hebben mij zeker geholpen. Helaas ben je door 
noodlottige omstandigheden niet in staat geweest om het laatste stukje wetenschap 
mee te maken. Ik hoop van harte dat je wel aanwezig kunt zijn bij de verdediging.
Dr. M. Dalinghaus, beste Michiel, ontzettend veel dank voor je niet-aflatende steun 
in de reis die promoveren heet. Je was altijd nauw betrokken bij de voortgang en 
ontwikkelingen. De discussies over druk-volume relaties maar zeker ook de proteomics 
zijn voor mij zeer nuttig geweest. Dank voor je geduld.
Prof.dr. D.J.G.M. Duncker, beste Dirk, hartelijk dank voor het beschikbaar stellen van 
een deel van je lab om onze experimenten uit te voeren. Geweldig om te zien hoe 
je steeds weer, vol enthousiasme en inspiratie, een frisse blik kon werpen op onze 
studies. Dank ook voor het zitting nemen in de kleine commissie, het beoordelen van 
mijn proefschrift en je deelname aan de oppositie.
Graag wil ik de overige leden van de kleine commissie, Prof.dr. D. Tibboel en Prof.dr. J.W. 
Roos-Hesselink, bedanken voor het beoordelen van het manuscript.
Dr. A. Verhoeven, beste Adrie, bedankt dat je in de laatste fase van mijn boekje bereidt 
bent geweest om mee te denken. Met name je inzet voor het HPLC werk heb ik erg 
gewaardeerd.
Ook de overige leden van de grote commissie, Prof.dr. I.K.M. Reiss, Prof.dr. A.J. Van der 
Heijden, Prof.dr. R.M.F. Berger en Prof.dr. W.S. Simonides wil ik van harte bedanken voor 
hun deelname aan de oppositie.
Faber.indd   189 28-02-12   12:48
Curriculum VitaeAppendix
190
Dr. P. Steendijk, beste Paul, hartelijk dank voor je inhoudelijke maar ook technische 
ondersteuning (Circlab) bij onze P-V studies. Fijn dat je altijd bereid was om mee te 
denken.
The Baltimore group:
Prof. J.E. Van Eyk, dear Jenny, thanks so much for having me around in your lab. Your 
enthousiasm and hospitality are incredible. Simon Sheng, thanks for your technical 
assistance with all the RP-HPLC, 2D-LC and Mass spectrometry equipment. Thanks to 
all other lab members for helping me around.
Inge Lankhuizen, mijn steun en toeverlaat bij alle experimenten. We hebben aardig 
wat uurtjes doorgebracht in het lab met de ratten, de gels, de paraffine blokjes 
enzovoort. Hartelijk dank voor je technische assistentie maar zeker ook je inhoudelijke 
commentaren op ons werk. 
Karel Bezstarosti en Dick Dekkers, hartelijk dank voor jullie hulp bij de 2D gels, 
westernblots en uiteraard de massa spectrometrie.
Jochem, Wilfred, Daniëlle, Diederik en alle andere onderzoekers, bedankt voor de leuke 
tijd! De gezamenlijke lunches, bakjes koffie met de bijbehorende verhalen...prima!
Mijn collega’s in het Sint Franciscus Gasthuis wil ik bedanken voor hun gezelligheid die 
het maakt dat ik daar een fantastische opleidingstijd heb. Binnenkort naar het Erasmus 
MC! Ik kom zeker nog eens “Snorren”.
Lieve vrienden, teamgenootjes, bedankt voor jullie interesse, steun en begrip (als ik 
weer eens niet op de training was...) tijdens dit hele traject. Maar bovenal bedankt voor 
alles wat niks met onderzoek te maken heeft! Remco en Melchior, fijn dat jullie mijn 
paranimfen willen zijn.
Mijn familie en met name mijn ouders wil ik bedanken voor hun onvoorwaardelijke 
steun, interesse, en liefde. Ja pa, na al die tijd is de afronding nabij, it giet oan!
Lieve Eline, bedankt dat je er voor me bent. Nu dit afgerond is hebben we gelukkig 
weer meer tijd voor elkaar. Tijd voor vakantie! Kus! 
Matthijs
Februari, 2012
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